"Rank","NCT Number","Title","Acronym","Status","Study Results","Conditions","Interventions","Outcome Measures","Sponsor/Collaborators","Gender","Age","Phases","Enrollment","Funded Bys","Study Type","Study Designs","Other IDs","Start Date","Primary Completion Date","Completion Date","First Posted","Results First Posted","Last Update Posted","Locations","Study Documents","URL"
1,"NCT02249676","Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders",,"Completed","No Results Available","Devic's Syndrome|Devic's Neuromyelitis Optica|Devic Syndrome|Devic's Disease|Devic Disease","Biological: Autologous mesenchymal stem cells","EDSS|Annual relapse rate|Lesion load|Retinal nerve fiber layer (RNFL)|Cognition|Immunological assessments|cerebral volume","Tianjin Medical University General Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB2013-055-02","January 2013","December 31, 2014","December 31, 2014","September 25, 2014",,"October 17, 2018","Tianjin Medical University General Hospital, Tianjin, Tianjin, China",,"https://ClinicalTrials.gov/show/NCT02249676"
2,"NCT02165904","Subarachnoid Administrations of Adults Autologous Mesenchymal Stromal Cells in SCI",,"Completed","Has Results","Spinal Cord Injury","Biological: Adult Autologous Mesenchymal Bone Marrow Cell","Efficacy-Sensivity Improvement Using the ASIA Score|Efficacy- Changes in Functional Independence Measure Scale|Efficacy-Change in Barthel Score|Efficacy-IANC-SCIFRS Scale|Efficacy-Changes in PENN Score.|Changes in ASHWORTH Score|Efficacy-Changes in EVA Score|Efficacy- Changes in Geffner Score|Efficacy- Changes in NBD Score|Efficacy-Changes in the Neurophysiological Parameters (SSEPs, Somatosensory Evoked Potentials)|Efficacy-Urodynammic in Terms of Detrusor Pressure|Efficacy-Urodynamic Studies Bladder Compliance|Efficacy-Urodynamic Studies Maximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)|Number of Adverse Events .|Efficacy- Expression of Neurotrophins in CSF (CerebroSpinal Fluid) Samples","Puerta de Hierro University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CME-LEM2|2011-005684-24","May 2014","May 2016","May 2016","June 18, 2014","July 19, 2019","July 19, 2019","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02165904"
3,"NCT01499459","Autologous Mesenchymal Stem Cell Transplantation in Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis","Genetic: autologous mesenchymal stem cell transplantation","clinical improvement|liver regeneration","Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","All","18 Years to 80 Years   (Adult, Older Adult)","Not Applicable","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11111111|1111111","June 2008","July 2012","August 2012","December 26, 2011",,"March 22, 2012","Gulhane Military Medical Academy Department of Gastroenterology, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT01499459"
4,"NCT02824393","Experimental Autologous Mesenchymal Stem Cell Therapy in Treatment of Chronic Autoimmune Urticaria",,"Completed","No Results Available","Urticaria|Autoimmune Diseases|Immune System Diseases|Skin Diseases","Biological: Autologous mesenchymal stem cell","Change from baseline in weekly urticaria activity scores.|Follow-up of the mesenchymal stem cell treatment-related side effects according to World Health Organisation (WHO) Toxicity Grading Scale for Determining The Severity of Adverse Events.|The changes in the ratios of peripheral blood cluster of differentiation 4 (CD4) T cell subsets.|The changes in ratios of peripheral blood inflammatory and anti-inflammatory cytokines.|The changes in the levels of peripheral blood anti-FcεRI autoantibody","Celal Bayar University|The Scientific and Technological Research Council of Turkey|Acıbadem Labcell","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TUBITAK-1001-215S612","March 3, 2017","May 15, 2018","July 15, 2018","July 6, 2016",,"July 18, 2018","Celal Bayar University, Medical School, Manisa, Turkey",,"https://ClinicalTrials.gov/show/NCT02824393"
5,"NCT02574572","Autologous Mesenchymal Stem Cells Transplantation in Cervical Chronic and Complete Spinal Cord Injury",,"Unknown status","No Results Available","Spinal Cord Injury","Biological: Autologous mesenchymal cells transplantation","Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging|Functional improvement in ASIA (American Spinal Injury Association) grade|Functional improvement regarding the AIS (ASIA Impairment Scale) scores (light touch, pin prik and motor force)|Improvements in sensorial mapping and neuropathic pain","Hospital Sao Rafael","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-003","September 6, 2017","December 31, 2019","June 30, 2020","October 14, 2015",,"November 28, 2017","Hospital São Rafael, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT02574572"
6,"NCT01157650","Treatment of Fistulous Crohn's Disease by Implant of Autologous Mesenchymal Stem Cells Derived From Adipose Tissue",,"Completed","No Results Available","Crohn Disease","Other: Autologous mesenchymal stem cells","Security and tolerance|therapeutic effect","Clinica Universidad de Navarra, Universidad de Navarra","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/CROH|2009-009880-71","June 2010","September 2013","September 2013","July 7, 2010",,"November 8, 2016","Clínica Universitaria de Navarra, Pamplona, Spain|Hospital Provincial de Navarra, Pamplona, Spain|Hospital Virgen del Camino, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT01157650"
7,"NCT01609283","A Dose-escalation Safety Trial for Intrathecal Autologous Mesenchymal Stem Cell Therapy in Amyotrophic Lateral Sclerosis",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: autologous mesenchymal stem cells","Number of patients with dose-limiting toxicities|Number of patients with adverse events|Change in serum sedimentation rate|Change in C-reactive protein levels|Change in complete blood counts|Change in total nucleated cell count in cerebrospinal fluid (CSF)|Change in protein level in cerebrospinal fluid (CSF)|Number of patients with presence of cancer cells in their cerebrospinal fluid (CSF)","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","11-008415","May 2012","January 31, 2019","January 31, 2019","May 31, 2012",,"September 3, 2019","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01609283"
8,"NCT01694927","Autologous Mesenchymal Stem Cells in Spinal Cord Injury (SCI) Patients","MSC-SCI","Unknown status","No Results Available","Spinal Cord Injury","Procedure: Autologous Mesenchymal Stem Cells","Safety of Autologous Expanded Mesenchymal Stem Cells transplantation in SCI patients|Functional improvement in muscle strength|Functional Improvement in sphincters control|Functional improvement in spasticity control","Clínica Las Condes. LIT INNOVA CORFO|Clinica las Condes, Chile","All","2 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","LIT-2012-ACF-001","January 2012","December 2013","June 2014","September 27, 2012",,"July 3, 2013","Clínica Las Condes, Santiago, RM, Chile",,"https://ClinicalTrials.gov/show/NCT01694927"
9,"NCT01056471","Autologous Mesenchymal Stem Cells From Adipose Tissue in Patients With Secondary Progressive Multiple Sclerosis",,"Completed","No Results Available","Autoimmune Diseases|Immune System Diseases|Demyelinating Diseases|Nervous System Diseases|Demyelinating Autoimmune Diseases, CNS|Autoimmune Diseases of the Nervous System","Other: Autologous mesenchymal stem cells from adipose tissue.","To evaluate safety and tolerability related to the intravenous infusion of autologous mesenchymal stem cells|To evaluate effects on MS disease activity measured by: clinical variables, imaging variables, immunological and neurophysiologic analysis, neuropsychological and quality of life scales.","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Carlos III Health Institute|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CMM/EM/2008","January 2010","June 2012","June 2015","January 26, 2010",,"August 7, 2015","Hospital Regional Universitario de Málaga, Málaga, Spain|Hospital Universitario Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01056471"
10,"NCT01228266","Mesenchymal Stem Cell Transplantation in MS","CMM-EM","Terminated","No Results Available","Multiple Sclerosis","Biological: autologous mesenchymal stem cells","To evaluate the safety as number of severe events along 1 year, and efficacy in terms of cumulative number of gadolinium-enhancing lesions in MRI at 6 months and at the end of the study|To evaluate effects on MS disease activity measured by: clinical variables, MRI, OCT, immunological analysis and quality of life scales","Albert Saiz|Instituto de Salud Carlos III|Hospital Clinic of Barcelona","All","18 Years to 50 Years   (Adult)","Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CMM-EM","December 2010","June 2013","December 2013","October 26, 2010",,"February 13, 2014","Neurology Service, Hospital Clinic de barcelona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01228266"
11,"NCT02574585","Autologous Mesenchymal Stem Cells Transplantation in Thoracolumbar Chronic and Complete Spinal Cord Injury Spinal Cord Injury",,"Not yet recruiting","No Results Available","Spinal Cord Injury","Biological: Autologous mesenchymal cells transplantation","Number of participants with treatment-related adverse events as assessed by magnetic resonance imaging spinal cord injury|Functional improvement in ASIA (American Spinal Injury Association) grade|Functional improvement regarding the AIS (ASIA Impairment Scale) scores (light touch, pin prik and motor force)|Improvements in sensorial mapping and neuropathic pain","Hospital Sao Rafael","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-005","December 2019","December 2021","January 2022","October 14, 2015",,"November 28, 2017",,,"https://ClinicalTrials.gov/show/NCT02574585"
12,"NCT00911365","Trial of Autologous Mesenchymal Stem Cells in Patients With Multiple System Atrophy",,"Completed","No Results Available","Multiple System Atrophy","Biological: autologous mesenchymal stem cells|Biological: normal saline","Scores on unified MSA rating scale","Yonsei University","All","up to 75 Years   (Child, Adult, Older Adult)","Phase 2","27","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","4-2008-0137","May 2008","June 2011","June 2011","June 1, 2009",,"August 4, 2011","Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT00911365"
13,"NCT00813969","Autologous Mesenchymal Stem Cell (MSC) Transplantation in MS",,"Completed","No Results Available","Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis|Progressive Relapsing Multiple Sclerosis","Biological: Autologous mesenchymal stem cell transplantation","To evaluate the feasibility of culturing MSCs, and infusion-related safety and tolerability of autologous MSC transplantation over one month in patients with relapsing forms of MS|To evaluate effects on MS disease activity measured by the number of Gd-enhancing brain MRI lesions|To evaluate safety and tolerability of autologous MSC transplantation over 6 months","The Cleveland Clinic|University Hospitals Cleveland Medical Center","All","18 Years to 55 Years   (Adult)","Phase 1","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS-MSC-001","March 2011","January 2014","May 2014","December 23, 2008",,"March 30, 2016","Cleveland Clinic Mellen Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT00813969"
14,"NCT01854957","MEsenchymal StEm Cells for Multiple Sclerosis","MESEMS","Unknown status","No Results Available","Multiple Sclerosis","Biological: Autologous Mesenchymal Stem Cells","Safety|efficacy|Efficacy","Antonio Uccelli|Azienda Ospedaliera Universitaria Integrata Verona|Ospedale San Raffaele|University of Genova","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MESEMS|2011-001295-19","July 2012","July 2014","September 2014","May 16, 2013",,"May 16, 2013","University of Genova, Genova, Italy",,"https://ClinicalTrials.gov/show/NCT01854957"
15,"NCT02497443","Safety of Autologous MSC Infusion to Treat Epilepsy","AMSCDRSE","Completed","No Results Available","Epilepsy","Biological: Autologous mesenchymal stem cells","Safety of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy|Efficacy of autologous bone marrow-derived Mesenchymal Stem Cells in patients with Drug-Resistant Symptomatic Epilepsy","Ministry of Public Health, Republic of Belarus","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","Minsk-MH001","April 2011","December 2017","December 2019","July 14, 2015",,"December 29, 2020",,,"https://ClinicalTrials.gov/show/NCT02497443"
16,"NCT02945462","Bone Marrow Mesenchymal Stem Cells in Erectile Dysfunction (ED)",,"Completed","No Results Available","Erectile Dysfunction","Biological: autologous mesenchymal stem cells","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Assessment the efficacy of intracavernous injection measured by SHIM/IIEF/EHS questionnaire|Evaluation the efficacy of intracavernous injection measured by Dynamic Infusion cavernosometry test.","University of Jordan","Male","25 Years to 65 Years   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EDUJCTC","September 2013","November 2015","October 2016","October 26, 2016",,"November 16, 2016",,,"https://ClinicalTrials.gov/show/NCT02945462"
17,"NCT01840540","MSC for Occlusive Disease of the Kidney",,"Completed","No Results Available","Atherosclerotic Renal Artery Stenosis|Ischemic Nephropathy|Renovascular Hypertension","Drug: Arterial infusion of autologous mesenchymal stem cells","Renal blood flow and function in the treated kidneys.|Level of kidney function.","Mayo Clinic","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-009298","April 2013","March 2014","April 2017","April 25, 2013",,"August 7, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01840540"
18,"NCT02987413","Escalated Application of Mesenchymal Stem Cells in Amyotrophic Lateral Sclerosis Patients",,"Completed","No Results Available","Motor Neuron Disease","Biological: Autologous Mesenchymal stem cells (MSCs)","Serious Adverse Events related to the treatment|Revised ALS Functional Rating Scale (ALSFRS-R)","Hospital e Maternidade Dr. Christóvão da Gama|IEP São Lucas - Instituto de Ensino e Pesquisa|Clinica Jordy Sinapse|TECHLIFE - Centro de Tecnologia Celular","All","18 Years and older   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HospitalMCG|IEPSaoLucas","April 28, 2015","March 2016","April 5, 2017","December 9, 2016",,"August 7, 2017","Hospital e Maternidade Dr Christovao da Gama, Santo Andre, Sao Paulo, Brazil|Instituto de Ensino e Pesquisas - IEP-São Lucas, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02987413"
19,"NCT02570932","Administration of Expanded Autologous Adult Bone Marrow Mesenchymal Cells in Established Chronic Spinal Cord Injuries",,"Completed","No Results Available","Spinal Cord Injury","Biological: Autologous Mesenchymal Bone Marrow Cell","Changes in IANR-SCIFRS score are considerate for the motor and sensory functions evaluation.|Neurotrophic factors levels in Cerebrospinal fluid (CSF) and/ or Number of Adverse Events related to treatment|Changes in PENN score are considerate for the motor and sensory functions evaluation|Changes in VAS score are considerate for quantification of pain|Changes in BDS score are considerate for the Assessment of the functional status|Changes in GEFFNER score are considerate for the Assessment of the functional status","Puerta de Hierro University Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CME-LEM3|2014-005613-24","July 2015","December 4, 2017","December 4, 2017","October 7, 2015",,"April 5, 2018","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02570932"
20,"NCT04312113","Angiographic Delivery of AD-MSC for Ulcerative Colitis",,"Recruiting","No Results Available","Ulcerative Colitis","Drug: Adipose derived, autologous mesenchymal stem cells","Number of participants with treatment-related adverse events|Number of participants with mucosal healing|Number of participants with clinical symptom response|Number of participants with improved healing on pathology","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-000826","November 16, 2020","December 31, 2022","December 31, 2022","March 18, 2020",,"September 30, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04312113"
21,"NCT02755922","Bone Regeneration With Mesenchymal Stem Cells",,"Completed","No Results Available","Mandibular Fractures","Biological: Application of autologous mesenchymal stem cells","Change of bone quality|Number of patients with infection ( increase of local temperature, tenderness, leukocyte count >10,000/ µL, confirmed by Gram stain and blood culture).|Number of patients with bleeding after surgery (Persistent bleeding, ineffectiveness stopping bleeding using dressings)|Number of patients with surgical wound dehiscence (subcutaneous tissue , bone or osteosynthesis material exposed and seen through opened skin )","Instituto Mexicano del Seguro Social","All","17 Years to 59 Years   (Child, Adult)","Phase 3","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2010-1301-27","April 2010","September 2010","December 2010","April 29, 2016",,"April 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02755922"
22,"NCT02981576","Safety and Effectiveness of BM-MSC vs AT-MSC in the Treatment of SCI Patients.",,"Completed","No Results Available","Spinal Cord Injuries","Biological: Autologous Mesenchymal Stem Cells","Comparing the number of side effects and the improvement on ASIA Impairment score between SCI patients receiving autologous AT-MSC vs BM-MSC.|Investigating the number of side effects in SCI patients receiving autologous BM-MSC.|Investigating the effectiveness of autologous BM-MSC in treating SCI patients.|Investigating the number of side effects in SCI patients receiving autologous AT-MSC.|Investigating the effectiveness of autologous AT-MSC in treating SCI patients.","University of Jordan","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","14","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCIUJCTC","November 2016","May 5, 2018","January 20, 2019","December 5, 2016",,"September 24, 2019","Cell Therapy Center, University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02981576"
23,"NCT02949414","A Study to Assess the Safety, Tolerability and Potential Efficacy of a Tracheal Replacement Consisting of a Tissue-engineered Tracheal Scaffold With Seeded Mesenchymal Cells",,"Suspended","No Results Available","Tracheomalacia|Tracheal Stenosis","Procedure: Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells","Number of treatment related SAE's as assessed by CTCAE grades as defined in version 4.0|Efficacy: Post Implant Stent free period|Efficacy: Post Implant Tracheostomy free period|Efficacy: Mean Airway Diameter evaluations as captured by CT scans|Efficacy: Changes in lung function results using a combination of FEV1, FEF50 and PEFR results|Number of treatment related AEs as assessed by CTCAE grading version 4.0","Cell Therapy Catapult|University College, London|Videregen","All","18 Years and older   (Adult, Older Adult)","Phase 1","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","D-00173-CT2013002","September 2016","September 2019","September 2024","October 31, 2016",,"March 29, 2018","Royal Nose Throat and Ear Institute, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02949414"
24,"NCT02460770","Bone Marrow-derived Mesenchymal Stem Cells (MSC) Administration in Weaning From Left Ventricular Assist Device","MESAD","Withdrawn","No Results Available","Chronic Myocardial Ischemia","Drug: Autologous mesenchymal stem cells","Feasibility of the full procedure|Ejection Fraction|Maximal Oxygen consumption|Walking distance in 6 minutes|weaning procedure|Quality of life|Measure of heart pressures|Brain natriuretic peptide|Troponin|Major bleeding|Systemic embolism|Deaths","University Hospital, Toulouse|Thoratec Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","13 150 03","June 2015","June 2017","June 2017","June 2, 2015",,"January 5, 2018","Cardiology Department of Rangueil Hospital - Rangueil Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02460770"
25,"NCT01730547","Mesenchymal Stem Cells for Multiple Sclerosis",,"Unknown status","No Results Available","Multiple Sclerosis","Biological: Autologous mesenchymal stem cells","To assess the safety of IV therapy with autologous Mesenchymal Stem Cells (MSCs) in MS patients.|To gather preliminary information of the efficacy of the experimental treatment in terms of combined MRI activity and clinical efficacy (incidence of relapses and disability progression).","Karolinska Institutet","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC-MS","February 2013","December 2015","December 2015","November 21, 2012",,"January 15, 2015","Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01730547"
26,"NCT02064062","Autologous Stem Cells in Achilles Tendinopathy","ASCAT","Unknown status","No Results Available","Achilles Tendinitis, Right Leg|Achilles Tendinitis|Achilles Degeneration|Achilles Tendon Thickening|Tendinopathy|Achilles Tendinitis, Left Leg","Biological: Autologous Mesenchymal Stem Cells","The primary safety outcome will be the incidence rate of Serious Adverse Reaction (SAR).|Incidence of success|Conventional ultrasound changes from baseline|Ultrasound Tissue Characterisation (UTC) changes from baseline|Inter-observer reliability of UTC against conventional US","University College, London","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12/0419|2013-000966-12","January 2015","December 2018",,"February 17, 2014",,"May 12, 2016","Royal National Orthopaedic Hospital, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT02064062"
27,"NCT01659762","A Phase I Study Evaluating Autologous Bone Marrow Derived Mesenchymal Stromal for Crohn's Disease.","EPIC/MSC/IBD","Completed","No Results Available","Crohn's Disease","Biological: autologous mesenchymal stromal cell","Number of adverse events|Crohn's disease activity Index (CDAI)","Emory University|Atlanta Clinical and Translational Science Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00051454|EPIC001","July 2012","July 2015",,"August 8, 2012",,"October 17, 2016","Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT01659762"
28,"NCT02065167","Evaluation of Mesenchymal Stem Cells to Treat Avascular Necrosis of the Hip","ORTHO-2","Completed","No Results Available","Avascular Necrosis of the Femoral Head","Biological: Cultured autologous Mesenchymal Cells","Complication rate|complication rate|Progression of disease to the next stage|Amount of necrotic bone in the femoral head in MRI|Pain (VAS)|serum levels of bone turnover markers","Universidad Autonoma de Madrid","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","26","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ORTHO -2|2012-002010-39","February 2014","June 2016","December 2017","February 17, 2014",,"October 14, 2021","Department of Orthopaedic Surgery, Hôpital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHU Tours, Tours, France|University Children's Hospital, Tübingen, Germany|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, Bologna, Italy|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT02065167"
29,"NCT01142856","Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: autologous mesenchymal stem cells","Safety|Neurologic disability score","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","09-001995","June 2010","April 2011","April 2011","June 11, 2010",,"May 3, 2012","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01142856"
30,"NCT00476060","Mesenchymal Stem Cell Transplantation in Decompensated Cirrhosis",,"Unknown status","No Results Available","Cirrhosis","Procedure: Autologous mesenchymal stem cell transplantation","MELD score, quality of life, liver volume, histological improvement (In a subset of patients with evidences of clinical and biochemical improvement, follow up liver biopsy will be performed at the end of follow up).|All cause mortality, tracking the infused cells in the patients' bodies.","University of Tehran","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","DDRC85-13","January 2007","August 2011","August 2011","May 21, 2007",,"January 11, 2011","Digestive Disease Research Center, Shariati Hospital, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00476060"
31,"NCT03333681","Evaluation of Stem Cell Therapy Effects on the Immune Response in Rheumatoid Arthritis Patients",,"Completed","No Results Available","Rheumatoid Arthritis","Biological: Autologous mesenchymal stem cells","Effect of mesenchymal stem cells therapy on the percentage of regulatory T cells","Mashhad University of Medical Sciences","Female","35 Years to 60 Years   (Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","931523|122","June 20, 2016","August 15, 2018","September 15, 2018","November 7, 2017",,"March 13, 2019",,,"https://ClinicalTrials.gov/show/NCT03333681"
32,"NCT02751125","Reconstruction of Jaw Bone Using Mesenchymal Stem Cells",,"Completed","No Results Available","Bone Atrophy","Drug: BCP with autologous mesenchymal stem cells (MSC).","Amount of newly formed bone induced by MSCs and the bone substitute. These measurements are based on radiological assessments.|Implant stability|Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]","University of Bergen|University of Ulm|Haukeland University Hospital|Université de Nantes","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2012-003139-50","June 2014","March 1, 2019","March 1, 2020","April 26, 2016",,"March 3, 2020","Institute of Clinical Dentistry, University of Bergen, Bergen, Hordaland, Norway",,"https://ClinicalTrials.gov/show/NCT02751125"
33,"NCT02384018","Mesenchymal Stem Cell and Islet Co-transplantation",,"Active, not recruiting","No Results Available","Chronic Pancreatitis|Diabetes","Biological: autologous mesenchymal stromal cell","C-peptide level after mixed meal tolerance test|Liver function, kidney function|The absence of severe hypoglycemic episodes","Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 1","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CCT-BMMSC15-001|5R21DK099696","December 2014","December 2026","December 2026","March 10, 2015",,"December 16, 2020","GI Surgery, Medical University of South Carolina, Charleston, South Carolina, United States",,"https://ClinicalTrials.gov/show/NCT02384018"
34,"NCT04432467","Fertility Restoration Using Autologous Mesenchymal Stem Cells",,"Enrolling by invitation","No Results Available","Chronic Endometritis|Uterus; Scar|Uterine Synechiae|Fallopian Tube Obstruction","Biological: Autologous mesenchymal stem cells|Other: standard treatment","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education","Female","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(Fertility)","October 1, 2020","September 30, 2021","September 30, 2021","June 16, 2020",,"December 8, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04432467"
35,"NCT02118519","Mesenchymal Stem Cells in Knee Cartilage Injuries",,"Completed","No Results Available","Articular Cartilage Disorder of Knee|Osteoarthritis, Knee","Biological: Autologous Mesenchymal Stem Cells","Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells.|Assessment of the articular cartilage healing in osteoarthritic patients through intra articular injection of Autologus Mesenchymal stem cell with/or without supported product.","University of Jordan","All","40 Years to 68 Years   (Adult, Older Adult)","Phase 2","13","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","KneeUJCTC","January 2014","August 2015","August 2015","April 21, 2014",,"February 24, 2016","Cell Therapy Center, Jordan University Hospital, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02118519"
36,"NCT01758055","Safety Study of Endobronchial Transplantation of Autologous Mesenchymal Stem Cells (MSCs) in Emphysema Patients",,"Unknown status","No Results Available","Emphysema","Biological: Autologous MSCs transplantation","forced vital capacity( FVC), forced expiratory volume(FEV1), FEV1/FVC|six minute walk test","Arda Kiani|Royan Institute|Masih Daneshvari Hospital","All","16 Years to 70 Years   (Child, Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","f-91-135","December 2012","December 2013","January 2014","December 31, 2012",,"December 31, 2012","Masih-Daneshvari Hospital, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01758055"
37,"NCT05086939","Multicenter Clinical Trial Comparing Treatment With Allogeneic Mesenchymal Cells Versus Autologous Mesenchymal Cells and Versus Active Control With Hyaluronic Acid in Patients With Knee Osteoarthritis (ARTROCELL)","ARTROCELL","Active, not recruiting","No Results Available","Knee Osteoarthritis","Drug: Autologous MSCs|Drug: Allogenic MSCs|Drug: Hyaluronic Acid","Range of motion.|Pain self-assessment.|Knee Osteoarthritis.|Functional response.|X-ray changes of osteoarthritis.|Radiological response using nuclear magnetic resonance imaging.|Perceived general well-being.|Feasibility assessment of a multicentre strategy production of both cell types with several Cell Production Units|Evaluation of presence of adverse events related with investigational medical product (IMP).","Fundación Instituto de Estudios de Ciencias de la Salud de Castilla y León|Spanish Clinical Research Network - SCReN|Hospital Universitari de Bellvitge|Institut d'Investigacions Biomèdiques August Pi i Sunyer|Instituto de Investigación Biomédica de Salamanca","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 3","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ARTROCELL|2019-002446-21","May 26, 2021","December 2025","December 2025","October 21, 2021",,"October 28, 2021","Centro Médico Teknon, Barcelona, Spain|Hospital Clinic, Barcelona, Spain|Hospital Clínico Universitario San Carlos, Madrid, Spain|Hospital Fundación Jiménez Díaz, Madrid, Spain|Hospital Gregorio Marañón, Madrid, Spain|Hospital Universitario Virgen de la Arrixaca, Murcia, Spain|Hospital Universitario Virgen de la Victoria, Málaga, Spain|Clínica Universidad de Navarra, Pamplona, Spain|Complejo Asistencial Universitario de Salamanca, Salamanca, Spain|Hospital Clínico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT05086939"
38,"NCT01919827","Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis","CMM/FPI","Completed","No Results Available","Idiopathic Pulmonary Fibrosis","Biological: Endobronchial infusion of adult mesenchymal stem cells|Biological: Autologous mesenchymal stem cells derived from bone marrow","Number of participants with adverse side effects.|Efficacy of the infusion of mesenchymal stem cells in stopping the fall in pulmonary function in patients with mild to moderate IPF","Clinica Universidad de Navarra, Universidad de Navarra","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1","17","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CMM/FPI","March 2013","May 1, 2018","May 1, 2018","August 9, 2013",,"May 3, 2018","Servicio de Neumología, Clínica Universidad de Navarra, Pamplona, Navarra, Spain|Servicio de Neumología. Hospital Universitario de Salamanaca, Salamanca, Spain",,"https://ClinicalTrials.gov/show/NCT01919827"
39,"NCT02292628","Study, Double Blind, Randomized, Comparing Two Groups to Evaluate the Safety and Efficacy of Autologous Mesenchymal Stem Cells From Adipose Tissue (CMMAd) in the Treatment of the Faecal Incontinence",,"Completed","No Results Available","Faecal Incontinence","Drug: Infusion of mesenchymal stem cells from adipose tissue|Other: Infusion of placebo","Number of Serious Adverse Events|Changes in the faecal incontinence diary|Anorectal manometry|Jorge-Wexner Score|Faecal Incontinence Quality of Life","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CMMAd/InFe/2011","October 2013","September 2017","September 2017","November 17, 2014",,"April 17, 2018","H. Juan Ramón Jiménez, Huelva, Spain|Fundación Jiménez Díaz, Madrid, Spain|Hospital Regional U de Málaga, Málaga, Spain|Hospital U Virgen del Rocio, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT02292628"
40,"NCT02045745","Clinical Trial Phase I/II Prospective, Open Nonrandomized for Treatmen of Postoperative Air Leak After Lung Resection in High Risk Patients Through the Administration of Mesenchymal Autologous Cells","CSM/FAP/2012","Unknown status","No Results Available","Postoperative Air Leaks in Risk Patients","Biological: Implantation of autologous mesenchymal stem cells (CSM) expanded ""in vitro"" and administered directly into the lung suture line","Safety of the procedure|Analyze the efficacy of the procedure","Red de Terapia Celular|Castilla y León Hematology and hemotherapy Foundation|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Spanish National Health System","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/FAP/2012|2013-000535-27","December 2013","December 2017","December 2017","January 27, 2014",,"March 30, 2017","University Clinical Hospital of Salamanca, Salamanca, Salamanca/Castilla León, Spain",,"https://ClinicalTrials.gov/show/NCT02045745"
41,"NCT00781872","Mesenchymal Stem Cells for the Treatment of MS",,"Completed","No Results Available","Multiple Sclerosis","Biological: Injection of autologous bone marrow derived mesenchymal stem cells","Safety of one or multiple intrathecaland intravenous injections of autologous MSC in Multiple sclerosis|Clinical effects in terms of changes in the expended disability status scale (EDSS) at 3-6 month intervals|Immunological effects of treatment with MSC in MS","Hadassah Medical Organization","All","35 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MS22MSC-HMO-CTIL","October 2006","December 2009","December 2009","October 29, 2008",,"March 29, 2021",,,"https://ClinicalTrials.gov/show/NCT00781872"
42,"NCT02166489","Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease",,"Completed","No Results Available","Chronic Renal Failure|Polycystic Kidney Disease","Biological: Intravenous injection autologous mesenchymal stem cells","Mass formation|Glomerular Filtration Rate (GFR)","Royan Institute","All","18 Years to 60 Years   (Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Kidney-003","March 2014","December 2015","January 2016","June 18, 2014",,"January 5, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02166489"
43,"NCT03778333","Mesenchymal Stem Cells for Progressive Multiple Sclerosis_Sweden",,"Completed","No Results Available","Autologous Mesenchymal Stem Cells|Multiple Sclerosis","Biological: Autologous mesenchymal stem cells","To evaluate number of participants with an adverse event related to the treatment.|To evaluate effects on MS disease activity measured by cumulative number of MRI T2 lesions.|To evaluate effects on MS disease activity measured by change in EDSS (expanded disability status scale).|To evaluate effect on peripheral blood immune cell populations.","Karolinska Institutet","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-progressive MS","December 1, 2012","December 2016","December 31, 2016","December 19, 2018",,"December 19, 2018","Karolinska Institute, Karolinska University Hospital Solna, Stockholm, Sweden|Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT03778333"
44,"NCT03799718","Safety and Efficacy of Repeated Administration of NurOwn (MSC-NTF Cells) in Participants With Progressive MS",,"Completed","No Results Available","Multiple Sclerosis, Chronic Progressive","Biological: NurOwn (MSC-NTF cells)","Incidence of treatment-emergent adverse events|Timed 25-foot walking speed or 9-Hole Peg Test - change from baseline.|Number of participants with changes in neurotrophic factors (such as Vascular endothelial growth factor and Hepatocyte growth factor) in the cerebrospinal fluid (CSF) following NurOwn® transplantation","Brainstorm-Cell Therapeutics","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BCT-101-US","March 13, 2019","March 11, 2021","March 30, 2021","January 10, 2019",,"September 1, 2021","University of Southern California, Los Angeles, California, United States|Stanford University School of Medicine, Redwood City, California, United States|The Mount Sinai Hospital, New York, New York, United States|Cleveland Clinic, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03799718"
45,"NCT03477942","Impact of Mesenchymal Stem Cells in Knee Osteoarthritis",,"Recruiting","No Results Available","Musculoskeletal Pain|Knee Osteoarthritis|Cartilage Injury|Cartilage Degeneration","Biological: Autologous Mesenchymal Stem Cells","Primary Endpoint: Incidence of treatment emergent major adverse events directly related to MSC injection|Secondary Endpoint: Development of Pain following injection based on Visual Analog Scale scoring.|Secondary Endpoint: Clinical Evaluation of Injection based on functional outcomes scoring using KOOS, IKDC and Lysholm scoring scales.|Secondary Endpoint: Reparative potential of intra-articular MSCs based on improvement in cartilage quality using MRI.","University Hospitals Cleveland Medical Center|Case Western Reserve University","All","18 Years to 60 Years   (Adult)","Phase 1","16","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","JV 1.1","October 1, 2018","June 2022","July 2022","March 27, 2018",,"September 10, 2021","University Hospital Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03477942"
46,"NCT01895439","Safety and Efficacy Study of Autologus Bone Marrow Mesenchymal Stem Cells in Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Biological: Autologous Mesenchymal Stem Cells","The number of patients with any relevant side effects observed|Assessing the therapeutic benefits of the injected Autologous Mesenchymal Stem Cells by Magnetic Resonance Imaging (MRI) and ophthalmological tests.","University of Jordan","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSUJCTC","October 2012","February 2016","February 2016","July 10, 2013",,"May 2, 2017","Cell Therapy Center, Jordan University Hospital, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT01895439"
47,"NCT02057211","Mesenchymal Stem Cells to Intervene in the Development of Type 1 Diabetes: a Blinded Randomized Study",,"Terminated","No Results Available","Type 1 Diabetes Mellitus","Biological: autologous mesenchymal stem cell transplantation|Procedure: sham transplantation of mesenchymal stem cells","∆-change of C-peptide Area Under the Curve (AUC) (0-120 min) for a mixed meal tolerance test at two year follow-up when compared to pre-treatment values at enrolment.","Uppsala University Hospital","All","18 Years to 40 Years   (Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Prevention","AS Dnr2013/195","April 2014","November 2017","November 2017","February 7, 2014",,"November 6, 2020","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT02057211"
48,"NCT05095532","Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT",,"Not yet recruiting","No Results Available","Chronic Pancreatitis|Mesenchymal Stem Cells","Biological: Bone marrow-derived mesenchymal stem cells|Other: Placebo","Change in Islet Cell Function|Change in HbA1C levels from baseline to 12 months.|Proportion of insulin-independent patients following IAT|Average daily insulin requirement|Beta cell function as assessed by beta-score","Medical University of South Carolina|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","All","18 Years and older   (Adult, Older Adult)","Phase 1","42","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","Pro00099487|R01DK126454","December 1, 2021","June 30, 2026","June 30, 2026","October 27, 2021",,"November 23, 2021",,,"https://ClinicalTrials.gov/show/NCT05095532"
49,"NCT01854125","Autologous Mesenchymal Stem Cell Transplantation in Cirrhosis Patients With Refractory Ascites",,"Unknown status","No Results Available","Immune Function in Blood|Liver Function in Blood|Variation of Ascites|Characters of Quality of Life|Child-Pugh Score","Biological: autologous bone marrow mesenchymal stem cells transplantation|Biological: autologous bone marrow msenchymal stem cells transplantation","change in immune function,liver function in blood","Nanjing PLA General Hospital","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NanjingPLAGH1|Jinling 01","May 2013","January 2014",,"May 15, 2013",,"May 15, 2013","Jinling Hospital, Nanjing, Jiangsu, China",,"https://ClinicalTrials.gov/show/NCT01854125"
50,"NCT03014219","Phase 1 Crohn's Pediatric Sub-study of MSC AFP",,"Withdrawn","No Results Available","Perianal Fistula","Drug: Only 1 arm: treatment with MSC-AFP","Number of Subjects with any Adverse Events that are related to study drug|Number of Subjects with healing in response to the study drug treatment","William A. Faubion, M.D.|Mayo Clinic","All","12 Years to 17 Years   (Child)","Phase 1","0","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-005574","July 2017","July 2019","July 2020","January 9, 2017",,"July 6, 2017","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03014219"
51,"NCT04326985","RCT Mesenchymal Stem Cells Versus Hyaluronic Acid in OA Knee):","MSC","Completed","No Results Available","Osteoarthritis, Knee","Biological: Autologous Mesenchymal Stem Cells Treatment (MSCs)|Drug: Hyaluronic acid (HA)","Knee Society Score|Knee Society Function Score|Magnetic resonance image (MRI) and X-ray assessment|Health related quality of life score (HRQoL) - SF36|Western Ontario and McMaster Osteoarthritis Index (WOMAC)|Visual Analogic Scale (VAS) pain evaluation","Chinese University of Hong Kong","All","18 Years to 65 Years   (Adult, Older Adult)","Early Phase 1","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","OA MSC Study protocol v 1.4","January 31, 2015","January 30, 2019","February 28, 2019","March 30, 2020",,"May 18, 2020","Department of Orthopaedics & Traumatology, Hong Kong, Hong Kong",,"https://ClinicalTrials.gov/show/NCT04326985"
52,"NCT02495766","Autologous Mesenchymal Stromal Cells for Multiple Sclerosis","EMMES","Completed","No Results Available","Relapsing-Remitting Multiple Sclerosis|Secondary Progressive Multiple Sclerosis","Drug: XCEL-MC-ALPHA|Drug: Placebo","Adverse events|Cumulative number of MRI Gd-enhancing lesions|Multiple Sclerosis Outbreaks|Expanded Disability Status Scale (EDDS) score|Cumulative number of lesions visualized on T2 sequence","Banc de Sang i Teixits|Vall d'Hebron Research Institute (VHIR)","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","8","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","XCEL-MS-02","May 11, 2015","November 27, 2017","November 15, 2018","July 13, 2015",,"January 21, 2020","Hospital Vall Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02495766"
53,"NCT04146519","Parkinson's Disease Therapy Using Cell Technology",,"Recruiting","No Results Available","Transplantation:Mesenchymal Stem Cell Transplantation","Biological: Autologous mesenchymal stem cells|Other: Placebo","motor symptoms change|non-motor symptoms change|sleep quality change|daytime sleepiness change|signs of depression change","Belarusian Medical Academy of Post-Graduate Education","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 2|Phase 3","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20171292","July 1, 2017","December 1, 2021","December 31, 2021","October 31, 2019",,"March 3, 2021","the Belarusian Medical Academy of Postgraduate Education, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04146519"
54,"NCT02062931","Autologous Mesenchymal Stem Cells Transplantation In Women With Premature Ovarian Failure",,"Unknown status","No Results Available","Premature Ovarian Failure","Biological: Stem Cell Preparation and Injection","Improvement of Cases","Sayed Bakry|Cairo University|Affiliated Hospital to Academy of Military Medical Sciences|Al-Azhar University","Female","20 Years to 40 Years   (Adult)","Phase 1|Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AzharU223101547","March 2012","May 2015","November 2016","February 14, 2014",,"May 13, 2014","Al-Azhar University hospitals and Al Azhar Regenerative Medicine International Center (ARMIC), Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02062931"
55,"NCT02440074","Lumbar Degenerative Disc Disease Treatment With Bone Marrow Autologous Mesenchymal Stem Cells (MSV)","MSV-DISC","Withdrawn","No Results Available","Degenerative Disc Disease","Other: Autologous bone marrow mesenchymal stem cells","Pain relief","Red de Terapia Celular|Instituto de Salud Carlos III|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Eudra-CT2008-001191-68|MSV-DISC-2008-01","June 2011","November 2012","December 2012","May 12, 2015",,"May 12, 2015",,,"https://ClinicalTrials.gov/show/NCT02440074"
56,"NCT02482194","Autologous Mesenchymal Stem Cells Transplantation for Spinal Cord Injury- A Phase I Clinical Study",,"Completed","No Results Available","Spinal Cord Injury","Biological: mesenchymal stem cells","Number of adverse events|Sensory and motor strength|Functional Independence|Muscle strength assessment","National Institute of Blood and Marrow Transplant (NIBMT), Pakistan|Armed Forces Institute of Regenerative Medicine","All","18 Years to 50 Years   (Adult)","Phase 1","9","Other|U.S. Fed","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AFBMTC-SCI-2013","June 2013","January 2016","March 2016","June 26, 2015",,"June 29, 2016","Armed Forces Bone Marrow Transplant Centre, Rawalpindi, Pakistan",,"https://ClinicalTrials.gov/show/NCT02482194"
57,"NCT04064879","The Use of Autologous Mesenchymal Stem Cell Preparation for Treatment of Refractory Migraine",,"Suspended","No Results Available","Chronic Migraine, Headache","Other: AD-SVF","Adverse Event Reporting|Headache Diary|Headache Impact Test (HIT-6)","Neurological Associates of West Los Angeles|Cell Surgical Network Inc.","All","18 Years and older   (Adult, Older Adult)","Not Applicable","10","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICSS-2018-014","August 16, 2018","August 15, 2022","August 16, 2023","August 22, 2019",,"March 4, 2021","Neurological Associates of West Los Angeles, Santa Monica, California, United States",,"https://ClinicalTrials.gov/show/NCT04064879"
58,"NCT00875654","Intravenous Stem Cells After Ischemic Stroke","ISIS","Completed","No Results Available","Ischemia|Stroke","Genetic: Autologous mesenchymal stem cells","feasibility and tolerance of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Clinical and functional effects of the intravenous injection of autologous mesenchymal stem cells in patients with carotid ischemic stroke|Determination of the most effective dose of stem cells|To define the best criteria for a future trial (phase III)|To define the best target population for a future study","University Hospital, Grenoble|Commissariat A L'energie Atomique|Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","31","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DCIC 06 25","August 2010","October 20, 2017","October 20, 2017","April 3, 2009",,"November 1, 2017","Neuroradiology/MRI, University Hospital of Grenoble, Grenoble, France|Stroke Unit, University Hospital of Grenoble, Grenoble, France|Tissular and cell therapy unit, UniversityHospitalof Grenoble, Grenoble, France",,"https://ClinicalTrials.gov/show/NCT00875654"
59,"NCT03827096","Utilization of Autologous Mesenchymal Cells in Posterolateral Spinal Fusion in Degenerative Spine Disease","AMSC-DSD-001","Terminated","No Results Available","Degenerative Disc Disease","Drug: Suspension of human autologous MSC 3P in 1.5 ml","Safety: To demonstrate absence of complications at the site of spinal fusion|Efficacy: To assess the quality of life determined by Oswestry Questionnaire.|Efficacy: To assess the quality of spinal fusion by X-ray imaging|Efficacy: To assess the quality of spinal fusion measured by computed tomography (CT).","Bioinova, s.r.o.|Department of Spine Surgery, University Hospital Motol, Prague, Czech Republilc","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-DSD-001","August 27, 2013","December 14, 2016","December 14, 2016","February 1, 2019",,"January 18, 2020",,,"https://ClinicalTrials.gov/show/NCT03827096"
60,"NCT01461720","Intravenous Autologous Mesenchymal Stem Cells Transplantation to Treat Middle Cerebral Artery Infarct",,"Unknown status","No Results Available","Middle Cerebral Artery Infarction","Other: Standard medical care|Biological: Autologous bone marrow-derived mesenchymal stem cells","Change in NIH Stroke Scale|Change in Barthel Index|Change in modified Rankin Scale|Change in size of infarct based on brain MRI stroke sequences|Change in Stroke Specific Quality of Life Scale|Change in Stroke Impact Scale","National University of Malaysia|Cytopeutics Sdn. Bhd.","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FF-115-2011","March 2012","December 2015","March 2016","October 28, 2011",,"April 1, 2015","UKM Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01461720"
61,"NCT04351932","Bone Marrow Versus Adipose Autologous Mesenchymal Stem Cells for the Treatment of Knee Osteoarthritis",,"Not yet recruiting","No Results Available","Osteo Arthritis Knee","Biological: bone marrow mesenchymal stem cells|Biological: Adipose Mesenchymal stem cells|Biological: bone marrow & adipose mesenchymal stem cells injection","knee pain assessed by Visual Analogue Scale.|knee function assessed by WOMAC (Wester Ontario McMaster Osteoarthritis Index). quosteionary.|Quantitative T2-Mapping Evaluation of Changes in Cartilage Matrix","Universidad Catolica Santiago de Guayaquil|Maastricht University Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 3","54","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UCSantiagodeGuayaquil001","June 7, 2020","June 7, 2021","September 7, 2021","April 17, 2020",,"April 17, 2020","Omnihospital, Guayaquil, Guayas, Ecuador","""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/32/NCT04351932/Prot_SAP_000.pdf","https://ClinicalTrials.gov/show/NCT04351932"
62,"NCT03361631","Intracavernous Injection of Autologous Mesenchymal Stem Cells in the Treatment of Erectile Dysfunction Resistant to Oral Treatment in Patients With Type I Diabetes","MESERIC","Unknown status","No Results Available","Erectile Dysfunction|Stem Cells|Diabetes Mellitus, Type 1","Drug: Autologous Bone Marrow derived Mesenchymal Stem Cells","To evaluate the occurrence of clinical adverse event (tolerance) to intracavernous injection of autologous MSC in patients 18 to 50 years of age with complicated type 1 diabetes mellitus with erectile dysfunction refractory to oral treatment.|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the clinical score IIEF-5 (International Index of Erectile Function-5)|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of the EHS score|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of arterial insufficiency|Evaluation of the efficacy of autologous MSC intracavernous injections at different doses with evaluation of venous insufficiency (venous leakage)|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the number of bone marrow extraction|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the quality of the bone marrow samples|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the quality of the cell culture of the marrow of diabetic patients|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the cell transport delay (between preparation and injection)|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the patient recruitment rate calculated by the ratio between the number of participants and the number of eligible patients|Evaluation of the feasibility of the autologous MSC intracavernous injection protocol by the Injection rate actually achieved","Central Hospital, Nancy, France","Male","18 Years to 50 Years   (Adult)","Phase 1","13","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PHRCI2016/MESERIC-EL OSTA/NK","June 30, 2018","July 30, 2018","December 31, 2019","December 5, 2017",,"December 5, 2017",,,"https://ClinicalTrials.gov/show/NCT03361631"
63,"NCT01399749","Autologous Mesenchymal Stem Cells vs. Chondrocytes for the Repair of Chondral Knee Defects","ASCROD","Unknown status","No Results Available","Articular Cartilage Lesion of the Femoral Condyle","Other: Implantation of autologous cells","Hyaline cartilage production for chondral knee lesions repair|Efficacy: Clinical evolution|Efficacy: Functional evolution|Efficacy: Histological evaluation|Efficacy: Radiological evaluation|Safety: Adverse events|Safety: Acute inflammatory events","Fundacion para la Investigacion Biomedica del Hospital Universitario la Paz","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HLPTRA-2009-01|2009-016628-29","September 2011","June 2012","June 2012","July 22, 2011",,"July 22, 2011","La Paz University Hospital. Orthopedic Surgery and Traumatology Department, Knee Unit; Cell Therapy Laboratory., Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01399749"
64,"NCT01720888","Intracoronary Autologous Mesenchymal Stem Cells Implantation in Patients With Ischemic Dilated Cardiomyopathy",,"Unknown status","No Results Available","Ischemic Dilated Cardiomyopathy","Other: BM-MSCs","Change in LV ejection fraction as measured by echocardiogram and cardiac MRI after implantation|Changes in functional status|Improvement in other LV parameters as assessed by echocardiogram and cardiovascular magnetic resonance(CMR).|Resolution of scar tissue volume/area on cardiac MRI|Change in serum N Terminal-pro B type natriuretic peptide(NT-proBNP)level|Freedom from major adverse cardiac events as defined by myocardial infarction, hospitalization for angina, myocardial infarction or heart failure, or death (all cause of mortality).","National University of Malaysia|Cytopeutics Sdn. Bhd.","All","35 Years to 75 Years   (Adult, Older Adult)","Phase 2","80","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ERGS/1/2011/SKK/UKM/02/72","July 2012","December 2015","December 2015","November 2, 2012",,"April 16, 2015","UKM Medical Centre, Cheras, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01720888"
65,"NCT00250302","Autologous Implantation of Mesenchymal Stem Cells for the Treatment of Distal Tibial Fractures",,"Completed","No Results Available","Tibial Fracture","Procedure: autologous mesenchymal stem cells implantation","Safety|Number of patients reaching clinical union of fracture","Hadassah Medical Organization|Teva Branded Pharmaceutical Products R&D, Inc.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-01-HMO-CTIL","April 2009","April 2011","April 2011","November 8, 2005",,"April 28, 2011","Hadassah Medical Organizaton, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT00250302"
66,"NCT02166021","Clinical Efficacy of Autologous Mesenchymal Bone Marrow Stem Cells in Active & Progressive Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis (MS)","Biological: Mesenchymal stem cells","Safety Assessment|Neurological efficacy|EDSS score|Ambulation score|Functional scores|Single injection vs. repeated MSCs injection|Relapse rate|T2-weighted flair lesions load in MRI|Total brain volume in MRI|Gadolinium enhancing lesions in MRI|Functional MRI|25-feet timed walking|9-hole peg test|Paced Auditory Serial Addition Test (PASAT)|Cognitive function: Controlled Oral Word Association Test (COWAT)|Optical coherence tomography (OCT)|Immunology","Dimitrios Karussis|Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","48","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","MSC-MS-001-IL","January 29, 2015","June 15, 2018","December 24, 2018","June 18, 2014",,"August 1, 2019","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT02166021"
67,"NCT04228666","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Alzheimer's Disease",,"Withdrawn","No Results Available","Alzheimer Disease","Biological: HB-adMSCs","Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|Tumor necrosis factor-alpha|Interleukin-1|Interleukin-6|C-reactive protein|Amyloid beta 40|Amyloid beta 42|Volumetric changes in hippocampus, ventriculus, and whole brain|Mini Mental Status Exam|Alzheimer's disease Cooperative Study Activities of Daily Living|Quality of Life Enjoyment and Satisfaction Questionnaire|Altoida Neuro Motor Index|Clinical Dementia Rating Questionnaire","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","50 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBALZ01","March 1, 2020","February 1, 2022","February 1, 2022","January 14, 2020",,"July 7, 2021","Clinical Trial Network, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04228666"
68,"NCT02359929","BMT Autologous MSCs for GvHD",,"Completed","No Results Available","Graft Versus Host Disease|Acute Graft Versus Host Disease|Chronic Graft Versus Host Disease","Biological: Autologous mesenchymal stromal cells (MSCs)","Safety and Tolerability of EPIC MSC2014-002 based on dose limiting toxicities (DLTs)|Overall Response Rate for acute GVHD subjects|Overall Response Rate for chronic GVHD subjects|Transplant-related mortality|Incidence of Relapse|Disease-free survival|Overall-survival","Emory University|CURE Foundation","All","12 Years and older   (Child, Adult, Older Adult)","Phase 1","11","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00076372","January 2015","June 15, 2020","January 11, 2021","February 10, 2015",,"March 4, 2021","Children's Healthcare of Atlanta/Emory University, Atlanta, Georgia, United States",,"https://ClinicalTrials.gov/show/NCT02359929"
69,"NCT03007576","Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stromal Cell Product (RegStem)",,"Completed","No Results Available","Osteoarthritis,Knee","Biological: RegStem","Safety of RegStem by incidence of adverse events and changes in physical examinations, vital signs and the results of clinical lab tests.|Clinical assessment of International Knee Documentation Committee (IKDC) score|Clinical assessment of Knee injury and Osteoarthritis Outcome Score (KOOS)|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of knee X-ray|Clinical assessment of knee MRI","EMO Biomedicine Corporation|Far Eastern Memorial Hospital","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","12","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EMOCT01","August 1, 2017","August 31, 2019","August 31, 2019","January 2, 2017",,"November 13, 2019","Far Eastern Memorial Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT03007576"
70,"NCT01436058","Side Effects of Autologous Mesenchymal Stem Cell Transplantation in Ankle Joint Osteoartritis",,"Completed","No Results Available","Osteoarthritis","Biological: mesenchymal stem cell","safety|pain|physical function|defect","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-007","September 2010","September 2011","September 2011","September 19, 2011",,"September 19, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01436058"
71,"NCT04290182","A Study of Local Administration of Autologous Mesenchymal Stromal Cells in Dysphonic Patients With Vocal Fold Scarring",,"Recruiting","No Results Available","Hoarseness|Dysphonia|Aphonia|Vocal Fold; Scar","Biological: MSC-KI-PL-204","Safety and tolerability of treatment|Assessment of VF function|Assessment of subjective voice ratings|Assessment of tissue metabolism and healing","Karolinska University Hospital|Swedish Foundation for Strategic Research","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019-06160 and 5.1-2019-92069","March 2020","June 2022","June 2023","February 28, 2020",,"February 28, 2020","Karolinska Trial Alliance, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT04290182"
72,"NCT04063215","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy",,"Recruiting","No Results Available","Traumatic Brain Injury","Biological: HB-adMSCs","Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total Bilirubin|White blood cell|Red blood cell|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basos|Absolute Neutrophils|Absolute Lymphs|Absolute monocytes|Absolute Eos|Absolute Basos|Immature Granulocytes|Absolute Immature Granulocytes|Platelets|Prothrombin Time|INR|Urine Pregnancy|Whole brain MRI|PET/DT-MRI|Glasgow Outcome Score|Galveston Orientation and Amnesia Test|Rivermead Post-Concussion Symptoms Questionnaire|Automated Neuropsychological Assessment Metrics|Verbal Selective Reminding Test|Verbal Fluency Test|Stroop|Interleukin 1-alpha|Interleukin 4|Tumor necrosis factor alpha|Interleukin 6|Interleukin 10","Hope Biosciences|The University of Texas Health Science Center, Houston","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","24","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBTBI01","January 1, 2020","August 29, 2021","August 29, 2021","August 21, 2019",,"July 6, 2021","Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04063215"
73,"NCT01777646","Autologous Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in Patients With Amyotrophic Lateral Sclerosis (ALS)",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF","Safety evaluation and tolerability of a single treatment administration in an escalating-dose of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale|Changes in muscle strength grading (MVIC) by muscle chart|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Change in upper and lower extremities circumference (cm)|Changes in EMG parameters","Brainstorm-Cell Therapeutics|Hadassah Medical Organization","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 2","14","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-NTF-002-HMO-CTIL","December 2012","September 2014","September 2015","January 29, 2013",,"March 8, 2018","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01777646"
74,"NCT02035514","Phase I-II Clinical Trial With Autologous Bone Marrow Derived Mesenchymal Stem Cells for the Therapy of Multiple Sclerosis",,"Completed","No Results Available","Relapsing Remitting Multiple Sclerosis (RRMS)","Biological: Bone marrow autologous mesenchymal stem cells transplantation","Change from baseline in safety|Change from baseline in effectiveness by MRI|Feasibility|Change in clinical efficacy|Change in Quality of life|Immunology|Axonal effect","Germans Trias i Pujol Hospital|Ministerio de Sanidad, Servicios Sociales e Igualdad","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","CELLTRiMS|2010-024081-21","December 2013","July 2016","July 2016","January 14, 2014",,"December 15, 2016","Germans Trias i Pujol Hospital, Badalona, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02035514"
75,"NCT01700920","PHASE II CLINICAL TRIAL Prospective, Open, Nonrandomized Treatment of Osteonecrosis of the Femoral Head by the Administration of Autologous Mesenchymal Stem Cells","CSM/ON/2011","Completed","No Results Available","Osteonecrosis of the Femoral Head","Procedure: bone marrow aspirate",,"Red de Terapia Celular|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Spanish National Health System","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","3","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/ON/2011","July 2012","December 2015","December 2015","October 4, 2012",,"March 30, 2017","University Hospital of Salamanca, Salamanca, Castilla y León, Spain",,"https://ClinicalTrials.gov/show/NCT01700920"
76,"NCT01429012","Treatment of Atrophic Nonunion Fractures by Autologous Mesenchymal Stem Cell Percutaneous Grafting",,"Withdrawn","No Results Available","Nonunion Fracture","Biological: Mesenchymal Stem Cells|Other: Culture medium without MSC.","Safety of Mesenchymal Stem Cells injection in nonunion fractures.|Proportion of patients receiving Mesenchymal Stem Cells that develop a partial or complete callus at 6 and 12 months, compared to patients receiving placebo.|Proportion of patients receiving Mensechymal Stem Cells that develop a partial or complete callus at 2, 3, 4, 8 and 10 months, compared to patients receiving placebo|Timing of development of a partial or complete callus in the 2 groups.|Patient evaluation of pain and global satisfaction.|Proportion of patients achieving different degrees of functional success.|Incidence of adverse events and severe adverse events in the 2 groups.|Evaluation of early homing of Mesenchymal Stem Cells.|Value of [18F]-NaF PET scans for early prediction of the onset of the bone healing process.","University of Liege","All","18 Years and older   (Adult, Older Adult)","Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TJT1101","November 2012","November 2016","November 2016","September 5, 2011",,"May 12, 2021","Liège University Hospital, Liège, Belgium",,"https://ClinicalTrials.gov/show/NCT01429012"
77,"NCT04078308","Mesenchymal Stem Cells Transplantation in Newly Diagnosed Type-1 Diabetes Patients","MSCTXT1DM","Unknown status","No Results Available","Diabetes Mellitus|Diabetes Mellitus, Type 1|Diabetes Mellitus, Insulin-Dependent","Biological: Intravenous Injection of autologous mesenchymal stem cells|Other: Intravenous injection of placebo","Number of participants with treatment-related adverse events as assessed by CTCAE v5.0|Change from baseline number of hypoglycemic Unawareness episodes at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline Fasting Blood Sugar (FBS) at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline C-peptide at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline HbA1C at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline 2-hour postprandial blood glucose at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline daily dose of exogenous insulin injected by patients (IU/kg/day) at 12 Months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from baseline Lability Index (LI) at 12 Months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline SF-36 Quality of life (QOL) questionnaire score at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Change from Baseline Diabetes Specific Quality of life (DQOL) questionnaire score at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Changes from baseline Autoantibodies levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells|Changes from baseline serum cytokines levels in patients' blood at 12 months after intravenous transplantation of autologous bone marrow derived Mesenchymal Stem Cells","Royan Institute|Tehran University of Medical Sciences|Iranian Stem Cell Council","All","8 Years to 40 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","RI-SCBT-94000019|IRCT2016070428786N1|94000019|REP-441","July 6, 2015","September 26, 2019","April 1, 2020","September 6, 2019",,"September 6, 2019","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT04078308"
78,"NCT02239393","Safety and Efficacy of Intravenous Autologous Mesenchymal Stem Cells for MS: a Phase 2 Proof of Concept Study","MESCAMS","Completed","No Results Available","Multiple Sclerosis","Biological: Mesenchymal Stem Cells","Safety|Efficacy","Ottawa Hospital Research Institute","All","18 Years to 50 Years   (Adult)","Phase 2","31","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","20140368","June 2015","December 2019","December 2019","September 12, 2014",,"March 4, 2020","Health Sciences Centre, Winnipeg, Manitoba, Canada|Ottawa Hospital - General Campus, Ottawa, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02239393"
79,"NCT02315027","Mesenchymal Stem Cell Therapy in Multiple System Atrophy",,"Active, not recruiting","No Results Available","MSA","Biological: Autologous Mesenchymal Stem Cells","Adverse event frequency (by severity, type, attribution, and intervention dose).|Rate of change of Unified Multiple System Atrophy Rating Scale (UMSARS) I score from baseline to 12 months (or last available date), compared with placebo limb of Rifampicin trial (historical control cohort).|Rate of change from baseline to 12 months (or last available date) in UMSARS II score.|Rate of change from baseline to 12 months (or last available date) in UMSARS total score.|Rate of change in COMPASS-select score from baseline to 12 months.|Change in CASS score and thermoregulatory sweat test (TST) % from baseline to 12 months.|MRI morphometric changes using dedicated algorithms to evaluate rate of atrophy of defined areas of brain from baseline to 12 months.|Change in CSF biomarkers from baseline to 2 months.","Mayo Clinic|Food and Drug Administration (FDA)|National Institute of Neurological Disorders and Stroke (NINDS)","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other|U.S. Fed|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-005950|R01FD004789|R01NS092625","October 2012","March 2024","March 2024","December 11, 2014",,"September 14, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02315027"
80,"NCT02230514","Mesenchymal Stromal Cells for the Treatment of Non-union Fractures of Long Bones",,"Completed","No Results Available","Atrophic Nonunion of Fracture","Drug: XCEL-MT-OSTEO-ALPHA|Other: autologous iliac crest|Procedure: Surgery","Efficacy assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures by imaging procedures|Safety assessment of XCEL-MT-OSTEO-ALPHA in non-union fractures|Efficacy assessment by quality of life test","Banc de Sang i Teixits|Hospital ASEPEYO Sant Cugat","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","19","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XCEL-PSART-01|2013-005025-23","November 20, 2014","March 5, 2019","December 20, 2019","September 3, 2014",,"April 12, 2021","Hospital ASEPEYO Sant Cugat, Sant Cugat, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02230514"
81,"NCT01676441","Safety and Efficacy of Autologous Mesenchymal Stem Cells in Chronic Spinal Cord Injury",,"Terminated","No Results Available","Spinal Cord Injury","Drug: cellgram-spine","Compared change of Motor Score of the American Spinal Injury Association (ASIA) scale|Sensory score of the American Spinal Injury Association (ASIA) scale|Electrophysiological change (Motor Evoked Potentials-MEP, Somatosensory Evoked Potentials-SSEP)|MRI and Diffusion Tensor Imaging of spinal cord","Pharmicell Co., Ltd.","All","16 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2|Phase 3","20","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cerecellgram-spine","August 2008","March 4, 2021","March 4, 2021","August 31, 2012",,"March 23, 2021","Asan medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01676441"
82,"NCT01741090","The Effectiveness and Safety for Mesenchymal Stem Cell for Alcoholic Liver Cirrhosis",,"Unknown status","No Results Available","Alcoholic Liver Cirrhosis","Biological: mesenchymal stem cell injection","The improvement of Liver Histologic grade|The evaluation of hepatic dendritic cells activity by immunohistochemistry|Liver fibrosis quantitative analysis using Hydroxyproline contents in liver tissue|Real-Time Polymerase Chain Reaction for relative mRNA expression of TGF-beta, collagen, procollagen, MMP2 or 9|Hepatic venous pressure gradient(HVPG)|Hepatic vein arrival time using microbubble contrast enhanced ultrasonography|Liver stiffness measurement with transient elastography|Child-Pugh score|MELD score","Yonsei University","All","20 Years to 60 Years   (Adult)","Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CR109021","September 2009","June 2013","August 2013","December 4, 2012",,"December 10, 2012","Yonsei University Wonju College of Medicine Wonju Christian Hospital, Wonju, Kangwon-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01741090"
83,"NCT03220243","Stem Cell Coated Fistula Plug in Patients With Crohn's RVF",,"Completed","No Results Available","Fistula Vagina|Crohn Disease","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","Mayo Clinic","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-002892","October 19, 2017","September 20, 2020","September 20, 2020","July 18, 2017",,"October 30, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03220243"
84,"NCT02807389","Stem Cell Fistula Plug in Post Surgical Leak Fistulas",,"Completed","No Results Available","Surgical Leak Fistula","Drug: MSC Fistula Plug","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Incidence of Fistula Closure","Mayo Clinic","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-004326","March 14, 2017","April 2, 2019","April 2, 2019","June 21, 2016",,"April 23, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02807389"
85,"NCT01716481","The STem Cell Application Researches and Trials In NeuroloGy-2 (STARTING-2) Study","STARTING-2","Unknown status","No Results Available","Stroke, Ischemic","Other: Mesenchymal stem cell","Categorical shift in modified Rankin scale (mRS)|Change of National Institutes of Health stroke scale (NIHSS)|Early improvement of National Institutes of Health stroke scale (NIHSS)|Dichotomized modified Rankin scale (mRS)|Change of modified Rankin scale (mRS)|Dichotomized modified Barthel index (mBI)|Change of modified Barthel index (mBI)|Change of gross motor function|Change of Fine motor function|Change of Mobility|Change of mini-mental status exam (MMSE)|Change of quality of life|Safety outcome","Samsung Medical Center|Pharmicell Co., Ltd.","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 3","60","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2011-10-047","November 2012","December 2017","December 2017","October 29, 2012",,"April 26, 2017","Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01716481"
86,"NCT01513694","Clinical Trial Based on the Use of Mesenchymal Stem Cells From Autologous Bone Marrow in Patients With Lumbar Intervertebral Degenerative Disc Disease",,"Completed","No Results Available","Intervertebral Disc Disease","Procedure: Instrumented posterolateral arthrodesis",,"Red de Terapia Celular|Haematology Service,University Hospital of Salamanca, MªConsuelo del Cañizo Fernández-Roldán|Spanish National Health System","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/Fusión/2009","January 2010","May 4, 2017","May 4, 2017","January 20, 2012",,"June 2, 2017","Trauma Service. Hospital Universitario de Salamanca, Salamanca, Castilla-León, Spain",,"https://ClinicalTrials.gov/show/NCT01513694"
87,"NCT03209700","Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas","MSC-AFP","Completed","No Results Available","Perianal Fistula|Cryptoglandular Perianal Fistula|Crohn's Perianal Fistula","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","William A. Faubion, M.D.|Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-004503","July 20, 2017","December 10, 2019","December 10, 2019","July 6, 2017",,"January 3, 2020","Mayo Clinic in Minnesota, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03209700"
88,"NCT02589119","Stem Cell Fistula Plug in Cryptoglandular Perianal Fistulas (MSC-AFP)",,"Completed","No Results Available","Perianal Fistula|Cryptoglandular Perianal Fistula","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity).|Number of participants with response to the treatment regarding potential cessation of drainage from their fistula.","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-003200","January 2016","September 2019","September 2019","October 28, 2015",,"December 6, 2019","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02589119"
89,"NCT01068951","Treatment of Patients With Newly Onset of Type 1 Diabetes With Mesenchymal Stem Cells",,"Completed","No Results Available","Type 1 Diabetes","Biological: Mesenchymal stem cells","The concentration of stimulated c-peptide at 90 minutes after the start of a mixed meal tolerance test at 365+/-10 days following the infusion or not with mesenchymal stem cells","Uppsala University Hospital","All","18 Years to 40 Years   (Adult)","Not Applicable","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","AS2010-0180","June 2010","September 2013","September 2013","February 17, 2010",,"February 5, 2014","Uppsala University Hospital, Uppsala, Sweden",,"https://ClinicalTrials.gov/show/NCT01068951"
90,"NCT04210440","The Treatment of Initial Stage of Hip Osteonecrosis: the Core Decompression","NEC15","Completed","No Results Available","Hip Necrosis|Hip Injuries","Procedure: Core decompression procedure","Avoiding arthroplasty|Harris Hip Score","Dante Dallari, MD|Istituto Ortopedico Rizzoli","All","18 Years to 50 Years   (Adult)","Not Applicable","52","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0029170","March 1, 2003","March 1, 2011","March 1, 2012","December 24, 2019",,"December 24, 2019","Istituto Ortopedico Rizzli, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT04210440"
91,"NCT04297813","Efficacy in Alveolar Bone Regeneration With Autologous MSCs and Biomaterial in Comparison to Autologous Bone Grafting","Maxibone","Recruiting","No Results Available","Alveolar Bone Atrophy","Combination Product: Advanced medicinal Therapy (MSC combined with biomaterial)|Procedure: Autologous bone graft","Change in bone width|Pain postoperatively in the two different treatments|Radiological examination of bone volume","University of Bergen|Université de Nantes|University of Ulm|Universidad Complutense de Madrid|University of Aarhus|Universitat Internacional de Catalunya|Assistance Publique - Hôpitaux de Paris|European Commission","All","18 Years and older   (Adult, Older Adult)","Phase 3","150","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-001227-39","March 2020","August 2022","September 2024","March 6, 2020",,"March 12, 2020","Syddansk Universitet SDU (University Hospital of Southern Denmark), Odense, Denmark|Assistance Publique - Hôpitaux De Paris, Créteil, France|CHU Nantes, Centre de Soins Dentaires, Nantes, France|University of Bergen, Institute of Clonical Dentistry, Bergen, Hordaland, Norway|Universidad Complutense De Madrid, Madrid, Calle Fernando De Castro Rodriguez,, Spain|Universitat Internacional De Catalunya, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT04297813"
92,"NCT01844661","Safety and Efficacy of Repeated Infusion of CELYVIR in Children and Adults With Metastatic and Refractory Tumors.",,"Completed","No Results Available","Children|Solid Tumors|Metastases","Biological: CELYVIR","Adverse effects after intravenous infusions|Clinical outcome","Hospital Infantil Universitario Niño Jesús, Madrid, Spain|Instituto de Salud Carlos III","All","6 Months to 75 Years   (Child, Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","EudraCT2008-000364-16","January 2013","December 2014","January 2016","May 1, 2013",,"February 19, 2016","Hospital Universitario Niño Jesús, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01844661"
93,"NCT01183728","Treatment of Knee Osteoarthritis With Autologous Mesenchymal Stem Cells","KDD&MSV","Completed","Has Results","Osteoarthritis, Knee|Knee Degenerative Disease|Knee Osteoarthritis","Other: Autologous bone marrow mesenchymal stem cells (MSV)","Feasibility and Safety of the Implementation of MSV in the Treatment of Osteoarthritis of the Knee.|Indication of Efficacy","Red de Terapia Celular|Fundacion Teknon, Centro Medico Teknon, Barcelona|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Institut de Terapia Regenerativa Tissular|EGARSAT Suma Intermutual, Barcelona, Spain|Cetir Sant Jordi, S.a..","All","18 Years to 76 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TerCel001|Eudra-CT 2009-017405-11|Protocol Code","May 2010","August 2014","September 2014","August 18, 2010","January 15, 2015","January 15, 2015","Teknon Medical Center, ITRT, Barcelona, Spain|Instituto de Biologia y Genetica Molecular (IBGM), University of Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01183728"
94,"NCT00976430","Autologous Mesenchymal Stem Cell Transplant for Parkinson's Disease",,"Terminated","No Results Available","Parkinson's Disease","Procedure: Autologous Bone marrow derived stem cells transplant","Improvement in clinical condition of the patient assessed using UPDRS (UNIFIED PARKINSON'S DISEASE RATING SCALE) and Time Tests.","Jaslok Hospital and Research Centre","All","35 Years to 70 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JHC525","July 2009","November 30, 2011","April 30, 2012","September 14, 2009",,"August 14, 2018","Jaslok Hospital And Research Centre, Mumbai, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT00976430"
95,"NCT04594850","Clinical Trial to Evaluate Efficacy and Safety of of Autologous Mesenchymal Stem Cells (MSC) Injected Intracavernously","Cellgram-ED","Recruiting","No Results Available","Erectile Dysfunction","Biological: Cellgram-ED","The amount of change in EF score in the International Erectile Function Questionnaire (IIEF) at administration of the clinical trial drug compared to the baseline value|Changes in SEP Q 2 and Q 3 evaluation after administration of investigational drug compared to baseline|Global Assessment Question (GAQ) evaluation after administration of investigational drugs|Changes in Penile Doppler Sonography(PDS) level after administration of clinical trial drug compared to baseline","Pharmicell Co., Ltd.","Male","19 Years to 79 Years   (Adult, Older Adult)","Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","PMC-P-10","October 19, 2020","October 31, 2023","October 31, 2023","October 20, 2020",,"October 26, 2020","Asan medical center, Seoul, Korea, Republic of|Samsung medical center, Seoul, Korea, Republic of|Seoul ST. Mary's hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04594850"
96,"NCT00644410","Autologous Mesenchymal Stromal Cell Therapy in Heart Failure",,"Completed","No Results Available","Congestive Heart Failure","Biological: Mesenchymal stromal cell|Biological: Saline","Improvements in left ventricular function|Clinical improvements","Rigshospitalet, Denmark","All","30 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","59","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","MSC heart failure","September 2008","March 2015","March 2015","March 26, 2008",,"March 17, 2015","The Heart Centre, Rigshospitalet University Hospital Copenhagen,, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT00644410"
97,"NCT01933802","Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Patients With Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Biological: intrathecal administration of autologous MSC-NP","Number of participants with adverse events|Number of participants with adverse events .|Preliminary evaluation of efficacy","Tisch Multiple Sclerosis Research Center of New York","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TISCHMS-MSCNP-001|IND 13889","April 2014","December 2016","March 2017","September 2, 2013",,"March 19, 2018","Tisch MS Research Center of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT01933802"
98,"NCT02034786","Safety Study of Filler Agent Composed of Autologous Mesenchymal Stem Cells and Hyaluronic Acid","LipAge","Unknown status","No Results Available","Lipodystrophies|Aesthetics Procedure","Procedure: Adipose tissue collection|Biological: Transdermal injection|Procedure: Transdermal injection","Adverse Events Analysis|Efficacy Analysis","Cryopraxis Criobiologia Ltda.|Hospital Federal de Bonsucesso","All","18 Years and older   (Adult, Older Adult)","Phase 1","25","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cryo 394.191|394.191","March 2015","May 2016","June 2016","January 13, 2014",,"February 4, 2015","Hospital Federal de Bonsucesso, Rio de Janeiro, Brazil",,"https://ClinicalTrials.gov/show/NCT02034786"
99,"NCT03355365","Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis",,"Active, not recruiting","No Results Available","Multiple Sclerosis","Biological: Intrathecal MSC-NP injection|Other: Intrathecal saline injection","Expanded Disability Status Scale (EDSS) Plus|Multiple sclerosis functional composite (MSFC)|Bladder function","Tisch Multiple Sclerosis Research Center of New York","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","TISCHMS-MSCNP-002","September 21, 2018","May 2022","November 2023","November 28, 2017",,"October 6, 2021","Tisch MS Research Center of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03355365"
100,"NCT03691909","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) for the Treatment of Rheumatoid Arthritis","HB-adMSCs","Completed","No Results Available","Rheumatoid Arthritis","Biological: HB-adMSCs","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|The effect of single inject of HB-adMSCs on TNF-a in patients with acute RA|The effect of single inject of HB-adMSCs on IL-6 in patients with acute RA|The effect of single inject of HB-adMSCs on CRP in patients with acute RA|The effect of single inject of HB-adMSCs on ESR in patients with acute RA|The effect of single inject of HB-adMSCs on joint count in patients with acute RA.","Hope Biosciences","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HBRA01","September 25, 2018","August 17, 2020","September 28, 2020","October 2, 2018",,"July 6, 2021","Accurate Clinical Research, Pasadena, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03691909"
101,"NCT02152657","Evaluation of Autologous Mesenchymal Stem Cell Transplantation in Chronic Spinal Cord Injury: a Pilot Study",,"Completed","No Results Available","Spinal Cord Injury","Other: Mesenchymal stem cell transplantation","Magnetic resonance imaging|Sensitivity and motor strength on the inferior limbs|Improvement in urological function|Improvements in sensorial mapping and neuropathic pain","Hospital Sao Rafael","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-002","January 2015","December 2015","December 2016","June 2, 2014",,"April 26, 2017","Hospital São Rafael, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT02152657"
102,"NCT00658073","Induction Therapy With Autologous Mesenchymal Stem Cells for Kidney Allografts",,"Completed","No Results Available","Renal Transplant Rejection","Procedure: Kidney transplantation with MSCs infusion|Procedure: kidney transplantation without MSC infusion","Incidence rate of biopsy-proven acute rejection and early renal function recovery|Patient and graft survival and prevalence of adverse events","Fuzhou General Hospital","All","18 Years to 60 Years   (Adult)","Not Applicable","165","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-K-2","March 2008","September 2010","October 2010","April 14, 2008",,"March 8, 2011","Stem cell therapy center,Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT00658073"
103,"NCT01377870","Evaluation of Autologous Mesenchymal Stem Cell Transplantation (Effects and Side Effects) in Multiple Sclerosis",,"Completed","No Results Available","Multiple Sclerosis","Biological: intravenous injection of mesenchymal stem cells|Biological: injection of cell free media","MRI metrics changes|Brain atrophy|number of sever relapses|EDSS|MSFC|quality of life|RAO Test|intravenous cell transplantation","Royan Institute","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","22","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royn-nerve-001","December 2011","March 2014","April 2014","June 21, 2011",,"March 7, 2018","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01377870"
104,"NCT01454336","Transplantation of Autologous Mesenchymal Stem Cell in Decompensate Cirrhotic Patients With Pioglitazone",,"Completed","No Results Available","Liver Fibrosis","Biological: Cell injection","ALT|AST|Serum Albumin|Liver Fibrosis|Progression of fibrosis","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","3","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-liver-003","June 2010","July 2013","July 2013","October 19, 2011",,"May 13, 2014","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01454336"
105,"NCT00955669","Comparison of Autologous Mesenchymal Stem Cells and Mononuclear Cells on Diabetic Critical Limb Ischemia and Foot Ulcer",,"Completed","No Results Available","Autologous Transplantation|Diabetic Foot","Biological: Symptoms and Objective Examination","Magnetic resonance angiography","Third Military Medical University","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ldb2008101","August 2009","August 2010","August 2010","August 10, 2009",,"December 1, 2010","the southwest Hospital, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT00955669"
106,"NCT03822858","Expanded Access to Intrathecal Administration of Autologous Mesenchymal Stem Cell-derived Neural Progenitors (MSC-NP) in Progressive Multiple Sclerosis",,"Available","No Results Available","Multiple Sclerosis","Drug: Intrathecal MSC-NP injection",,"Tisch Multiple Sclerosis Research Center of New York","All","18 Years to 70 Years   (Adult, Older Adult)",,,"Other","Expanded Access:Treatment IND/Protocol",,"TISCHMS-MSCNP-003",,,,"January 30, 2019",,"October 13, 2021","Tisch MS Research Center of New York, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT03822858"
107,"NCT04349631","A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to Provide Protection Against COVID-19",,"Completed","No Results Available","COVID-19","Biological: HB-adMSCs","Incidence of hospitalization for COVID-19|Incidence of symptoms for COVID-19|absence of upper/lower respiratory infection|Glucose|Calcium|Albumin|Total Protein|Sodium|Total carbon dioxide|Potassium|Chloride|BUN|Creatinine|Alkaline phosphatase|Alanine aminotransferase|Aspartate aminotransferase|Total bilirubin|White blood cells|Red blood cells|Hemoglobin|Hematocrit|Mean corpuscular volume|Mean corpuscular hemoglobin|Mean corpuscular hemoglobin concentration|Red cell distribution width|Neutrophils|Lymphs|Monocytes|Eos|Basophils|Absolute neutrophils|Absolute lymphs|Absolute monocytes|Absolute eosinophils|Absolute basophils|Immature granulocytes|Absolute Immature granulocytes|Platelets|Prothrombin time|INR|TNFalpha|Interleukin-6|Interleukin-10|C-reactive protein|SF-36|PHQ-9","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","Child, Adult, Older Adult","Phase 2","56","Other|Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","HBCOV01","April 22, 2020","November 24, 2020","May 1, 2021","April 16, 2020",,"July 7, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04349631"
108,"NCT03969680","Mesenchymal Stem Cell Transplantation for Osteoarthritis",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Auotologous BMSCs plus autologous PRP|Biological: Auotologous PRP","Physical function change|Change in pain density|Cartilage repair|Change in MOS item short from health survey(SF-36)|Change in Lequesne Index|Change in knee society score (KSS)","Yantai Yuhuangding Hospital","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2019-002","July 8, 2019","June 30, 2020","December 31, 2020","May 31, 2019",,"January 22, 2020","Yantai Yuhuangding Hospital, Yantai, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03969680"
109,"NCT01206179","Treatment of Non Union of Long Bone Fractures by Autologous Mesenchymal Stem Cell",,"Completed","No Results Available","Nonunion Fractures","Biological: cell injection","Radiological progression of bone fusion|Reduction of pain using VAS|Cost analysis based on length of hospital stay","Royan Institute","All","12 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-004","March 2009","March 2011","May 2011","September 21, 2010",,"December 14, 2011","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01206179"
110,"NCT02917681","Study of Two Intrathecal Doses of Autologous Mesenchymal Stem Cells for Amyotrophic Lateral Sclerosis",,"Unknown status","No Results Available","AMYOTROPHIC LATERAL SCLEROSIS","Other: Two intrathecal MSC injections","Safety|Change in Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (ALSFRS-R)|Change in Handheld dynamometry|Change in Electrical Impedance Myography|Change in Forced Vital Capacity (FVC)|Change in Isometric Strength|Changes in morphometric parameters of MRI of encephalon and spinal cord","University of Sao Paulo General Hospital|Pontifícia Universidade Católica do Paraná","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","28","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","401922/2014-6","September 2016","February 2019","August 2019","September 28, 2016",,"September 28, 2016","University of Sao Paulo School of Medicine Clinics Hospital, Sao Paulo, SP, Brazil",,"https://ClinicalTrials.gov/show/NCT02917681"
111,"NCT01459640","Intra-Articular Autologous Bone Marrow Mesenchymal Stem Cells Transplantation to Treat Mild to Moderate Osteoarthritis",,"Unknown status","No Results Available","Osteoarthritis","Drug: Hyaluronic Acid|Biological: Autologous bone marrow-derived mesenchymal stem cells","Change from baseline in cartilage thickness at 12 months by MRI|Visual Analog Score|IKDC Subjective Knee Evaluation Form (2000)|Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray)","National University of Malaysia|Cytopeutics Pte. Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","FF-114-2011","March 2011","March 2014","March 2014","October 25, 2011",,"October 25, 2011","UKM Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01459640"
112,"NCT03840343","Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease",,"Recruiting","No Results Available","Diabetic Kidney Disease|Diabetic Nephropathies|Diabetes Mellitus, Type 2|Diabetes Mellitus, Type 1|Chronic Kidney Disease|Diabetic Nephropathy Type 2|Kidney Failure|Kidney Insufficiency","Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Lower Dose|Biological: Autologous adipose-derived mesenchymal stem/stromal cells (MSC) Higher Dose","Adverse Events|Kidney Function","Mayo Clinic|Regenerative Medicine Minnesota","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-002423|RMM 091718 CT 001","October 23, 2019","December 2024","December 2025","February 15, 2019",,"February 26, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03840343"
113,"NCT02012153","Mesenchymal Stromal Cells in Kidney Transplant Recipients",,"Recruiting","No Results Available","Kidney Transplant Rejection","Biological: Mesenchymal Stromal Cells","Circulating naïve and memory T cell count (CD45RA/CD45RO) (flow cytometry analysis).|T-cell function by ELISPOT assay in mixed lymphocyte reaction.|Number of adverse events.|Circulating regulatory T cell count.|Urinary FOXP3 mRNA expression evaluated by real time quantitative PCR.","Mario Negri Institute for Pharmacological Research|A.O. Ospedale Papa Giovanni XXIII","All","18 Years and older   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-Tx tolerance|2013-003221-29","December 2013","December 2022","March 2023","December 16, 2013",,"November 5, 2020","U.O. Nefrologia e Dialisi, Bergamo, Italy",,"https://ClinicalTrials.gov/show/NCT02012153"
114,"NCT00420134","Improvement of Liver Function in Liver Cirrhosis Patients After Autologous Mesenchymal Stem Cell Injection:a Phase I-II Clinical Trial",,"Completed","No Results Available","Liver Failure|Cirrhosis","Procedure: injection of progenitor of hepatocyte drived from Mesenchymal stem cell","Liver function test|MELD score|Cirrhosis mortality after 6 months","Shahid Beheshti University of Medical Sciences|Tarbiat Modarres University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Single|Primary Purpose: Treatment","348","February 2006","May 2009","June 2009","January 9, 2007",,"September 17, 2009","Research Center for Gastroenterology and Liver Diseases, Tehran, Iran, Islamic Republic of|Research center of Gastroenterology and Liver Disease, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00420134"
115,"NCT04759105","Efficacy of Intradiscal Injection of Autologous BM-MSC in Worker Patients Affected by Chronic LBP Due to Multilevel IDD","ACTIVE","Recruiting","No Results Available","Intervertebral Disc Degeneration|Chronic Low-back Pain","Drug: Autologous BM-MSC|Other: Sham Procedure","Pain clinical relief|Functional disability index improvement|Work ability improvement|Measure pain relief of the patient|Measure functional disability index of the patient|Evaluate disability and quality of life evolution of the patient|Disability and quality of life evolution|Assess rescue painkillers medication|Structural assessment|Evaluation of cost|Incidence of Adverse Events (AE)|Assessment of vital signs|Evaluation of blood and urine analysis|Analysis of chemical biomarkers for tissue degeneration","Campus Bio-Medico University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Center for Outcomes Research and Clinical Epidemiology, Italy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","ACTIVE trial_(BRIC2018-ID03)|2019-004476-19","November 17, 2020","July 31, 2021","June 30, 2022","February 18, 2021",,"February 18, 2021","Campus Bio-Medico University of Rome, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT04759105"
116,"NCT05080465","Long Term Follow up Mesenchymal Stem Cell Therapy for Patients Virus-related Liver Cirrhosis",,"Active, not recruiting","No Results Available","Liver Cirrhosis","Biological: Autologous BM MSC","MR Elastography|The level of serum alanine aminotransferase (ALT)|Clinical Examination|The level of glomerular filtration rate (GFR)|The level of serum albumin (ALB)|The level of serum total bilirubin (TB)","Ukraine Association of Biobank","All","18 Years to 69 Years   (Adult, Older Adult)","Phase 3","700","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","UAB00240818-1","December 2, 2018","October 7, 2021","February 2, 2022","October 15, 2021",,"October 15, 2021","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,"https://ClinicalTrials.gov/show/NCT05080465"
117,"NCT02351011","Human Autologous MSCs for the Treatment of Mid to Late Stage Knee OA",,"Completed","No Results Available","Osteoarthritis of Knee","Biological: 1 x 10^6 MSCs|Biological: 10 x 10^6 MSCs|Biological: 50 x 10^6 MSCs","Safety as determined by the occurrence of local and systemic adverse events and/or serious adverse events.|Knee Injury and Osteoarthritis Outcome Score (KOOS)|Marx Activity Scale (Patient-reported activity)|Short-Form 36 (Health-related quality of life)|Whole Organ MRI Score (WORMS), Gadolinium-enhanced MRI, T2 Mapping (To assess joint structure, inflammation, and cartilage status over time)|Cartilage oligomeric matrix protein (COMP)|Hyaluronic acid (HA)|C-terminal telopeptide of type II collagen (CTXII)|Types I and II collagen cleavage (C1,2C)|Type II collagen cleavage (C2C)|IL-6/TNFα/IL-15","Jas Chahal|University Health Network, Toronto","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","MSC-001","February 2015","December 2018","December 2018","January 30, 2015",,"September 27, 2019","Toronto Western Hospital, Toronto, Ontario, Canada",,"https://ClinicalTrials.gov/show/NCT02351011"
118,"NCT04821479","Repeated Mesenchymal Stem Cell Injections in ALS",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: Mesenchymal stem cells (MSC)","Safety of multiple intrathecal MSC administration. Incidence of adverse events following multiple intrathecal MSC injections during 2 years follow-up period|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of ALSFRSr|Effect of repeated intrathecal MSC injections on the progression rate (monthly changes) of respiratory forced vital capacity FVC","Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","0208-16-HMO","January 1, 2016","June 30, 2020","December 31, 2020","March 29, 2021",,"March 29, 2021",,,"https://ClinicalTrials.gov/show/NCT04821479"
119,"NCT04243681","Combination of Autologous MSC and HSC Infusion in Patients With Decompensated Cirrhosis",,"Completed","No Results Available","Cirrhosis, Liver","Combination Product: CD 34 and MSC infusion|Drug: Standard of care for Cirrhosis management","To assess the safety of combination of hematopoetic and mesenchymal stem cell in patients of liver cirrhosis.|Change in MELD (Model for End stage Liver disease) score.|Change in Child Pugh score.|Change in the percentage of CD 34 cells in liver.","Asian Institute of Gastroenterology, India","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 4","5","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ECR/346/Inst/AP/2013","July 1, 2019","August 1, 2020","September 1, 2020","January 28, 2020",,"October 22, 2020","Asian Institute Of Gastroenterology, Hyderabad, Telangana, India",,"https://ClinicalTrials.gov/show/NCT04243681"
120,"NCT03585855","Mesenchymal Stem Cell Transplantation in the Treatment of Chronic Antibody Mediated Kidney Graft Rejection (ABMR)",,"Terminated","No Results Available","Interventional","Other: MSC transplantation","Safety of MSC transplantation as assessed by adverse events according to CTCAE Version 5Estimated glomerular filtration rate (eGFR)|Estimated glomerular filtration rate (eGFR)|Graft survival rate","University Medical Centre Ljubljana|Slovenian Research Agency","All","18 Years and older   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P3-0323","January 1, 2019","July 23, 2019","July 23, 2019","July 13, 2018",,"July 25, 2019","University Medical Centre Ljubljana, Ljubljana, Slovenia",,"https://ClinicalTrials.gov/show/NCT03585855"
121,"NCT05066334","Efficacy of Intradiscal Injection of Autologous BM-MSC in Subjects With Chronic LBP Due to Multilevel Lumbar IDD","DREAM","Recruiting","No Results Available","Intervertebral Disc Degeneration|Chronic Low-back Pain","Drug: Autologous BM-MSC|Procedure: Sham","Pain Change|Functional disability index evaluation|Disability evolution|Quality of life evolution|Drug consumption of rescue painkillers medication|Measurement of pain|Employment and work status assessment|Structural assessment|Evaluation of costs|Body Mass Index evaluation|Haematological evaluation: safety parameter|Coagulation status: safety parameter|Metabolic functions: safety parameter|Inflammation: safety parameter|Urinalysis|Spine examination|Specific Adverse Events Evaluation","Campus Bio-Medico University|Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico|Center for Outcomes Research and Clinical Epidemiology, Italy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","52","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","DREAM (GR - 2018-12367168)|2019-002749-40","March 22, 2021","May 31, 2022","June 9, 2023","October 4, 2021",,"October 4, 2021","Campus Bio-Medico University of Rome, Roma, Italy",,"https://ClinicalTrials.gov/show/NCT05066334"
122,"NCT03838666","Utilization of AMSC to Enhance Rotator Cuff Repair - Safety and Efficacy","AMSC-RC-001","Terminated","No Results Available","Rotator Cuff Tear","Drug: Suspension of human autologous MSC 3P","Safety: To assess the occurrence of adverse events of treatment by hAMSC - systemic reactions.|Safety: To assess the occurrence of adverse events of treatment by autologous mesenchymal stem cells - local reactions.|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - Visual Analogue Score (VAS)|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - Constant Shoulder Score|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - UCLA Shoulder Rating Score|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - MRI imaging - Continuation / discontinuation of the rotator cuff|Efficacy: To evaluate the effect of hAMSCs applied during arthroscopic rotator cuff repair - MRI imaging - Fatty degeneration","Bioinova, s.r.o.|Department of Neurology, University Hospital Motol, Prague, Czech Republic","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-RC-001","December 12, 2012","November 18, 2015","November 18, 2015","February 12, 2019",,"February 15, 2019",,,"https://ClinicalTrials.gov/show/NCT03838666"
123,"NCT01824121","Clinical Trial to Evaluate Bone Marrow Stem Cell Therapy for PSP, a Rare Form of Parkinsonism",,"Unknown status","No Results Available","Progressive Supranuclear Palsy","Biological: stem cell therapy","incidence of adverse events|changes in brain images","Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico","All","40 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","032011|2011-004051-39","December 2012","December 2014","December 2014","April 4, 2013",,"April 4, 2013","ICP Parkinson Institute, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT01824121"
124,"NCT02544802","Mesenchymal Stem Cell Treatment for Primary Osteoarthritis Knee",,"Unknown status","No Results Available","Osteoarthritis Knee","Drug: Adipose-Derived Mesenchymal Stem Cells","Safety of intra-articular injection of autologous ADMSCs by incidence of adverse events and alterations in vital signs, blood chemistry profiles, complete blood count, urinalysis, and also the physical examination of the knees.|Clinical assessment of visual analogue scale (VAS)|Clinical assessment of Short Form 36 questionnaire (SF-36)|Clinical assessment of Western Ontario and McMaster Universities Arthritis Index (WOMAC)|Clinical assessment of Hospital for Special Surgery (HSS) Knee Score|Clinical imaging assessment of knee X-ray|Clinical imaging assessment of MRI of the knee","Steminent Biotherapeutics Inc.","All","50 Years to 70 Years   (Adult, Older Adult)","Phase 1","4","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-VGH-201102","June 2015","February 2017","July 2017","September 9, 2015",,"April 20, 2016","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT02544802"
125,"NCT03449069","Pediatric MSC-AFP Sub-study for Crohn's Fistula",,"Recruiting","No Results Available","Fistula in Ano|Crohn Disease","Drug: MSC-AFP","Number of participants with treatment-related adverse events (safety and toxicity)|Number of participants with response to the treatment regarding cessation of drainage from the treated fistula.|Number of participants with radiographic response to the treatment regarding the treated fistula.","Mayo Clinic","All","12 Years to 17 Years   (Child)","Phase 1","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-010539","July 23, 2018","February 28, 2022","February 28, 2022","February 28, 2018",,"April 1, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03449069"
126,"NCT02033525","Mesenchymal Stromal Cells for Degenerative Meniscus Injury",,"Completed","No Results Available","Chronic Meniscal Injury","Drug: XCEL-M-ALPHA and standard rehabilitation|Other: Rehabilitation","VAS for pain|Safety|Efficacy by MRI|Efficacy by clinical questionnaires","Banc de Sang i Teixits|Hospital Universitari Quirón Dexeus|Ministerio de Sanidad, Servicios Sociales e Igualdad","All","40 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","XCEL-MEN-01|2011-006270-13","January 31, 2014","May 2, 2017","May 2, 2017","January 10, 2014",,"January 9, 2018","ICATME-Hospital Quiron Dexeus, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT02033525"
127,"NCT04642911","Longterm Follow-up of Subjects With Diabetes 2 Type Treatment With ex Vivo Gene Therapy","AUB001","Active, not recruiting","No Results Available","Diabete Type 2|Mesenchymal Stem Cell","Other: Long term follow up","Overall survival of subject with diabetes 2 type with gene therapy drug product (Mesenchymal Stem Cell) in a Ukraine Association of Biobank bio-sponsored clinical trial who agree to participate in this study","Ukraine Association of Biobank","All","Child, Adult, Older Adult",,"91","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UAB00171120-1","October 15, 2020","September 1, 2021","October 10, 2030","November 24, 2020",,"October 15, 2021","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,"https://ClinicalTrials.gov/show/NCT04642911"
128,"NCT02017912","Phase 2, Randomized, Double Blind, Placebo Controlled Multicenter Study of Autologous MSC-NTF Cells in Patients With ALS","NurOwn","Completed","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Biological: Autologous MSC-NTF cells|Biological: Placebo","Number of patients with adverse events|Change in Amyotrophic Lateral Sclerosis (ALS) Functional Rating Scale (ALS-FRS) slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation.|Change in SVC slopes from the pre-transplantation period to the post-transplantation period between the treatment and placebo groups through 24 weeks post-transplantation","Brainstorm-Cell Therapeutics","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","48","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","BCT-001-US","May 2014","March 2016","July 2016","December 23, 2013",,"July 18, 2018","Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02017912"
129,"NCT04675970","Long Term Follow up Patients With Premature Ovarian Failure ex Vivo Gene Therapy","UB-OVF","Active, not recruiting","No Results Available","Primary Ovarian Insufficiency|Premature Ovarian Failure","Other: Observational","Antral follicular count (AFC) serum levels|anti-Müllerian hormone (AMH) serum levels|Regular menstruation and/or pregnancy","Ukraine Association of Biobank","Female","18 Years to 40 Years   (Adult)",,"86","Other","Observational","Observational Model: Case-Only|Time Perspective: Prospective","UAB1220-2","September 1, 2020","September 15, 2022","September 15, 2022","December 19, 2020",,"October 15, 2021","Institute of Bio-Stem Cell Rehabilitation, Kharkov, Ukraine",,"https://ClinicalTrials.gov/show/NCT04675970"
130,"NCT01915927","Stem Cell Fistula Plug in Perianal Crohn's Disease","MSC-AFP","Completed","No Results Available","Perianal Crohn's Disease","Drug: MSC-AFP","To determine the safety and toxicity of using autologous MSC coated fistula plug in patients with fistulizing Crohn's Disease.|To assess in preliminary fashion the response of fistula healing induced by the GORE plug containing MSC","William A. Faubion, M.D.|Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","12-009716","July 2013","December 2019","December 2019","August 5, 2013",,"January 3, 2020","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT01915927"
131,"NCT04681118","Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS",,"Available","No Results Available","Amyotrophic Lateral Sclerosis","Biological: NurOwn (MSC-NTF cells)",,"Brainstorm-Cell Therapeutics","All","18 Years to 63 Years   (Adult)",,,"Industry","Expanded Access:Intermediate-size Population|Treatment IND/Protocol",,"BCT-003-US",,,,"December 23, 2020",,"December 23, 2020","University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|UMass Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04681118"
132,"NCT02501811","Combination of Mesenchymal and C-kit+ Cardiac Stem Cells as Regenerative Therapy for Heart Failure","CONCERT-HF","Completed","Has Results","Ischemic Cardiomyopathy","Biological: Mesenchymal Stem Cells (MSC)|Biological: c-kit+ cells|Biological: Placebo (Plasmalyte A)","Change From Baseline in Left Ventricular Ejection Fraction (LVEF)|Change From Baseline in Global Strain (HARP MRI)|Change From Baseline in Regional Strain (HARP MRI)|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)|Change From Baseline in Left Ventricular Sphericity Index|Change From Baseline in Scar Size Percent (DEMRI)|Change From Baseline in Scar Tissue Mass (DEMRI)|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)|Change From Baseline in Left Ventricular Ejection Fraction (LVEF)-Trajectory|Change From Baseline in Global Strain (HARP MRI)-Trajectory|Change From Baseline in Regional Strain (HARP MRI)-Trajectory|Change From Baseline in Left Ventricular End Diastolic Volume Index (LVEDVI)-Trajectory|Change From Baseline in Left Ventricular End Systolic Volume Index (LVESVI)-Trajectory|Change From Baseline in Left Ventricular Sphericity Index-Trajectory|Change From Baseline in Scar Size Percent (DEMRI)-Trajectory|Change From Baseline in Scar Tissue Mass (DEMRI)-Trajectory|Change From Baseline in Maximal Oxygen Consumption (Peak VO2)-Trajectory|Change From Baseline in Exercise Tolerance (Six Minute Walk Test)-Trajectory|Change From Baseline in Minnesota Living With Heart Failure Questionnaire (MLHFQ) Score-Trajectory|Change From Baseline in N-Terminal Pro-Brain Natriuretic Peptide (NT-proBNP)-Trajectory|Participants With Major Adverse Cardiac Events (MACE)|Participants Experiencing Other Significant Clinical Events|Cumulative Days Alive and Out of Hospital for Heart Failure","The University of Texas Health Science Center, Houston|National Heart, Lung, and Blood Institute (NHLBI)","All","21 Years to 79 Years   (Adult, Older Adult)","Phase 2","125","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HSC-SPH-15-0413|5UM1HL087318","October 2015","June 25, 2020","July 22, 2020","July 17, 2015","April 26, 2021","April 26, 2021","Stanford University School of Medicine (Falk Cardiovascular Research Center), Stanford, California, United States|University of Florida-Department of Medicine, Gainesville, Florida, United States|University of Miami-Interdisciplinary Stem Cell Institute, Miami, Florida, United States|Indiana Center for Vascular Biology and Medicine, Indianapolis, Indiana, United States|University of Louisville, Louisville, Kentucky, United States|Minneapolis Heart Institute Foundation, Minneapolis, Minnesota, United States|Texas Heart Institute, Houston, Texas, United States","""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02501811/ICF_000.pdf|""Study Protocol and Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/11/NCT02501811/Prot_SAP_001.pdf","https://ClinicalTrials.gov/show/NCT02501811"
133,"NCT03258164","Cosmetic Fat Transplantation Using Expanded ASC Enriched Fat Grafts",,"Unknown status","No Results Available","Breast Hypoplasia and Facial Ageing","Biological: ASC enriched lipofilling|Biological: Standard Lipofilling","Change in volume over time after breast augmentation|Change in cosmetic facial appearance over time after facial filling","Stemform|Aleris-Hamlet Hospitaler København","Female","18 Years to 65 Years   (Adult, Older Adult)","Phase 3","32","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","H-16046960","March 22, 2017","January 1, 2021","June 1, 2021","August 23, 2017",,"June 24, 2019","Stemform, Copenhagen, Søborg, Denmark",,"https://ClinicalTrials.gov/show/NCT03258164"
134,"NCT01824069","Treatment CLI Nonrevascularizable Lower Limb With Cell Therapy","HULPVAS","Completed","No Results Available","Nonrevascularizable Critical Ischemia of the Lower Limbs","Other: Intramuscular injection of a suspension of adult mesenchymal stem cells derived","Safety of inject mesenchymal stem cells in MMII|Quality of life of patients after treatment","Instituto de Investigación Hospital Universitario La Paz|Hospital Universitario La Paz","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HULPVAS-2011-01|2012-000290-23","April 2013","April 2014","September 2015","April 4, 2013",,"June 15, 2016","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01824069"
135,"NCT03280056","Safety and Efficacy of Repeated Administrations of NurOwn® in ALS Patients",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis (ALS)","Biological: NurOwn® (MSC-NTF cells)|Other: Placebo|Other: Bone Marrow aspiration","To evaluate the efficacy and safety of NurOwn® (autologous MSC-NTF cells) as compared to placebo as measured by the amyotrophic lateral sclerosis functional rating scale (ALSFRS-R)|Biomarkers","Brainstorm-Cell Therapeutics|California Institute for Regenerative Medicine (CIRM)","All","18 Years to 60 Years   (Adult)","Phase 3","263","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","BCT-002-US","August 28, 2017","October 30, 2020","October 30, 2020","September 12, 2017",,"October 6, 2021","University of California Irvine Alpha Stem Cell Clinic, Irvine, California, United States|Cedars-Sinai Medical Center, Los Angeles, California, United States|California Pacific Medical Center, San Francisco, California, United States|Massachusetts General Hospital, Boston, Massachusetts, United States|University of Massachusetts Medical School, Worcester, Massachusetts, United States|Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03280056"
136,"NCT01804153","Stem Cells Tratment for the Local Feminine Stress Urinary Incontinence Treatment (HULPURO)","HULPURO","Unknown status","No Results Available","Urinary Incontinence","Drug: Adipose-derived expanded stem cells","Evaluate the feasability and security of the autologous ASC for the feminine stress urinary incontinence|Quality of life assessment using the SF-12 Questionnaire|Adverse events","Instituto de Investigación Hospital Universitario La Paz","Female","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HULPURO-2010-01|2010-024331-16","September 2012","October 2013","April 2014","March 5, 2013",,"March 5, 2013","Hospital Universitario La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01804153"
137,"NCT01957826","Mesenchymal Stem Cells for Idiopathic Dilated Cardiomyopathy",,"Unknown status","No Results Available","Primary Idiopathic Dilated Cardiomyopathy","Other: bone marrow-derived MSCs injection|Other: placebo intervention","Major adverse cardiac adverse events. SAEs and AEs.|NYHA functional class.|Incidence of complications with the use of NOGA XPTM catheters.|Laboratory parameters including C-reactive protein an brain natriuretic peptide|NYHA Functional Class|Max.oxygen consumption(MVO2),functional capacity.|Quality of life questionnaires|Extension. of perfusion defects(MRI/SPECT).|LVEF, ventricular vol.,wall motion score index(echocard./MRI/SPECT|LVEF(left ventriculogram, electromech. mapping parameters(NOGA XPTM))","Hospital General Universitario Gregorio Marañon|Ministerio de Sanidad, Servicios Sociales e Igualdad","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","FIBHGM-ECNC017-2010|2010-024406-35|MIYOCYTE","March 2013","March 2018","March 2018","October 8, 2013",,"November 18, 2016","Hospital General Universitario Gregorio Marañón, Madrid, Spain|Hospital Clinico Universitario de Valladolid, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01957826"
138,"NCT01392625","PercutaneOus StEm Cell Injection Delivery Effects On Neomyogenesis in Dilated CardioMyopathy (The POSEIDON-DCM Study)","PoseidonDCM","Completed","Has Results","Non-ischemic Dilated Cardiomyopathy","Biological: Autologous hMSCs|Biological: Allogeneic hMSCs","Incidence of Any Treatment-emergent Serious Adverse Events (TE-SAEs)|Measurement of Changes in Peak VO2|Measurement of Changes in 6 Minute Walk|Measurement of Changes in Global Ejection Fraction|Measurement of Changes in New York Heart Association (NYHA)|Measurement of Changes in Minnesota Living With Heart Failure (MLHF) Questionnaire","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|University of Miami","All","18 Years to 95 Years   (Adult, Older Adult)","Phase 1|Phase 2","37","Other|NIH","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20100968|1R01HL110737-01","May 19, 2011","August 28, 2016","August 28, 2017","July 12, 2011","February 15, 2018","February 15, 2018","University of Miami School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT01392625"
139,"NCT01087996","The Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis Pilot Study (The POSEIDON-Pilot Study)",,"Completed","Has Results","Stem Cell Transplantation","Biological: Auto-hMSCs|Biological: Allo-hMSCs","Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|CT Infarct Size From Early Enhanced Defect: - Difference Between the Baseline and 13-month|CT Measure of Left Ventricular Ejection Fraction|CT Measure of End Diastolic Volume|CT Measure of End Systolic Volume|CT Measure of Scar Size as % of LV Mass|Change in Distance Walked in 6-minutes From Baseline.|Change in Minnesota Living With Heart Failure Total Score|Change in New York Heart Association Class at 12-months","University of Miami|National Heart, Lung, and Blood Institute (NHLBI)|The Emmes Company, LLC","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","20090352|R01HL110737|R01HL107110|R01HL084275|P20HL101443|R01HL094849","March 2010","April 2011","October 2012","March 16, 2010","May 27, 2015","May 27, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT01087996"
140,"NCT01803347","Clinical Trial to Evaluate the Efficacy and Safety of Stem Cells","FISPAC","Completed","No Results Available","Anal Fistula","Drug: ◦Drug: ASCs. + fibrin glue|Drug: fibrin glue","Safety/efficacy","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","All","18 Years and older   (Adult, Older Adult)","Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","2012-001178-28","February 2013","October 2017","October 2017","March 4, 2013",,"April 19, 2018","Hospital Clínico Lozano Blesa, Zaragoza, Aragón, Spain|Hospital Clínico Universitario, Salamanca, Castilla-Leon, Spain|Hospital General Universitario, Valencia, Comunidad Valenciana, Spain|Hospital Universitario La Paz, Madrid, Spain|Clínica Universitaria de Navarra, Pamplona, Spain",,"https://ClinicalTrials.gov/show/NCT01803347"
141,"NCT03726255","Stem Cell Therapy: a Compassionate Use Program in Perianal Fistula","RESCeCUF","Completed","No Results Available","Perianal Fistula","Procedure: Mesenchymal Stem Cell injection","Number of patients with fistula healed|Number of adversus events","Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz","All","24 Years to 70 Years   (Adult, Older Adult)",,"52","Other","Observational","Observational Model: Cohort|Time Perspective: Retrospective","EO166-18_FJD","April 1, 2014","January 26, 2018","July 26, 2018","October 31, 2018",,"November 13, 2018","Instituto Investigación Sanitario Fundación Jiménez Díaz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03726255"
142,"NCT04711811","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Musculoskeletal Pain","CMP","No longer available","No Results Available","Chronic Pain","Biological: HB-adMSC",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences",,"18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access:Individual Patients",,"HBCMP01",,,,"January 15, 2021",,"July 7, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04711811"
143,"NCT04823000","Effects of Repeated Mesenchymal Stem Cells (MSC) in Patients With Progressive Multiple Sclerosis","MSC-pMS","Completed","No Results Available","Multiple Sclerosis","Biological: Mesenchymal Stem Cells (MSC)","Appearance of adverse events|The changes in Expanded Disability Status Scale (EDSS) score 0-10 scale, higher scores show worsening of disability)|Changes in the percentage of CD4/CD25/FoxP3 triple positive stained cells (T regulatory cells), following MSC-treatment|Changes in the percentage of CD3+CD69+ cells (activated lymphocytes), following MSC-treatment|Changes in the percentage of CD11c+/CD86+/Lin- cells (dendritic cells and antigen-presenting macrophages), following MSC-treatment|Changes in the proliferation ability of mononuclear cells to PHA, following MSC-treatment","Hadassah Medical Organization","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-MS-001","January 1, 2013","December 1, 2016","April 1, 2020","March 30, 2021",,"March 30, 2021",,,"https://ClinicalTrials.gov/show/NCT04823000"
144,"NCT01981330","Pilot Study of Stem Cell Treatment of Patients With Vocal Fold Scarring",,"Completed","No Results Available","Improved Healing of Scarred Vocal Folds|Improved Vocal Fold Status|Improved Vocal Fold Function","Biological: aMSC|Biological: aMSC+hyaluronan gel","Improved healing of scarred vocal folds","Karolinska University Hospital|The Swedish Research Council|Laryngfonden|Karolinska Institutet","All","18 Years and older   (Adult, Older Adult)","Phase 1","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2010/1650 and 2014-51432","January 2012","February 24, 2020","February 24, 2020","November 11, 2013",,"February 25, 2020","Karolinska University Hospital, Stockholm, Sweden",,"https://ClinicalTrials.gov/show/NCT01981330"
145,"NCT04434794","Treatment of Gingival Recession Using Mesenchymal Stem Cells",,"Completed","No Results Available","Gingival Recession","Biological: mesenchymal stem cells|Other: standard treatment","number of patients cured","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","27","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(GR2)","January 1, 2018","December 31, 2019","December 31, 2019","June 17, 2020",,"June 17, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04434794"
146,"NCT03563495","Tissue Engineered Constructs for Alveolar Cleft Repair",,"Completed","No Results Available","Cleft Lip and Palate","Other: tissue engineered group|Procedure: autogenous bone graft group","Assessment of changes in the bone volume at the grafted alveolar cleft site from the immediate postoperative to 6 months|Assessment of changes in the bone density at the grafted alveolar cleft site from the immediate postoperative to 6 months","Cairo University","All","8 Years to 14 Years   (Child)","Not Applicable","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","MSCs in alveolar cleft repair","February 2015","July 2017","September 2017","June 20, 2018",,"June 20, 2018",,,"https://ClinicalTrials.gov/show/NCT03563495"
147,"NCT01468064","Autologous Bone Marrow Stromal Cell and Endothelial Progenitor Cell Transplantation in Ischemic Stroke","AMETIS","Completed","No Results Available","Stroke|Infarction, Middle Cerebral Artery","Genetic: Autologous BMSCs transplantation|Genetic: Autologous EPCs transplantation|Genetic: IV infusion of placebo","Number of adverse events after infusion of BMSCs or EPCs.|Changes in functional outcomes measured by the modified Rankin Scale (mRS) and the Barthel index (BI).","Southern Medical University, China|The Second People's Hospital of Nanhai District of Foshan|The First People's Hospital of Haizhu District Guangzhou|Cellonis Biotechnology Co. Ltd.","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ZJH-001|2011A030400007","November 2011","December 2015","March 2017","November 9, 2011",,"April 2, 2021","Zhujiang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01468064"
148,"NCT02287974","Clinical Trial I/II Opened, Randomized and Controlled for the Study of the Use of Stem Cells Therapy in Insulinized Diabetic Patients Type 2 With Critical Ischemia in Lower Limbs (CLI): Study of the Needs of Insulin",,"Terminated","No Results Available","Critical Limb Ischemia (CLI)","Drug: Stem cell infusion","Serious Adverse Events|Efficacy measured by: The changes in the requirements of insulin, Peptide C, Resistance to the insulin, inflammatory Cytokines, pancreatic Reservation, Quantification of the degree of neovascularization (angio/arteriogenesis and vasculogenesis)","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CeTMMoTa/ICPDI/2010","September 2011","July 2018","July 2018","November 11, 2014",,"December 19, 2018","Hopsital U. Virgen Macarena, Sevilla, Seville, Spain|CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine), Seville, Spain",,"https://ClinicalTrials.gov/show/NCT02287974"
149,"NCT04446897","Treatment of Chronic Medium-severe Periodontitis With Mesenchymal Stem Cells Predifferentiated in Osteogenic Direction",,"Completed","No Results Available","Periodontitis, Chronic","Biological: mesenchymal stem cells|Other: standard treatment","number of patients cured","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian Medical Academy of Post-Graduate Education","All","70 Years to 70 Years   (Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(periodontitis)","August 3, 2020","December 31, 2020","December 31, 2020","June 25, 2020",,"February 9, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04446897"
150,"NCT03478215","Mesenchymal Stromal Cells in Living Donor Kidney Transplantation",,"Recruiting","No Results Available","Renal Transplantation|Mesenchymal Stem Cells","Biological: Mesenchymal Stromal Stem Cells (MSCs) Infusion|Other: Normal Saline (Placebo) Infusion","Number of participants without any infusional toxicity, occurring within 24 hours of infusion.|Number of participants without any acute rejection, graft loss, or death at 6 months post transplant.","The Methodist Hospital Research Institute|Center for Cell and Gene Therapy, Baylor College of Medicine","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Other","Pro00012858|U1111-1169-2289","February 2016","July 2021","July 2021","March 27, 2018",,"December 14, 2020","Houston Methodist Hospital System, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03478215"
151,"NCT01552707","Safety Study of Mesenchymal Stem Cells and Spinal Fusion",,"Completed","No Results Available","Lumbar Spondylolisthesis Involving L4-L5, and/or|Degenerative Discopathy Involving L4-L5","Biological: XCEL-MT-OSTEO-ALPHA|Procedure: Standard treatment","safety of XCEL-MT-OSTEO-ALPHA (tissue engineering product composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Feasibility of XCEL-MT-OSTEO-ALPHA (composed by ""ex-vivo"" expanded autologous mesenchymal stem cells fixed in allogenic bone tissue in spinal fusion)|Efficacy spinal fusion by imaging procedures (X-Ray).|Efficacy spinal fusion by imaging procedures (computerized helicoidal tomography)|Clinical outcomes (VAS)|Clinical outcomes (SF-36)|Clinical outcome (Oswestry Disability Index)","Banc de Sang i Teixits|TFS Trial Form Support|Ministerio de Sanidad, Servicios Sociales e Igualdad|Ministerio de Ciencia e Innovación, Spain","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","69","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XCEL-MT-10-02","July 19, 2012","May 3, 2018","October 21, 2019","March 13, 2012",,"January 21, 2020","Hospital Universitari Germans Trias i Pujol, Badalona, Barcelona, Spain|Parc de Salut Mar, Barcelona, Spain|Hospital de la Santa Creu i Sant Pau, Barcelona, Spain|Institut Universitari Dexeus (ICATME), Barcelona, Spain|Hospital Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01552707"
152,"NCT01605383","Mesenchymal Stem Cells in Osteonecrosis of the Femoral Head",,"Completed","No Results Available","Avascular Necrosis of Femur Head","Biological: XCEL-MT-OSTEO-ALPHA|Procedure: Standard treatment","Safety of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Feasibility of XCEL-MT-OSTEO-ALPHA in osteonecrosis of the femoral head|Bone regeneration by measuring the necrotic angle using the modified Kerboul method|Dynamic changes of signal intensity|Clinical outcomes (pain) by Visual Analogue Scale (VAS)|Clinical outcomes (SF-36)|Clinical outcome (WOMAC)","Banc de Sang i Teixits|Ministerio de Sanidad, Servicios Sociales e Igualdad|Ministerio de Ciencia e Innovación, Spain|European Regional Development Fund","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","23","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XCEL-MT-10-01|2010-023998-18","May 5, 2015","April 11, 2018","June 27, 2019","May 24, 2012",,"January 21, 2020","Hospital Universitari Vall d'Hebron, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01605383"
153,"NCT04876326","Potential Use of Autologous and Allogeneic Mesenchymal Stem Cells in Patients With Multiple System Atrophy",,"Recruiting","No Results Available","Multiple System Atrophy|Parkinsonism|Multiple System Atrophy, Parkinson Variant","Biological: Autologous Adipose Mesenchymal Stem Cell Implantation|Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell Implantation|Biological: Allogeneic Umbilical Cord Mesenchymal Stem Cell and Adipose Secretome Implantation","Changes of Clinical Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of structures improvement of the eyes from Baseline to 1,3,6,9 and 12 months after second implantation|Changes of the eyesight from Baseline to 1,3,6,9 and 12 months after second implantation|Imaging Evaluation from Baseline to 1,3,6,9 and 12 months after second implantation","Indonesia University","All","Child, Adult, Older Adult","Not Applicable","15","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","TGHISMMSCMSA","October 5, 2020","October 5, 2021","October 5, 2021","May 6, 2021",,"May 6, 2021","Cipto Mangunkusumo General Hospital, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04876326"
154,"NCT01967186","Intraportal or Intramuscular Site for Islets in Simultaneous Islet and Kidney Transplantation",,"Unknown status","No Results Available","Type 1 Diabetes|End Stage Renal Disease","Procedure: Intraportal islet transplantation|Procedure: Intramuscular islet transplantation|Procedure: Intramuscular transpl with stemcells|Procedure: Kidney transplantation","C-peptide derived from the Mixed Meal Tolerance Test (MMTT)","The Nordic Network For Clinical Islet Transplantation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","36","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SIK01","April 2007","January 2016","July 2016","October 22, 2013",,"October 6, 2015",,,"https://ClinicalTrials.gov/show/NCT01967186"
155,"NCT03956719","Treatment of Early Knee Osteoarthritis With Autologous Adipose-derived Mesenchymal Stem Cells",,"Active, not recruiting","No Results Available","Knee Osteoarthritis","Drug: Autologous adipose-derived mesenchymal stem cells|Procedure: abdominal liposuction","Hospital for special surgery knee score postoperative 1 month|Hospital for special surgery knee score postoperative 3 month|Hospital for special surgery knee score postoperative 6 month|Visual Analogue Scale Postoperative 1 month|Visual Analogue Scale Postoperative 3 month|Visual Analogue Scale Postoperative 6 month|Evaluation of cartilage repair under MRI postoperative 3 month|Evaluation of cartilage repair under MRI postoperative 6 month|Degree of meniscus injury under MRI postoperative 3 month|Degree of meniscus injury under MRI postoperative 6 month|Squatting to Standing Time postoperative 1 month|Squatting to Standing Time postoperative 3 month|Squatting to Standing Time postoperative 6 month|Satisfaction of patients postoperative 1 month|Satisfaction of patients postoperative 3 month|Satisfaction of patients postoperative 6 month","Qilu Hospital of Shandong University","All","15 Years to 65 Years   (Child, Adult, Older Adult)","Not Applicable","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2019042","March 2, 2019","September 9, 2020","November 1, 2020","May 21, 2019",,"September 16, 2020","Qilu hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03956719"
156,"NCT03268603","Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)",,"Recruiting","No Results Available","ALS|Amyotrophic Lateral Sclerosis","Drug: Autologous Adipose-derived Mesenchymal Stromal Cells","Number of Adverse Events|Change in slope of ALS Functional Rating Scale - Revised (ALSFRS-R)","Mayo Clinic|State of Minnesota Regenerative Medicine Minnesota","All","18 Years and older   (Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-008008|UL1TR000135","October 10, 2017","December 2022","December 2022","August 31, 2017",,"May 6, 2021","Mayo Clinic, Scottsdale, Arizona, United States|Mayo Clinic, Jacksonville, Florida, United States|Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03268603"
157,"NCT01649700","Treatment of Sequelae Caused by Severe Brain Injury With Autologous Adipose-derived Mesenchymal Stem Cells",,"Completed","No Results Available","The Sequelae Caused by Severe Brain Injury","Biological: autologous adipose-derived mesenchymal stem cells","Safety evaluation|Positron emission tomography|Magnetic Resonance Imaging|Electroencephalogram|Neuropsychological assessment|Electrodiagnostic Testing|Assessment of language and swallowing functions|Measure of the severity of disability|Assessment of spasticity and strength|Assessment of brain motor control","National Yang Ming University","All","20 Years to 40 Years   (Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SB-VGH-201101","October 2011","May 2013","May 2013","July 25, 2012",,"September 12, 2014","Taipei Veterans General Hospital, Taipei, Taiwan",,"https://ClinicalTrials.gov/show/NCT01649700"
158,"NCT01157403","Autologous Transplantation of Mesenchymal Stem Cells for Treatment of Patients With Onset of Type 1 Diabetes",,"Unknown status","No Results Available","Evidence of Liver Transplantation","Biological: Autologous transplantation","C peptide release test","Lu Debin|Third Military Medical University","All","10 Years to 40 Years   (Child, Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","ldb201001","July 2010","July 2014","August 2014","July 7, 2010",,"June 18, 2013","Endocrine Department, the south west Hospital of the Third Military Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT01157403"
159,"NCT03461458","Autologous, Culture-Expanded Mesenchymal Stromal Cells for Degenerative Disc Disease",,"Active, not recruiting","No Results Available","Degenerative Disc Disease","Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells","Number of patients who experience adverse events (AEs)|Change in low back pain and function following injection of AD-MSCs|Changes from Baseline in disc height index as measured by X-ray at 12 months and 24 months|Changes from Baseline in T2 weighted signal intensity of the Nucleus Pulposus (NP) as measured by MRI without contrast","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","1","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-002136","October 17, 2018","September 30, 2021","September 30, 2021","March 12, 2018",,"December 29, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03461458"
160,"NCT02326935","Multi-Center Study Safety of Adipose Derived Mesenchymal Stem Cells for the Treatment of Multiple Sclerosis",,"Terminated","No Results Available","Multiple Sclerosis","Biological: Autologous adipose derived mesenchymal cells","Standard Complication Questionnaire|MS Impact Scale - MSIS-29|Modified SF-36 Cell-Based Therapy Follow Up|Physical Evaluation","American CryoStem Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","2","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CRYO-MS-ADSC-006","November 2014","May 18, 2018","May 18, 2018","December 30, 2014",,"May 22, 2018","The Da Vinci Center, George Town, Cayman Islands",,"https://ClinicalTrials.gov/show/NCT02326935"
161,"NCT03343782","Outcomes of Expanded Autologous Bone Marrow-derived Mesenchymal Stem Cells Therapy in Type II Diabetes","ASD2","Completed","No Results Available","Type 2 Diabetes Mellitus","Combination Product: Expanded autologous bone marrow-derived mesenchymal stem cell","Insulin dose|Adverse events|Hemoglobin A1c (HbA1c) level","Vinmec Research Institute of Stem Cell and Gene Technology","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VinmecRISCGT70","November 1, 2017","August 1, 2019","August 1, 2019","November 17, 2017",,"June 18, 2021","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03343782"
162,"NCT02338271","Autologous Adipose Derived Stem Cell Therapy for Intervertebral Disc Degeneration",,"Unknown status","No Results Available","Low Back Pain","Other: autologous adipose derived mesenchymal stem cell","Evaluation of Safety and Tolerability (Adverse events)|Change in the T2 MRI signal intensity of the nucleus pulposus|Overall improvement in the Disc Height Index|improvement in Visual Analogue Scale (VAS)|improvement in Oswestry Disability Index (ODI)|improvement in Short Form-36","Inbo Han|CHA University|Bundang CHA Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ADMSC-DD-Han","January 2015","December 2017","December 2017","January 14, 2015",,"January 14, 2015","CHA University, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02338271"
163,"NCT03979898","Safety and Effectiveness of Autologous Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With CP","CP","Completed","No Results Available","Cerebral Palsy","Biological: ASTROSTEM","Kaufman Assessment Battery for Children (K-ABC)|Blood concentration test|Gross Motor Function Measurement (GMFM)|Box and Block Test|Modified Ashworth Scale (MAS)|SF-36|Verification of ASTROSTEM's effect on the brain through fMRI & MRS (Magnetic Resonance Spectroscopy) scan","R-Bio|Kyung Hee University Hospital at Gangdong","All","36 Months to 12 Years   (Child)","Early Phase 1","1","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","biostar-CP","June 15, 2017","April 23, 2019","May 13, 2019","June 7, 2019",,"June 7, 2019","KyungHee University Gandong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03979898"
164,"NCT04446884","Treatment of Stress Urinary Incontinence in Women With Autologous Adipose-derived Mesenchymal Stem Cells",,"Completed","No Results Available","Stress Urinary Incontinence","Biological: Autologous adipose-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus","Female","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(UIW)","March 1, 2018","December 31, 2019","December 31, 2019","June 25, 2020",,"June 25, 2020","Hrodna City Clinical Hospital, Hrodna, Belarus",,"https://ClinicalTrials.gov/show/NCT04446884"
165,"NCT05018871","Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intravenous Infusion for CP",,"Suspended","No Results Available","Cerebral Palsy","Biological: autologous adipose derived mesenchymal stem cells","Safety (adverse events)|Efficacy: Gross Motor Function Measure (GMFM)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-GR-8-04","December 2021","December 2025","December 2025","August 24, 2021",,"October 15, 2021","Mitera Hospital Athens Greece, Marousi, Greece",,"https://ClinicalTrials.gov/show/NCT05018871"
166,"NCT05018793","Safety of Cultured Autologous Adult Adipose Derived Mesenchymal Stem Cell Intrathecal Injection for SCI",,"Suspended","No Results Available","Spinal Cord Injuries","Biological: autologous adipose derived mesenchymal stem cells","Safety (adverse events)|Efficacy: American Spinal Injury Association Impairment Scale (ASIA)","The Foundation for Orthopaedics and Regenerative Medicine","All","Child, Adult, Older Adult","Phase 1","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SC-8-GR-10-02","December 2021","December 2025","December 2025","August 24, 2021",,"October 15, 2021","Mitera Hospital Athens Greece, Marousi, Greece",,"https://ClinicalTrials.gov/show/NCT05018793"
167,"NCT02477540","A Safety and Efficacy Study of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia",,"Withdrawn","No Results Available","Critical Limb Ischemia","Drug: Cellgram-CLI","Ankle Brachial Pressure Index, ABPI|Collateral vessel formation on digital subtraction angiography (DSA)|Difference of Wound size|Improved transcutaneous oxygen pressure (TCPO2)|Pain on the Visual Analogue Scale(VAS)|Reduced limb amputation|Temperature change on thermography|Dose about using analgesic medicine|Change in Rutherford classification|Frequency about using analgesic medicine","Pharmicell Co., Ltd.","All","20 Years to 80 Years   (Adult, Older Adult)","Phase 1","0","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cellgram-CLI","December 2019","June 2020","June 2020","June 22, 2015",,"March 22, 2019",,,"https://ClinicalTrials.gov/show/NCT02477540"
168,"NCT02327832","Safety Study of Liver Regeneration Therapy Using Cultured Autologous BMSCs",,"Unknown status","No Results Available","Liver Regeneration","Procedure: Autologous BMSCs|Drug: bone marrow-derived mesenchymal stem cells","The incidence of adverse events|Child-Pugh score|Serum albumin levels|Serum fibrosis markers|Improvement or disappearance of lower extremity edema|Subjective symptom scores (SF-36)","Yamaguchi University Hospital","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ICHINAI-BMSC1","December 2014","March 2017",,"December 30, 2014",,"December 30, 2014","Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Yamaguchi, Japan",,"https://ClinicalTrials.gov/show/NCT02327832"
169,"NCT02805855","Autologous Culture Expanded Mesenchymal Stromal Cells for Knee Osteoarthritis",,"Recruiting","No Results Available","Osteoarthritis, Knee","Drug: Autologous Adipose-Derived Mesenchymal Stromal Cells","Number of subjects experiencing adverse events.","Jacob L. Sellon, M.D.|Mayo Clinic","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","15-008179","October 26, 2016","April 26, 2023","April 26, 2023","June 20, 2016",,"January 6, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02805855"
170,"NCT04426643","Treatment of Urinary Incontinence in Men After Prostatectomy With Autologous Adipose-derived Mesenchymal Stem Cells",,"Completed","No Results Available","Urinary Incontinence","Biological: Autologous adipose-derived mesenchymal stem cells|Other: Standard treatment according to the Clinical protocols","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|The state institution N. N. Alexandrov National Cancer Centre of Belarus","Male","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(UIM)","August 1, 2020","February 20, 2021","March 31, 2021","June 11, 2020",,"May 25, 2021","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04426643"
171,"NCT01745783","Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis",,"Active, not recruiting","No Results Available","Multiple Sclerosis","Other: Bone marrow mesenchymal stem cells autologous|Other: Placebo comparator","Absence of unexpected serious adverse reactions as a measure of safety and reduction in number and volumes of the lesions on magnetic resonance image|Differences the results obtained in the two groups of patients due to determined parameters.","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","26","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CeTMMo/EM/2010|2010-023368-42","January 2013","June 2021","February 2022","December 10, 2012",,"July 22, 2021","University Hospital Reina Sofia, Córdoba, Spain|University Regional Hospital Carlos Haya, Málaga, Spain|University Hospital Virgen Macarena, Sevilla, Spain",,"https://ClinicalTrials.gov/show/NCT01745783"
172,"NCT04520373","Autologous Adipose Derived Mesenchymal Stem Cells for Spinal Cord Injury Patients",,"Recruiting","No Results Available","Spinal Cord Injuries|Paralysis","Other: Best Medical Management: Occupational and Physical Therapy|Biological: Autologous, Adipose Derived Mesenchymal Stem Cells","•Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|change in Neurogenic Bladder Symptom Score (NBSS)|change in Neurogenic Bowel Symptom Score|Incidence of abnormal CSF composition|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Correlation of adverse events to study drug","Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 2","40","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","19-011706","June 25, 2020","June 2022","June 2024","August 20, 2020",,"September 5, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT04520373"
173,"NCT04457037","Treatment of Patients With Trophic Ulcers Using Mesenchymal Stem Cells",,"Completed","No Results Available","Trophic Ulcer","Biological: Autologous adipose-derived mesenchymal stem cells","Number of patients with tropic ulcers cured|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_MSC(TrophicUlcer)","October 1, 2009","December 31, 2013","December 31, 2013","July 7, 2020",,"July 7, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04457037"
174,"NCT01624779","Intrathecal Transplantation Of Autologous Adipose Tissue Derived MSC in the Patients With Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Drug: autologous adipose tissue derived mesenchymal stem cells","Significant MRI Change before and after intervention|Significant neurologic funtion Change before and after intervention|Significant Electrophysiological Change before and after intervention|Adverse event","Bukwang Pharmaceutical","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1","15","Industry","Interventional","Intervention Model: Factorial Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KOR-01","April 2012","May 2014","May 2014","June 21, 2012",,"February 13, 2015","Korea University Anam Hospital, Seoul, Seongbukgu, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01624779"
175,"NCT00891501","The Use of Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Articular Cartilage Defects",,"Unknown status","No Results Available","Degenerative Arthritis|Chondral Defects|Osteochondral Defects","Procedure: Bone Marrow Aspiration|Procedure: Bone marrow mesenchymal stem cell implantation","Improvement in Clinical Scores and Radiological images","Cairo University","All","15 Years to 55 Years   (Child, Adult)","Phase 2|Phase 3","25","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Amgad","November 2006","December 2014","December 2014","May 1, 2009",,"May 1, 2009","Deaprtment of Orthopedic Surgery and Tissue Culture Unit of the Department of Medical Biochemistry - Cairo University School of Medicne - Kasr Al Ainy Hospitals -Al-Saray Street, El Manial, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT00891501"
176,"NCT03955497","Effectiveness of Autologous Adipose-derived Stem Cells in the Treatment of Knee Cartilage Injury",,"Recruiting","No Results Available","Knee Osteoarthritis|Cartilage Degeneration","Other: Autologous Adipose-derived Mesenchymal Stem Cell Gel|Drug: Sodium Hyaluronate|Procedure: Extraction of abdominal fat","Hospital for special surgery knee score postoperative 1 month|Hospital for special surgery knee score postoperative 3 month|Hospital for special surgery knee score postoperative 6 month|Hospital for special surgery knee score postoperative 12 month|Hospital for special surgery knee score postoperative 24 month|Hospital for special surgery knee score postoperative 36 month|Visual Analogue Scale Postoperative Day 1|Visual Analogue Scale Postoperative Day 2|Visual Analogue Scale Postoperative Day 3|Visual Analogue Scale Postoperative Day 7|Visual Analogue Scale Postoperative 1 month|Visual Analogue Scale Postoperative 3 month|Visual Analogue Scale Postoperative 6 month|Visual Analogue Scale Postoperative 12 month|Visual Analogue Scale Postoperative Day One|Visual Analogue Scale Postoperative 24 month|Visual Analogue Scale Postoperative 36 month|Evaluation of cartilage repair under MRI postoperative 12 month|Evaluation of cartilage repair under MRI postoperative 24 month|Evaluation of cartilage repair under MRI postoperative 36 month|Degree of meniscus injury under MRI postoperative 12 month|Degree of meniscus injury under MRI postoperative 24 month|Degree of meniscus injury under MRI postoperative 36 month|Evaluation of cartilage repair under arthroscope postoperative 12 month|Degree of meniscus injury under arthroscope postoperative 12 month|Squatting to Standing Time postoperative 1 month|Squatting to Standing Time postoperative 3 month|Squatting to Standing Time postoperative 6 month|Squatting to Standing Time postoperative 12 month|Squatting to Standing Time postoperative 24 month|Squatting to Standing Time postoperative 36 month","Qilu Hospital of Shandong University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2018023","October 1, 2018","October 1, 2022","December 1, 2022","May 20, 2019",,"September 16, 2020","Qilu hospital of Shandong University, Jinan, Shandong, China",,"https://ClinicalTrials.gov/show/NCT03955497"
177,"NCT01302015","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Buerger's Disease",,"Completed","No Results Available","Buerger's Disease","Biological: RNL-Vascostem®","Treadmill Walking Distance|VAS(Visual Analog Scale)|Toe-Brachial Pressure Index, TBPI|Transcutaneous oxygen pressure, TcPO2|Arterial Brachial Pressure Index, ABPI|Pain Free Walking Distance, PFWD|Angiography|Laser Doppler|dose and frequency in use of a analgesic medicine|Safety Evaluation","R-Bio","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","15","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Vascostem","December 2007","December 2013","December 2013","February 23, 2011",,"June 5, 2019","Seoul St. Mary's Hospital, Seoul, Korea, Republic of|SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01302015"
178,"NCT05011474","Safety and Efficacy Study of Matrilin-3 Pretreated Autologous Adipose Derived Mesenchymal Stem Cells Implantation in Chronic Low Back Pain Patients With Lumbar Intervertebral Disc Degeneration","MANT3_ASC","Enrolling by invitation","No Results Available","Patients With Chronic Low Back Pain Due to Degenerative Lumbar Disc","Biological: administered an autologous adipose-derived mesenchymal stem cell spheroid pretreated with matrillin 3","1) Adverse reaction and serious adverse reaction evaluation 2) laboratory inspection 3) Vital signs 4) Biochemical examination 5) Lumbar MRI 6) Monitoring systemic infection|Confirmation of the degree of pain improvement in VAS|Confirmation of the degree of improvement in disability (ODI)|Confirmation of increase in water content in the nucleus using MRI","Inbo Han|CHA University","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2018-10-013","April 23, 2021","January 20, 2022","December 31, 2022","August 18, 2021",,"August 25, 2021","CHA University, CHA Bundang Medical Center, Seongnam-si, Gyeonggi-do, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT05011474"
179,"NCT01306513","Safety and Feasibility Study of Administration of Mesenchymal Stemcells for Treatment of Emphysema",,"Completed","No Results Available","Emphysema","Biological: autologous bone marrow derived mesenchymal stromal cells","Number of Participants with Adverse Events as a Measure of Safety and Tolerability","Leiden University Medical Center","All","40 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL28562.000.09","October 2010","June 2012","November 2012","March 2, 2011",,"November 19, 2012","Department of Pulmonology, Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT01306513"
180,"NCT01643681","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Lumbar Intervertebral Disc Degeneration",,"Withdrawn","No Results Available","Lumbar Intervertebral Disc Degeneration","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","Magnetic Resonance Imaging|Changes of Neurological Functions|Safety evaluation","R-Bio|Korea University Anam Hospital","All","19 Years to 70 Years   (Adult, Older Adult)","Not Applicable","0","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-MSCs-LIDD","July 2012","March 2014","December 2015","July 18, 2012",,"June 5, 2019","Korea University Anam Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01643681"
181,"NCT03608579","Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA",,"Recruiting","No Results Available","Osteoarthritis, Hip","Drug: Autologous Adipose Derived Mesenchymal Stromal Cells","Nature, incidence and severity of adverse events (AEs)|Change in Visual Analog Scale (VAS) for pain in the target hip following completion of treatment cycles|Change in Tegner activity scale in the target hip following completion of treatment cycles|Change in modified Harris Hip Score (mHHS) in the target hip following completion of treatment cycles|Change in Hip disability and osteoarthritis Outcome Score (HOS) in the target hip following completion of treatment cycles|Change in radiographic joint morphology|Change in cartilage thickness|Change in cartilage volume|Change in cartilage morphology|Change in subchondral bone morphology|Change periarticular soft-tissues|Change in synovial fluid biomarkers within the target hip","Mayo Clinic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","18-000015","November 5, 2018","December 31, 2021","December 31, 2021","August 1, 2018",,"December 24, 2020","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03608579"
182,"NCT03876197","Mesenchymal Stem Cells for Radiation-induced Xerostomia",,"Enrolling by invitation","No Results Available","Radiation Toxicity|Xerostomia Due to Radiotherapy|Dry Mouth|Hyposalivation|Mesenchymal Stem Cells|Mesenchymal Stromal Cells|Long Term Adverse Effects","Biological: Autologous adipose-derived mesenchymal stem/stromal cells|Other: Placebo","Safety: Serious Adverse Events (SAEs) and new chronic diseases|Overall survival|Relapse of oropharyngeal cancer|New malignancies|Zoonotic Diseases|Patient-reported outcome measures-Health-related quality of life (HRQoL","Rigshospitalet, Denmark","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Other","CVB2019-1|2014-004349-29","August 1, 2020","December 1, 2022","December 1, 2023","March 15, 2019",,"October 22, 2020","Department of Otolaryngology, University Hospital of Copenhagen, Copenhagen, Denmark",,"https://ClinicalTrials.gov/show/NCT03876197"
183,"NCT01274975","Autologous Adipose Derived MSCs Transplantation in Patient With Spinal Cord Injury.","MSC","Completed","No Results Available","Spinal Cord Injury","Other: Autologous Adipose Derived Mesenchymal Stem Cells","safety evaluation","R-Bio","Male","19 Years to 60 Years   (Adult)","Phase 1","8","Industry","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Astrostem","July 2009","November 2009","February 2010","January 12, 2011",,"March 26, 2014",,,"https://ClinicalTrials.gov/show/NCT01274975"
184,"NCT04352803","Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease",,"Not yet recruiting","No Results Available","Covid-19 Pneumonia|Cyotokine Storm","Biological: Autologous Adipose MSC's","Safety - Incidence of unexpected adverse events|Efficacy - Frequency of progression to mechanical ventilation|Efficacy - Changes in length of mechanical ventilation|Efficacy - Changes in length of weaning of mechanical ventilation|Efficacy - Changes in length of hospital stay|Efficacy - Changes in mortality rate","Regeneris Medical","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","COVID-MSCIV","April 2020","April 2024","April 2026","April 20, 2020",,"April 21, 2020",,,"https://ClinicalTrials.gov/show/NCT04352803"
185,"NCT01895413","Autologous Bone Marrow Mesenchymal Stem Cells Transplantation for Articular Cartilage Defects Repair",,"Completed","No Results Available","Osteoarthritis","Procedure: Bone marrow aspiration","Change in WOMAC (Western Ontario and McMaster Universities)score|Change from baseline in cartilage thickness at 6 months by MRI|Knee pain relief (WOMAC and Lequesne scores)|Change from baseline in progression of osteoarthritis at 12 months by plain radiograph (X-ray)","Alexandra Cristina Senegaglia|Pontifícia Universidade Católica do Paraná|Consultório Médico Dr. Alcy Vilas Boas Jr., Paraná, Brasil|Hospital Marcelino Champagnat, Paraná, Brasil|Fundação Araucária","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CTM_LESÃO ARTICULAR-461/2010","September 2012","July 2013","January 2016","July 10, 2013",,"December 13, 2017","Centro de Tecnologia Celular, Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil",,"https://ClinicalTrials.gov/show/NCT01895413"
186,"NCT03279796","Treatment of Tendon Disease Using Autologous Adipose-derived Mesenchymal Stem Cells",,"Not yet recruiting","No Results Available","Rotator Cuff Tear|Lateral Epicondylitis","Biological: Autologous adipose-derived MSCs|Drug: Compound betamethasone","Change from baseline in Visual Analog Scale(VAS) at 3, 6 and 12 weeks|Change from baseline in Constant-Murley Score(CMS) at 3, 6 and 12 weeks,|American Shoulder and Elbow Surgeons (ASES) Shoulder Score|The Disabilities of the Arm, Shoulder and Hand(DASH) Score|Adverse events","Second Affiliated Hospital, School of Medicine, Zhejiang University|Zhejiang Xingyue Biotechnology Co., Ltd.","All","18 Years to 90 Years   (Adult, Older Adult)","Phase 2","200","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","2017.No.55","October 1, 2018","December 31, 2019","December 31, 2021","September 12, 2017",,"April 26, 2018","Weiliang Shen, Hangzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT03279796"
187,"NCT03828123","Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis","AMSC-ALS-001","Completed","No Results Available","Motor Neuron Disease, Amyotrophic Lateral Sclerosis","Biological: Suspension of human autologous MSC 3P in 1.5 ml","Safety: Complications related to the medicinal product application - new neurological deficit and occurrence of other adverse events|Efficacy: Inhibition of the disease progression - ALS functional rating scale|Efficacy: Inhibition of the disease progression - Norris scale|Efficacy: Inhibition of the disease progression - Forced vital capacity (FVC)","Bioinova, s.r.o.|Department of Neurology, University Hospital Motol, Prague, Czech Republic","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","26","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AMSC-ALS-001","January 2012","August 18, 2017","August 18, 2017","February 4, 2019",,"February 12, 2019",,,"https://ClinicalTrials.gov/show/NCT03828123"
188,"NCT03325504","A Comparative Study of 2 Doses of BM Autologous H-MSC+Biomaterial vs Iliac Crest AutoGraft for Bone Healing in Non-Union","ORTHOUNION","Active, not recruiting","No Results Available","Non Union Fracture","Biological: Cultured Mesenchymal Stem Cells|Procedure: Autologous iliac crest graft","Bone consolidation|Radiological Bone consolidation|Level of Pain|Complications|Health status","Universidad Autonoma de Madrid","All","18 Years to 99 Years   (Adult, Older Adult)","Phase 3","42","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ORTHOUNION|2015-000431-32|EUCTR2015-000431-32-ES","September 5, 2017","June 30, 2021","June 30, 2022","October 30, 2017",,"October 6, 2021","CHU Clermont-Ferrand, Clermont-Ferrand, France|Department of Orthopaedic Surgery, Hospital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHU Nantes, Nantes, France|Department of Orthopaedic Surgery Toulouse University Hospital, Toulouse, France|Department of Orthopaedic Surgery, CHU Tours, Tours, France|Universitätsklinikum Frankfurt, Department of Trauma, Hand and Reconstructive Surgery, Frankfurt, Germany|Universitätsklinikum Freiburg, Klinik für Orthopädie und Unfallchirurgie, Freiburg, Germany|Universitätsklinikum München, Munich, Germany|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, SSD Fisiopatologia Ortopedica e Medicina Rigenerativa, Bologna, Italy|Arienda Spedali Civili di Brescia II Ortopedia e Traumatologia, Brescia, Italy|Istituto Ortopedico Galeazzi, Chirugia dell´Anca l, Milano, Italy|Azienda Ospedaliero- Universitaria di Modena, Reparto di Ortopedia e Traumatologia, Modena, Italy|Azienda Universitaria Ospedaliera di Pisa- II, Clinica di Ortopedia e Traumatologia, Pisa, Italy|Hospital U. Puerta de Hierro-Majadahonda, Servicio de Cirugía Ortopédica y Traumatología, Majadahonda, Madrid, Spain|Hospital Clínica San Carlos, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. 12 de Octubre, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. Gregorio Marañon, Servicio de Cirugía Ortopédica y Traumatología, Madrid, Spain|Hospital U. La Princesa, Servicio de CirugíaOrtopédica y Traumatología, Madrid, Spain|Hospital Universitario Ramón y Cajal, Madrid, Spain|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT03325504"
189,"NCT03308565","Adipose Stem Cells for Traumatic Spinal Cord Injury","CELLTOP","Active, not recruiting","No Results Available","Spinal Cord Injuries|Paralysis","Biological: Autologous, Adipose derived Mesenchymal Stem Cells","Incidence of acute adverse events|Incidence of delayed adverse events|Severity of adverse events|Relationship of adverse events to study drug|Incidence of serious adverse events (SAE)|Change in sensory and motor function following completion of treatment as measured by the American Spinal Injury Association (ASIA) Impairment Scale (AIS)|Change in sensory and motor function following completion of treatment as measured by motor evoked potentials (MEP)|Change in sensory and motor function following completion of treatment as measured by Somatosensory Evoked Potentials (SSEPs)|Number of subjects who develop a new pathologic mass at the spinal cord area of injection or anywhere along the spinal cord.|Change in number of red blood cells following treatment|Change in white blood cells with differential following treatment|Change in number of platelets following treatment|Change in Serum C-Reactive Protein (CRP)|Change in Erythrocyte Sedimentation Rate (ESR)|Change in Blood Urea Nitrogen (BUN)|Change in Creatinine|Change in Sodium|Change in Potassium|Change in Chloride|Change in Aspartate Aminotransferase (AST)|Change in Glucose|Change in Carbon Dioxide","Allan Dietz, Ph.D.|Mayo Clinic","All","18 Years and older   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","17-004621","December 5, 2017","November 2022","November 2023","October 12, 2017",,"November 17, 2021","Mayo Clinic, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT03308565"
190,"NCT04675359","Adipose-derived MSCs After Enzymatic Digestion vs. Mechanically Fragmented Fat Transfer in Knee Osteoarthritis Treatment",,"Not yet recruiting","No Results Available","Knee Osteoarthritis|Chondropathy","Procedure: Autologous adipose derived Mesenchymal Stromal Cells (MSC) injection into the knee joint","Changes in patients reported outcome measures - Knee Injury and Osteoarthritis Outcome Score (KOOS)|Changes in flexibility of the knee joint|Changes in X-ray imaging of the knee joint in a standing position (AP view)|Changes in MRI with T-2 Mapping of the knee cartilage","Medical University of Warsaw","All","18 Years and older   (Adult, Older Adult)","Phase 4","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","MSC","July 1, 2021","June 30, 2023","December 1, 2023","December 19, 2020",,"January 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04675359"
191,"NCT01643655","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Avascular Necrosis of the Femoral Head",,"Completed","No Results Available","Avascular Necrosis of the Femoral Head","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","Magnetic Resonance Imaging|SPECT/CT|Hip X-ray|HHS (Harris Hip Score)|WOMAC (Western Ontario and McMaster Universities) Index|UCLA (University of California Los Angeles) hip questionnaire|Safety evaluation","R-Bio|SMG-SNU Boramae Medical Center","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-MSCs-AVN","May 2012","December 2014","March 2015","July 18, 2012",,"August 31, 2017","SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01643655"
192,"NCT04749667","Study of Mesenchymal Autologous Stem Cells as Regenerative Treatment for Multiple Sclerosis","SMART-MS","Recruiting","No Results Available","Multiple Sclerosis|Progressive Multiple Sclerosis","Other: MSCs|Drug: Saline","Neurophysiological parameters - Combined evoked potentials|Neurophysiological parameters - Somatosensoric evoked potantials|Neurophysiological parameters - Motor evoked potentials|Neurophysiological parameters - Visual evoked potentials|MRI-Lesion volumes|MR- Brain volumes|Expanded disability status scale|Patient reported outcomes (PROs)|Nine-Hole-Peg Test (9-HPT)|Timed 25 Foot Walk (T25FW)|Visual function|Optical coherence tomography (OCT)|Rate and nature of adverse- and serious adverse events","Haukeland University Hospital|University of Bergen|University Hospital Ulm|University Hospital, Akershus|St. Olavs Hospital|University Hospital of North Norway","All","18 Years to 55 Years   (Adult)","Phase 1|Phase 2","18","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","159326","August 9, 2021","October 4, 2024","January 4, 2025","February 11, 2021",,"September 8, 2021","University hospital of North Norway, Tromsø, Troms Og Finnmark, Norway|St.Olav university hospital, Trondheim, Trøndelag, Norway|Haukeland University Hospital, Bergen, Vestland, Norway|Akershus university hospital, Lørenskog, Viken, Norway",,"https://ClinicalTrials.gov/show/NCT04749667"
193,"NCT04834609","Adipose Derived Mesenchymal Stem Cell Characteristics in Anal Fistulas",,"Completed","No Results Available","Perianal Fistula|Adipose Tissue|Tissue Transplantation","Procedure: Injection of autologous adipose tissue in anal fistula","Investigation of cell proliferation of AT-MSCs|Investigation of differentiation potential of AT-MSCs to differentiate into adipocyte|Investigation of differentiation potential of AT-MSCs to differentiate into osteoblast|Measurement of gene expression profile of AT-MSCs|Healing of anal fistula after treatment|Evaluation of fistula healing after treatment|Functional gastroenterological outcome after treatment|Defecation disorder evaluation after treatment|Functional urological outcome after treatment","University of Aarhus|University of Southern Denmark|UiT The Arctic University of Norway","All","18 Years to 70 Years   (Adult, Older Adult)","Not Applicable","27","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AT-MSCs_Anal fistulas","January 2015","October 2017","February 2021","April 8, 2021",,"April 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04834609"
194,"NCT04064957","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Chronic Spinal Cord Injury",,"No longer available","No Results Available","Spinal Cord Injuries","Biological: HB-adMSCs",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years and older   (Adult, Older Adult)",,,"Other|Industry","Expanded Access:Individual Patients",,"HBSCI02",,,,"August 22, 2019",,"July 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04064957"
195,"NCT02330978","Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma.",,"Completed","Has Results","Retinal Degeneration|Primary Open-angle Glaucoma","Procedure: Intravitreal transplantation of mesenchymal stem cell|Biological: Culture and isolation of autologous bone-marrow mesenchymal stem cells","Type and Severity of Adverse Effects (AE) and Adverse Reactions (AR)|Changes in Visual Acuity|Changes in Visual Field|Changes in Optical Coherence Tomography Parameters Related to Glaucoma|Changes in Retinal Ganglion Cells Function by ERG","University of Sao Paulo|Conselho Nacional de Desenvolvimento Científico e Tecnológico","All","40 Years to 90 Years   (Adult, Older Adult)","Phase 1","2","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HCRP 14151/2010","January 2014","September 2016","September 2016","January 5, 2015","July 8, 2019","July 8, 2019","Ribeirão Preto Medical School, Ribeirao Preto, Sao Paulo, Brazil",,"https://ClinicalTrials.gov/show/NCT02330978"
196,"NCT04855955","Autologous Human Adipose-Derived Mesenchymal Stem Cells in Alzheimer's Disease",,"Available","No Results Available","Alzheimer Disease","Drug: Adipose-Derived Mesenchymal Stem Cells",,"Celltex Therapeutics Corporation",,"Child, Adult, Older Adult",,,"Industry","Expanded Access:Individual Patients",,"CTXSP0001",,,,"April 22, 2021",,"April 22, 2021",,,"https://ClinicalTrials.gov/show/NCT04855955"
197,"NCT02564328","Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Ischemic Stroke",,"Unknown status","No Results Available","Stroke","Genetic: Intravenous stem cell transplantation","Change from baseline in Fugl-Meyer Scale at 12 months|Change from baseline in NIH Stroke Scale at 12 months|Change from baseline in Barthel Index at 12 months|Change from baseline in SSS at 12 months|Change from baseline in mRS at 12 months|Improvement of vision measured by brain visual examination","Southern Medical University, China|Second Affiliated Hospital of Guangzhou Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","201400000003-2","November 2014","November 2016","November 2017","September 30, 2015",,"September 30, 2015","Xiaodan Jiang, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02564328"
198,"NCT01909154","Safety Study of Local Administration of Autologous Bone Marrow Stromal Cells in Chronic Paraplegia","CME-LEM1","Completed","Has Results","Spinal Cord Injury","Biological: Mesenchymal stromal cell therapy","Safety-Number of Adverse Events|Efficacy-Sensitivity Recovery Using ASIA Scale|Efficacy-Changes in the Level of Chronic Pain Based on the IANR-SCIFRS Scale (Pain Section)|Efficacy- Changes in the Neurophysiological Parameters Measured as the Number of Patients With SSEPs (Somatosensory Evoked Potentials)|Efficacy-Urodynamic Studies in Terms of máximum Cystometric Capacity|Efficacy-modification of Magnetic Resonance Imaging (MRI)","Puerta de Hierro University Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CME-LEM1|2010-023285-46","March 2013","April 2014","March 2015","July 26, 2013","March 29, 2019","March 29, 2019","Hospital Puerta de Hierro, Majadahonda, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01909154"
199,"NCT05094011","Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease",,"Not yet recruiting","No Results Available","Idiopathic Parkinson's Disease","Biological: Aadipose-Derived Mesenchymal Stem Cells","Grading of Adverse Events|Routine physical examinations|Changes in physical examinations: clinical standard neurological examination [Safety of Mitocell]|Changes in vital signs: blood pressure [Safety of Mitocell]|Changes in vital signs: pulse rate [Safety of Mitocell]|Changes in vital signs: body temperature [Safety of Mitocell]|Changes in clinical laboratory safety screen: haematology - hemoglobin [Safety of Mitocell]|Changes in clinical laboratory safety screen: Platelet count [Safety of Mitocell]|Changes in clinical laboratory safety screen: white blood cell (WBC) counts [Safety of Mitocell]|Changes in clinical laboratory safety screen: International Normalized Ratio (INR) [Safety of Mitocell]|Changes in clinical laboratory safety screen: activated partial thromboplastin time (aPTT) [Safety of Mitocell]|Electrocardiogram (ECG)|Magnetic Resonance Imaging (MRI)|MDS-UPDRS (Movement Disorder Society unified Parkinson's disease rating scale)|Modified Hoehn & Yahr staging|18F-DOPA PET|levodopa equivalent daily dose (LEDD)|PDQ-39 (Parkinson's Disease Questionnaire)|Beck Depression Inventory (BDI-II) scores|Hamilton Depression Rating Scale (HAM-D-17) scores|Mini Mental State Examination (MMSE) Scores","Taiwan Mitochondrion Applied Technology Co., Ltd.","All","45 Years to 70 Years   (Adult, Older Adult)","Phase 1","9","Industry","Interventional","Allocation: N/A|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MITOCELL-01","February 1, 2022","September 30, 2022","July 31, 2024","October 26, 2021",,"November 23, 2021",,,"https://ClinicalTrials.gov/show/NCT05094011"
200,"NCT02881489","Autologous Bone Marrow Mesenchymal Stem Cells in the Treatment of Patients With Amyotrophic Lateral Sclerosis","UwmBmmscALS","Unknown status","No Results Available","Amyotrophic Lateral Sclerosis","Other: Biological: Cell-based therapy","Changes in the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) between patients before and after stem cell transplantation.","University of Warmia and Mazury","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UWM/ALS-MSC.2015/002","November 2015","April 2018","December 2018","August 29, 2016",,"August 29, 2016",,,"https://ClinicalTrials.gov/show/NCT02881489"
201,"NCT01300598","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Transplantation in Patient With Degenerative Arthritis",,"Completed","No Results Available","Degenerative Arthritis","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","Safety evaluation|WOMAC(Western Ontario and McMaster Universities) Index|Magnetic Resonance Imaging|KSCRS(Knee Society Clinical rating System)|VAS(11-point box visual analogue scale)|Histological evaluates","R-Bio","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Jointstem","December 2008","September 2011","March 2012","February 21, 2011",,"June 5, 2019","SMG-SNU Boramae Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01300598"
202,"NCT01714167","Autologous Bone Marrow Mesenchymal Stem Cell Transplantation for Chronic Stroke",,"Unknown status","No Results Available","Stroke","Genetic: intracerebral stem cell transplantation","Change from baseline in NIH Stroke Scale at 12 months|Improvement of infarct size measured by brain MRI","Wenzhou Medical University|University of North Texas Health Science Center","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","WZMC-2011-8","June 2012","October 2015","December 2015","October 25, 2012",,"June 8, 2015","The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, Zhejiang, China",,"https://ClinicalTrials.gov/show/NCT01714167"
203,"NCT04815213","The Use of Expandeded Mesenchymal Stromal Cells (MSC) in Premature Ovarian Failure (POF) in Adult Humans",,"Recruiting","No Results Available","Premature Ovarian Failure","Biological: expanded autologous bone marrow derived MSC","Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]|Number of patients with enhanced hormonal profile, ovarian changes and endometrial changes|Number of patients with positive ovarian changes|Number of patients with increased endometrial thickness","University of Jordan","Female","18 Years to 38 Years   (Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Other","POF.UJCTC","January 1, 2020","January 31, 2022","January 31, 2022","March 24, 2021",,"March 24, 2021","Cell Therapy Center, University of Jordan, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT04815213"
204,"NCT02646007","Autologous Bone Marrow Derived Mesenchymal Stromal Cells Transplantation(BM-MSC) for Kienbock's Disease",,"Unknown status","No Results Available","Kienböck's Disease","Biological: BM-MSC transplantation","Pain|Bone density|Quality of life evaluated by Visual Analogue Score (VAS)|Infection: Presence of any sign or symptoms of infection|Cyst formation: Presence of any cyst or mass formation","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-014","November 2015","November 2018","December 2018","January 5, 2016",,"July 20, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02646007"
205,"NCT04212728","Treatment of Knee Osteoarthritis With Autologous Adipose-derived Mesenchymal Stem Cells",,"Recruiting","No Results Available","Knee Osteoarthritis","Biological: Auotologous AMSCs plus autologous PRP|Biological: Auotologous PRP","Physical function change|Change in pain density|Cartilage repair|Change in MOS item short from health survey(SF-36)|Change in Lequesne Index|Change in knee society score (KSS)","Yantai Yuhuangding Hospital","All","40 Years to 70 Years   (Adult, Older Adult)","Not Applicable","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","2019-003","December 2019","December 2020","December 2021","December 27, 2019",,"December 27, 2019","Yantai Yuhuangding Hospital, Yantai, Shandong, China",,"https://ClinicalTrials.gov/show/NCT04212728"
206,"NCT01389661","Treatment Of Maxillary Bone Cysts With Autologous Bone Mesenchymal Stem Cells (MSV-H)","BIOMAX","Completed","No Results Available","Maxillary Cyst|Bone Loss of Substance","Biological: MSV treatment","To evaluate the feasibility and safety of the implementation of MSV in the treatment of maxillary cysts|Indication of efficacy","Red de Terapia Celular|Sanidad de Castilla y León|University of Valladolid|Centro en Red de Medicina Regenerativa de Castilla y Leon|Citospin","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","11","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","TerCel0002|2010-024246-30|EC10-255|BIOMAX-VA-2010","April 2011","April 25, 2016","April 25, 2016","July 8, 2011",,"April 27, 2017","Río Hortega University Hospital, Valladolid, Valladid, Spain|Bionand, Parque Tecnológico de Andalucía, Universidad de Málaga, Malaga, Spain|Instituto de Biologia y Genetica Molecular, Valladolid, Spain",,"https://ClinicalTrials.gov/show/NCT01389661"
207,"NCT02057965","Mesenchymal Stromal Cell Therapy in Renal Recipients","MSCs","Active, not recruiting","No Results Available","Renal Transplant Rejection|Fibrosis","Drug: Mesenchymal Stromal Cells","Fibrosis by quantitative Sirius Red scoring of MSC treated and untreated groups|Renal function and proteinuria|Number of participants with CMV and BK infection an other opportunistic infections between groups|Number of participants with adverse events|composite end point efficacy failure (biopsy proven acute rejection, graft loss or death)|Presence of donor specific antibodies and immunologic monitoring|Progression of subclinical cardiovascular disease in the different treatment groups bij assessing echocardiographic parameters","Leiden University Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","70","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NL43712.000.13|2013-000819-25","March 2014","January 2020","January 2022","February 7, 2014",,"September 17, 2020","Leiden University Medical Center, Leiden, Netherlands",,"https://ClinicalTrials.gov/show/NCT02057965"
208,"NCT01809769","Autologous Adipose Tissue Derived Mesenchymal Stem Cells Therapy for Patients With Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Mesenchymal stem cells low-dose group|Biological: Mesenchymal stem cells mid-dose group|Biological: Mesenchymal stem cells high-dose group","Recording of Adverse Events and Serious Adverse Events|Electrocardiogram|Vital signs|Physical examination|WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Laboratory tests|SF-36|NRS-11|The volume of articular cartilage","Cellular Biomedicine Group Ltd.|RenJi Hospital","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","18","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","CBMG-KOA-1.1","March 2013","March 2015","July 2015","March 13, 2013",,"April 4, 2016","Department of Rheumatology,Ren Ji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai,China, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT01809769"
209,"NCT02344849","Safety of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Erectile Dysfunction",,"Completed","No Results Available","Erectile Dysfunction","Drug: mesenchymal stem cell","Number and severity of adverse events|Change From Baseline in the International Index of Erectile Function(IIEF)|Penile Doppler Sonography, PDS|Change From Baseline in Sexual Encounter Profile (SEP) Question 2|Global Assessment Question (GAQ)","Pharmicell Co., Ltd.","Male","20 Years and older   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cellgram-ED","July 2015","January 31, 2018","April 2018","January 26, 2015",,"January 9, 2019","Asan medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02344849"
210,"NCT04428801","Autologous Adipose-derived Stem Cells (AdMSCs) for COVID-19",,"Not yet recruiting","No Results Available","COVID-19","Biological: autologous adipose-derived stem cells","Tolerability and acute safety of AdMSC infusion by assessment of the total number of AEs/SAEs related and non-related with the medication|The overall proportion of subjects who develop any AEs/SAEs related and non-related with the AdMSC infusions as compared to the control group|COVID-19 incidence rates in both the study and control groups|The proportion of subjects who are infected by SARS-Cov-2 measured by PCR or other nuclear level-based SARS-Cov-2 virus testing in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method.|The proportion of subjects who are infected by SARS-Cov-2 virus develop symptoms including mild, classic, severe and critical sever cases between study group and control group.|Change of proportion of subjects who are infected by SARS-Cov-2 and develop IgM/IgG antibodies against SARS-Cov-2 between study group and control group.|Change of lymphocyte count in white blood cell counts from the baseline|Change of PaO2 arterial blood gases from the baseline|Compare the proportion of subjects who develop severe COVID-19 pneumonia cases for both study and control groups|COVID-19 mortality rates for both study and control groups|Change of C-reactive protein (CRP) (mg/L) from the baseline|Change of D-dimer (mg/L) from the baseline|Change of Procalcitonin (ug)/L from the baseline|Change of pro-type B natriuretic peptide (pro-BNP) (pg/mL) from the baseline|Change of Bilirubin (mg/dL) from the baseline|Change of Creatinine (mg/dL) from the baseline|Change in blood test values for cytokine panels (IL-1β, IL-6, IL-8, IL-10, TNFα) from the baseline|The proportion of subjects from SARS-CoV-2 RT-PCR positive to negativity in respiratory tract specimens (oropharyngeal samples) collected by oropharyngeal swab using the CDC standard method. as compared to control group|Quantifying viral RNA in stool for baseline and final follow-up.","Celltex Therapeutics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CTX0020-003","September 2021","September 2022","September 2024","June 11, 2020",,"July 23, 2021",,,"https://ClinicalTrials.gov/show/NCT04428801"
211,"NCT02853942","Autologous Adipose Mesenchymal Stem Cell Transplantation in the Treatment of Patients With Hemifacial Spasm",,"Unknown status","No Results Available","Injury of Facial Nerve, Unspecified Side, Initial Encounter","Biological: Autologous adipose stem cell therapy|Drug: Mecobalamin","House-Brackmann facial nerve grading scale","Xinhua Hospital, Shanghai Jiao Tong University School of Medicine","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","XH-16-012","October 2016","October 2017","December 2017","August 3, 2016",,"August 9, 2016",,,"https://ClinicalTrials.gov/show/NCT02853942"
212,"NCT01769872","Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cell Implantation in Patients With Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","ASIA (American Spinal Injury Association) scale|Magnetic Resonance Imaging|MEP/SSEP|ADL (activities of daily living)|SF-36|ODI (Oswestry Disability Questionnaire)|Frequency of Adverse Events","R-Bio|Korea University Anam Hospital","All","19 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-MSCs-SPI","January 2013","January 2016",,"January 17, 2013",,"August 2, 2016","Korea University Anam Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01769872"
213,"NCT04448106","Autologous Adipose Tissue-Derived Mesenchymal Stem Cells (AdMSCs) for Osteoarthritis","AdMSCs","Not yet recruiting","No Results Available","Osteoarthritis, Knee|Osteoarthritis, Hip|Osteoarthritis Shoulder","Biological: Celltex- AdMSCs","the frequency and nature of adverse events occurring during the study based on the annualized rate of all AdMSC-associated adverse events (AEs) in all subjects.|Any organ damage or safety concerns determined by SMAC 20 blood test.|Change of Knee injury and Osteoarthritis Outcome Score (KOOS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Knee Society Score (KSS, 0 is the worst and 100 is the best) from the baseline for OA-knee patients|Change of Hip disability and Osteoarthritis Outcome Score (HOOS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of Harris Hip Score (HHS, 0 is the worst and 100 is the best) from the baseline for OA-hip patients|Change of the American Shoulder and Elbow Surgeons Shoulder Score (ASES, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|Change of Constant shoulder score (CSS, 0 is the worst and 100 is the best) from the baseline for OA-shoulder patients|changes in joint images (X-ray or MRI) from the baseline","Celltex Therapeutics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","300","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","CTX0020-002","August 1, 2021","August 1, 2022","August 15, 2024","June 25, 2020",,"July 8, 2021",,,"https://ClinicalTrials.gov/show/NCT04448106"
214,"NCT02474342","Autologous Adipose Tissue Derived Mesenchymal Stem Cells for Rotator Cuff Disease",,"Completed","No Results Available","Rotator Cuff Disease","Biological: Autologous Adipose Tissue Derived MSCs Transplantation","SPADI(Shoulder pain and disability index)Score|Constant-Murley score|Visual Analog Scale_pain in motion|Changes in the size of rotator cuff tears determined by MRI|Changes in the size of rotator cuff tears determined by arthroscopy|Adverse event","Seoul National University Hospital","All","19 Years and older   (Adult, Older Adult)","Not Applicable","18","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BRM-15-01","July 7, 2015","November 2016","November 7, 2016","June 17, 2015",,"March 7, 2017","Joint & Spine Center, SMG-SNU Boramae Medical Center, Department of Orthopedic Surgery, Seoul National University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02474342"
215,"NCT03187431","Role of Stem Cell Therapy in Interstitial Pulmonary Fibrosis",,"Unknown status","No Results Available","Stem Cell Transplant Complications","Biological: autologous bone marrow mesenchymal stem cells","number of participants with treatment related side effects as infection, allergic reaction, disease acute exacerbation, and ectopic tissue formation|Post therapy diffusing capacity of CO% (DLCO)predicted|post therapy forced vital capacity (FVC)% predicted.","Assiut University","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","AssiutU4","December 11, 2017","October 1, 2018","December 1, 2018","June 15, 2017",,"June 15, 2017",,,"https://ClinicalTrials.gov/show/NCT03187431"
216,"NCT00850187","Autologous Transplantation of Mesenchymal Stem Cells (MSCs) and Scaffold in Full-thickness Articular Cartilage",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Bone marrow derived mesenchymal stem cells","Knee cartilage defects|pain","Royan Institute|Tehran University of Medical Sciences","All","45 Years to 60 Years   (Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan - Bone - 001","August 2008","July 2010","December 2010","February 24, 2009",,"January 5, 2012","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT00850187"
217,"NCT04650568","Biologic Augmentation With Mesenchymal Stem Cells in Patients Undergoing Anterior Cruciate Ligament Reconstruction","BMAC","Enrolling by invitation","No Results Available","Anterior Cruciate Ligament Injury|Anterior Cruciate Ligament Rupture","Device: Autologous Bone Marrow Derived Mesenchymal Stem Cells|Other: Sham incision","Signal to Noise Quotient|Side to side difference in anterior tibial translation|Patient reported outcomes- Tegner Score|Patient reported outcomes- Knee Injury and Osteoarthritis Outcome Score for Joint Replacement (KOOS Jr)|Patient reported outcomes- International Knee Documentation Committee (IKDC) Score","Rush University Medical Center","All","18 Years to 60 Years   (Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Outcomes Assessor)|Primary Purpose: Treatment","17082504","November 3, 2017","December 3, 2021","December 3, 2021","December 2, 2020",,"February 5, 2021","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT04650568"
218,"NCT03743155","Clinical Trial to Evaluate the Effect and Safety of MSV in Xerostomy",,"Unknown status","No Results Available","Xerostomia Due to Radiotherapy","Biological: mesenchymal cells","Changes in the characteristics and degree of discomfort of xerostomia trough OHIP questionnaire|Changes in the characteristics and degree of discomfort of xerostomia.|Sialometry results|Restoration of the glandular structure.|Measurement of submaxillary gland functionalism changes based on Gammagraphy|AEs and SAEs","Institut de Terapia Regenerativa Tissular","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XRS-ITRT-2018","December 15, 2018","May 30, 2019","May 30, 2021","November 16, 2018",,"November 16, 2018","Institut de Terapia Regenerativa Tissular, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT03743155"
219,"NCT01257776","Human Adipose Derived Mesenchymal Stem Cells for Critical Limb Ischemia (CLI) in Diabetic Patients",,"Completed","No Results Available","Critical Limb Ischemia (CLI)|Diabetes","Drug: Autologous adipose derived mesenchymal stem cells","Angiographic assessment of neovasculogenesis (angiogenesis plus arteriogenesis)|Major adverse event (death, target limb amputation)|Ankle Brachial Index|University of Texas Classification at target limb","Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud|Iniciativa Andaluza en Terapias Avanzadas|Andalusian Network for Design and Translation of Advanced Therapies","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","33","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CeTMAd/ICPD/2008","December 2010","February 2013","July 2015","December 10, 2010",,"August 5, 2015","University Hospital Virgen Macarena, Seville, Spain|CABIMER (Andalusian Center for Molecular Biology and Regenerative Medicine), Seville, Spain",,"https://ClinicalTrials.gov/show/NCT01257776"
220,"NCT03639506","Clinical Application of Autologous Mitochondria Transplantation for Improving Oocyte Quality.",,"Unknown status","No Results Available","Repetition Failure","Procedure: autologous mitochondria transplantation|Combination Product: autologous mitochondria from bone marrow mesenchymal stem cells into oocyte as well as intracytoplasmic sperm injection (ICSI)|Drug: intracytoplasmic sperm injection (ICSI)","live birth rate|clinical pregnancy rate|number of oocytes retrieved|fertility rate|normal fertility rate|good quality embryo rate","Sun Yat-sen University","Female","20 Years to 43 Years   (Adult)","Not Applicable","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","newivf20180817","September 2018","December 2020","September 2021","August 21, 2018",,"August 21, 2018",,,"https://ClinicalTrials.gov/show/NCT03639506"
221,"NCT02808208","Autologous Adipose Derived Mesenchymal Stem Cells (AMSC) in Reducing Hemodialysis Arteriovenous Fistula Failure",,"Enrolling by invitation","No Results Available","End Stage Renal Disease (ESRD)|Vascular Access Complication","Biological: Single Application of Adipose Derived Mesenchymal Stem Cells (AMSC)|Drug: Placebo|Biological: Two Applications of Adipose Derived Mesenchymal Stem Cells (AMSC)","Hemodialysis outflow vein diameter|Hemodialysis AVF Blood flow","Mayo Clinic","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","74","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Investigator)|Primary Purpose: Treatment","15-009053","June 7, 2017","December 2021","December 2021","June 21, 2016",,"July 26, 2021","Mayo Clinic in Rochester, Rochester, Minnesota, United States",,"https://ClinicalTrials.gov/show/NCT02808208"
222,"NCT02195323","Autologous Bone Marrow Derived Mesenchymal Stromal Cells (BM-MSCs) in Patients With Chronic Kidney Disease (CKD)",,"Completed","No Results Available","Chronic Kidney Disease","Biological: Intravenous injection","mass formation|Creatinin|GFR","Royan Institute","All","25 Years to 60 Years   (Adult)","Phase 1","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Kidney-004","April 2014","December 2015","January 2016","July 21, 2014",,"January 5, 2016","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02195323"
223,"NCT03070275","Dental Implant Placement in Adjunction With Autologous Alveolar Bone-Marrow Derived Mesenchymal Stem Cells (aBM-MSCs)","Implant_bone","Completed","No Results Available","Implant Therapy","Biological: Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Procedure: Two-stage surgical implant placement","A reduction in the marginal bone levels|Radiographic changes in the marginal bone levels|Reduction in the thickness of the buccal/lingual bone|Changes in the alveolar mucosa|Changes in the width of keratised mucosa","Aristotle University Of Thessaloniki","All","20 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","ELKE_91480","February 2015","June 2017","December 2017","March 3, 2017",,"November 1, 2018",,,"https://ClinicalTrials.gov/show/NCT03070275"
224,"NCT01162915","Transfer of Bone Marrow Derived Stem Cells for the Treatment of Spinal Cord Injury",,"Suspended","No Results Available","Spinal Cord Injury","Biological: Autologous bone marrow-derived mesenchymal stem cells.","Safety","TCA Cellular Therapy","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2009-SCI-I","July 2010","May 2014","May 2014","July 15, 2010",,"May 9, 2014","TCA Cellular Therapy, LLC, Covington, Louisiana, United States",,"https://ClinicalTrials.gov/show/NCT01162915"
225,"NCT02162693","Clinical Trial of Autologous Adipose Tissue-Derived Mesenchymal Progenitor Cells (MPCs) Therapy for Knee Osteoarthritis",,"Completed","No Results Available","Knee Osteoarthritis","Biological: Mesenchymal progenitor cells|Biological: Sodium Hyaluronate","WOMAC Score(The Western Ontario and McMaster Universities Osteoarthritis Index)|Recording of Adverse Events and Serious Adverse Events","Cellular Biomedicine Group Ltd.|RenJi Hospital|General Hospital of Chinese Armed Police Force","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","53","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CBMG-KOA-Ⅱb","November 2013","May 2016","November 2016","June 13, 2014",,"November 17, 2017","General Hospital of Chinese Armed Police Force, Beijing, China|Shanghai Renji Hospital, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02162693"
226,"NCT04489732","MSCs for Radiation-induced Xerostomia",,"Not yet recruiting","No Results Available","Xerostomia Following Radiotherapy","Biological: Autologous bone-marrow derived, interferon gamma stimulated mesenchymal stromal cells","Percentage of subjects experiencing dose limiting toxicity (DLT)|Change in Saliva production rate|Saliva composition analysis: Change in salivary pH|Saliva composition analysis: Change in total protein concentration in saliva|Saliva composition analysis: Change in amylase concentration in saliva|Saliva composition analysis: Change in mucin concentration in saliva|Change in The University of Michigan Xerostomia Related Quality of Life (XeQOL) score|Change in The MD Anderson Dysphagia Index (MDADI) score|Change in Visual Analogue Scale (VAS) xerostomia score|Change in salivary gland size","University of Wisconsin, Madison|University of Wisconsin Carbone Cancer Center (UWCCC)|National Institute of Dental and Craniofacial Research (NIDCR)","All","18 Years and older   (Adult, Older Adult)","Phase 1","30","Other|NIH","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2020-1290|A533300|SMPH/HUMAN ONCOLOGY/HUMAN ONCO|UW20025|NCI-2021-00070|1UG3DE030431-01","November 2021","June 2023","May 2024","July 28, 2020",,"August 26, 2021",,,"https://ClinicalTrials.gov/show/NCT04489732"
227,"NCT02462330","Administration of Mesenchymal Stem Cells in Patients With Chronic Ischemic Cardiomyopathy (MESAMI2)","MESAMI2","Recruiting","No Results Available","Chronic Myocardial Ischemia","Drug: Autologous MSC from bone marrow|Drug: Placebo comparator","Change in VO2max|Left ventricular viability|NYHA/CCS class|Quality of life (Minnesota questionnaire)|VO2 max|6'walking-test|Echocardiography|Myocardial perfusion imaging|BNP blood test","University Hospital, Toulouse","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","90","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","10 142 01","February 19, 2016","December 2022","December 2022","June 4, 2015",,"October 28, 2021","University hospital of Henri Mondor, Créteil, France|University hospital of Grenoble, Grenoble, France|University hospital of Lille, Lille, France|University hospital of Nantes, Nantes, France|University hospital of Pitié-Salpêtrière, Paris, France|Cardiology Department of Rangueil Hospital - Rangueil Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02462330"
228,"NCT00768066","The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)","TAC-HFT","Completed","Has Results","Stem Cell Transplantation|Ventricular Dysfunction, Left","Biological: Autologous human mesenchymal cells (hMSCs)|Biological: Autologous human bone marrow cells (hBMCs)|Biological: Placebo","Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade, Ventricular Arrhythmias >15 Sec. or With Hemodynamic Compromise or Atrial Fibrillation|Serial Troponin Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Serial Creatine Kinase Values (Every 12 Hours for the First 48 Hours Post-catheterization).|Incidence of the Major Adverse Cardiac Events (MACE) Endpoint, Defined as the Composite Incidence of (1) Death, (2) Hospitalization for Heart Failure, or (3) Non-fatal Recurrent MI.|Ectopic Tissue Formation.|Number of Deaths|Change From Baseline in Distance Walked in Six-minutes (Six-minute Walk Test).|Change From Baseline in the Minnesota Living With Heart Failure (MLHF) Questionnaire Total Score.|Percent Change From Baseline in Scar Mass as a Fraction of Left Ventricle Mass by Cardiac MRI or CT.","University of Miami|The Emmes Company, LLC","All","21 Years to 90 Years   (Adult, Older Adult)","Phase 1|Phase 2","65","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20070443","August 2008","August 2012","September 2013","October 7, 2008","December 14, 2015","December 14, 2015","University of Miami Miller School of Medicine, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT00768066"
229,"NCT02503280","The Transendocardial Autologous Cells (hMSC) or (hMSC) and (hCSC) in Ischemic Heart Failure Trial.","TAC-HFT-II","Withdrawn","No Results Available","Chronic Ischemic Left Ventricular Dysfunction|Myocardial Infarction","Drug: Autologous hMSCs|Drug: Autologous Human C-Kit CSCs II|Drug: Placebo|Device: Biosense Webster MyoStar NOGA Injection Catheter System","Incidence of any treatment emergent serious adverse events (TE-SAEs)|Treatment Emergent adverse event rates|Ectopic tissue formation|48-hour ambulatory electrocardiogram (ECG) recordings.|Hematology value changes post-catheterization|Urinalysis results changes post-catheterization|Clinical chemistry values post-catheterization|Pulmonary function|Serial troponin I values|Creatine kinase-MB (CK-MB) value changes post-catheterization|Post-cardiac catheterization echocardiogram.|Magnetic resonance imaging (MRI) measures of infarct scar size (ISS)|Echocardiographic measures of infarct scar size (ISS)|Magnetic resonance imaging (MRI) of Left Regional Ventricular Function|Echocardiographic measures of Left Regional Ventricular Function|Magnetic resonance imaging (MRI) of Global Ventricular Function|Echocardiographic measures of Global Ventricular Function|Tissue perfusion measured by MRI.|Peak oxygen consumption (Peak VO2) (by treadmill determination).|Six-minute walk test.|New York Heart Association (NYHA) functional class.|Minnesota Living with Heart Failure (MLHF) questionnaire.|Incidence of Major Adverse Cardiac Events (MACE)","Joshua M Hare|University of Miami","All","21 Years to 89 Years   (Adult, Older Adult)","Phase 1|Phase 2","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","20120203","March 1, 2025","March 2030","March 2032","July 20, 2015",,"October 22, 2020","ISCI / University of Miami, Miami, Florida, United States",,"https://ClinicalTrials.gov/show/NCT02503280"
230,"NCT04484402","Treatment of Patients With Inflammatory-dystrophic Diseases of the Cornea Using Autologous Stem Cells",,"Completed","No Results Available","Corneal Ulcer|Corneal Disease|Corneal Dystrophy","Biological: mesenchymal stem cells|Biological: limbal stem cells|Other: standard treatment","Number of cured patients|Number of patients with treatment-related adverse events","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus|Belarusian State Medical University","All","18 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","25","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IBCE_LSC","October 3, 2016","December 30, 2019","December 30, 2019","July 23, 2020",,"July 30, 2020","Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT04484402"
231,"NCT05116540","Randomized Double-Blind Phase 2 Efficacy and Safety of Autologous HB-MSCs vs Placebo for Treatment of Multiple Sclerosis","HBMS01","Recruiting","No Results Available","Multiple Sclerosis","Biological: HB-adMSCs|Drug: Placebo","To investigate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by improvements in the Multiple Sclerosis Quality of Life (MSQOL) 54 Instrument.|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Expanded Disability Status Scale (EDSS)|To evaluate the efficacy of intravenous infusions of HB-adMSCs vs placebo in patients with Multiple Sclerosis as determined by changes in the Barthel Index|To determine the efficacy of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in 9-Hole Peg Test|To identify the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by changes in Patient Health Questionnaire (PHQ-9)|To assess the safety of intravenous infusions of HB-adMSCs vs. Placebo in patients with Multiple Sclerosis as determined by the incidence of adverse events or serious adverse events","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBMS01","November 22, 2021","November 22, 2023","November 22, 2023","November 11, 2021",,"November 11, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT05116540"
232,"NCT02449005","Autologous Alveolar Bone Marrow Mesenchymal Stem Cells for the Reconstruction of Infrabony Periodontal Defects","PerioRegen","Completed","No Results Available","Chronic Periodontitis","Biological: BM-MSCs/fibrin glue/collagen fleece|Other: Fibrin glue/collagen fleece|Procedure: Open flap debridement","A reduction in the distance in mm from the bottom of the periodontal pocket to the cementoenamel junction using a manual probe (Hu-Friedy XP-23/QW, Hu-Friedy, Chicago, IL, USA) with 20-25g of pressure by a single calibrated examiner.|A reduction in the distance in mm between the gingival margin and the bottom of the defect using a manual periodontal probe (Hu-Friedy XP-23/QW) by a single calibrated examiner.","Aristotle University Of Thessaloniki|University of Glasgow","All","20 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ELKE-90467","March 2014","September 2016","December 2016","May 20, 2015",,"November 1, 2018","Dental School, Aristotle University, Thessaloniki, Greece",,"https://ClinicalTrials.gov/show/NCT02449005"
233,"NCT03626090","Mesenchymal Stem Cell Therapy for Liver Cirrhosis",,"Recruiting","No Results Available","Liver Cirrhosis","Biological: Autologous BM MSC","Clinical Examination|MR Elastography|The level of serum alanine aminotransferase (ALT)|The level of glomerular filtration rate (GFR)|The level of serum prothrombin time (PT)|The level of serum total bilirubin (TB)|The level of serum albumin (ALB)|MELD Score","Stem Med Pte. Ltd.|Parkway Cancer Centre|Asian American Liver Centre|Desmond Wai Liver & Gastrointestinal Diseases Centre","All","21 Years to 69 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P-SM-L0001","August 18, 2018","October 22, 2021","October 22, 2021","August 10, 2018",,"March 17, 2021","Asian American Liver Centre - Gleneagles Hospital (Annexe Block), Singapore, Singapore|Parkway Cancer Centre - Gleneagles Hospital, Singapore, Singapore|Desmond Wai Liver & Gastrointestinal Disease Centre - Mount Elizabeth Novena Specialist Centre, Singapore, Singapore",,"https://ClinicalTrials.gov/show/NCT03626090"
234,"NCT04744051","ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion",,"Recruiting","No Results Available","Post-Concussion Syndrome","Drug: 50 Adipose Derived Stem Cell Infusion|Drug: 150 Adipose Derived Stem Cell Infusion|Drug: 300 Adipose Derived Stem Cell Infusion|Drug: Placebo Infusion","Health Status using the 36 item Short Form Health Survey (SF-36)|Assessment of Visual Attention and Task Switching|Assessment of Contextual Verbal Learning|Assessment of Verbal Fluency|Assessment of Attention and Executive functions|Assessment of Unstructured Verbal Learning and Memory|Assessment of Visuospatial Learning and Memory|Assessment of Symptoms of Anxiety over Time|Assessment of Pain|Assessment of Sleep Quality|Assessment of Treatment by Participant|Assessment of Depression by Participant","American CryoStem Corporation","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","20","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CRYO_PCS_ADSC_001|FDA File No. 019089","February 2021","September 2021","November 2021","February 8, 2021",,"February 9, 2021","BioSolutions Clinical Research Center, La Mesa, California, United States",,"https://ClinicalTrials.gov/show/NCT04744051"
235,"NCT05017298","Clinical Study for Subjects With COVID-19 Using Allogeneic Adipose Tissue-Derived Mesenchymal Stem Cells","AdMSCs","Not yet recruiting","No Results Available","Corona Virus Infection|Covid19","Biological: Autologous adipose-derived stem cells","Safety of AdMSC injection will be evaluated by assessment of the frequency and nature of adverse events occurring during the study based on the rate of all AdMSC-associated adverse events (AEs) in all subjects.|Safety for AdMSCs based upon incidence of all AEs|Compare the mortality rate|Recognized immune measurements evaluating patients' symptom changes and overall function|Organ functional tests including blood specific enzymes and proteins|Duration (days) of weaning from mechanical ventilation|Duration (days) of ICU monitoring|Duration (days) of vasoactive agent's usage|Duration of hospitalization (days)|Proportions of SARS-CoV-2 RT-PCR change to negative from respiratory tract specimens (oropharyngeal swabs) using CDC standard method|Proportions of quantifying viral RNA in stool change to negative in final follow-up using CDC standard method|Proportions of blood SARS-CoV-2 antibodies IgM/IgG show positive","Celltex Therapeutics Corporation","All","18 Years and older   (Adult, Older Adult)","Phase 2","30","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTX0020-004","November 1, 2021","November 1, 2022","November 15, 2024","August 23, 2021",,"August 23, 2021",,,"https://ClinicalTrials.gov/show/NCT05017298"
236,"NCT01456819","Intramuscular Mononuclear Cells and Mesenchymal Stem Cells Transplantation to Treat Chronic Critical Limb Ischemia",,"Unknown status","No Results Available","Critical Limb Ischemia","Biological: Mononuclear and mesenchymal stem cells|Biological: Mononuclear cells","Change in angiogenesis|Change in ulcer size|Visual Analog Score|Exercise Treadmill Test|Improvement in vascularity and blood supply","National University of Malaysia|Cytopeutics Sdn. Bhd.","All","20 Years and older   (Adult, Older Adult)","Phase 2","50","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","FF-113-2011|NMRR-11-904-9763","March 2011","December 2015","February 2016","October 21, 2011",,"April 10, 2015","UKM Medical Centre, Kuala Lumpur, Malaysia",,"https://ClinicalTrials.gov/show/NCT01456819"
237,"NCT01143168","Stem Cell Therapy for Type 1 Diabetes Mellitus",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells","Rate of reducing exogenous insulin requirement; Hemoglobin A1c; Fast blood glucose (FBG) and postmeal blood glucose (PBG); C-peptide levels.|Serious adverse event frequency and severity","Cellonis Biotechnology Co. Ltd.","All","18 Years to 50 Years   (Adult)","Phase 1","24","Industry","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Cellonis-CR-1.3","August 2010","August 2011","December 2011","June 14, 2010",,"June 14, 2010","Armed Police General Hospital, P. R. China, Beijing, China",,"https://ClinicalTrials.gov/show/NCT01143168"
238,"NCT01842477","Evaluation of Efficacy and Safety of Autologous MSCs Combined to Biomaterials to Enhance Bone Healing","OrthoCT1","Completed","No Results Available","Delayed Union After Fracture of Humerus, Tibial or Femur","Procedure: Implantation of bone substitute plus autologous cultured mesenchymal cells","Complication rate as percentage of patients with local complications regarding the non-union treatment in the follow-up|Number of patients with proven bone healing|Amount of radiological callus|Clinical consolidation|No reoperation done or scheduled|Changes in serum levels of bone turnover markers","Institut National de la Santé Et de la Recherche Médicale, France","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","C11-12|2011-005441-13","May 2013","February 5, 2016","February 5, 2016","April 29, 2013",,"December 2, 2017","Depatment of Orthopaedic Surgery, Hôpital Henri Mondor, Créteil, France|Department of Orthopaedic Surgery, CHRU Tours, Tours, France|Department of Orthopaedic Trauma, University of Ulm, Ulm, Germany|Istituto Ortopedico Rizzoli, Bologna, Bologna, Italy|Servicio de Cirugía Ortopédica y Traumatología ""A"", Hospital La Paz, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01842477"
239,"NCT03346967","Outcomes of Adipose Derived Mesenchymal Stem Cells on Sexual Hormone Deficiency","MSCSHD","Unknown status","No Results Available","Hormone Deficiency","Combination Product: adipose-derived mesenchymal stem cells","Serum levels of follicle-stimulating hormone (FSH), Anti-Mullerian Hormone (AMH) and estradiol (E2) for female and testosterone level for male","Vinmec Research Institute of Stem Cell and Gene Technology","All","35 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","VinmecRISCGT72","November 1, 2017","February 28, 2020","March 30, 2020","November 20, 2017",,"November 26, 2018","Vinmec Research Institute of Stem Cell and Gene Technology, Hanoi, Vietnam",,"https://ClinicalTrials.gov/show/NCT03346967"
240,"NCT00993941","Bone Mesenchymal Stem Cell (BMSC) Transplantation in Liver Cirrhosis Via Portal Vein",,"Unknown status","No Results Available","Liver Cirrhosis","Procedure: Autologous BMSCs transplantation|Drug: Conserved therapy","The levels of serum alanine aminotransferase (ALT), total bilirubin (TB),prothrombin time (PT), albumin (ALB), prealbumin(PA), precollagenⅢ(PCⅢ), collagenⅣ(Ⅳ-C), laminin(LN), hyaluronidase(HN), liver histological improvement.","Sun Yat-sen University","All","18 Years to 60 Years   (Adult)","Phase 2","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","1-Bingliang","October 2009","October 2010","April 2011","October 14, 2009",,"December 6, 2010","Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT00993941"
241,"NCT01446614","Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease",,"Unknown status","No Results Available","Parkinson's Disease","Biological: bone marrow derived mesenchymal stem cells","Number of participants with adverse events|Effect assessment","Guangzhou General Hospital of Guangzhou Military Command","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-2011-10","October 2011","June 2013","June 2014","October 5, 2011",,"October 5, 2011","Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01446614"
242,"NCT03166189","Autologous Bone Marrow-derived Mesenchymal Stem Cells for Atrophic Endometrium in Patients With Repeated IVF Failures",,"Completed","No Results Available","Infertility, Female|Infertility of Uterine Origin|Asherman Syndrome","Biological: bone marrow-derived MSC and HRT|Other: hormonal replacement therapy","Assessment of endometrial receptivity|Clinical pregnancy rate|Treatment-Emergent Adverse Events","D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology","Female","21 Years to 44 Years   (Adult)","Phase 2","46","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-001","December 20, 2017","March 16, 2019","December 28, 2019","May 25, 2017",,"January 2, 2020","D.O. Ott Research Institute of Obstetrics, Gynecology, and Reproductology, Saint Petersburg, Russian Federation",,"https://ClinicalTrials.gov/show/NCT03166189"
243,"NCT04064983","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Parkinson's Disease",,"No longer available","No Results Available","Parkinson Disease","Biological: HB-adMSCs",,"Hope Biosciences","All","18 Years and older   (Adult, Older Adult)",,,"Industry","Expanded Access:Individual Patients",,"HBPD01",,,,"August 22, 2019",,"July 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04064983"
244,"NCT02796079","A Clinical Study Using Autologous Bone Marrow Stem Cell for Diabetes Related Vascular Complications",,"Unknown status","No Results Available","Peripheral Vascular Disease|Ischemia|Diabetic Foot","Biological: mesenchymal stem cells|Biological: saline","Area of diabetic foot ulcers|Improvement of transcutaneous oxygen partial pressure (TcPO2)|Improvement of microvascular cutaneous reactivity by laser Doppler perfusion monitoring (LDPM)|Pain (Visual-Analog Scale)|Walking distance (treadmill) if possible","Jie Shen|Nanfang Hospital of Southern Medical University|Academy Military Medical Science, China|The Fifth Affiliated Hospital of Southern Medical University|Southern Medical University, China|The Third Affiliated Hospital of Southern Medical University","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1","240","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","ThirdSouthernMedical","January 2015","December 2017","December 2018","June 10, 2016",,"April 6, 2017","the Third Affiliated Hospital of Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT02796079"
245,"NCT01446640","Mesenchymal Stem Cells Transplantation to Patients With Spinal Cord Injury","MSC","Unknown status","No Results Available","Spinal Cord Injury","Biological: bone marrow derived mesenchymal stem cells","Number of participants with adverse events|Electromyogram and Electroneurophysiologic test|Muscle strength assessment|Motor and sensory assessment","Guangzhou General Hospital of Guangzhou Military Command","All","16 Years to 60 Years   (Child, Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HM-2011-09","October 2011","June 2013","June 2014","October 5, 2011",,"October 5, 2011","Guangzhou General Hospital of Guangzhou Military Command, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01446640"
246,"NCT04739930","Autologous Bone Marrow Concentrate in Knee Osteochondral Allograft Transplantation",,"Recruiting","No Results Available","Cartilage Injury","Procedure: Autologous bone marrow aspirate will be harvested and concentrated to a bone marrow aspirate concentrate (BMAC) containing bone marrow derived mesenchymal stem cells and delivered to site of operation|Procedure: Control group incision","Synovial Fluid Cytokine Measurement","Rush University Medical Center|Joint Restoration Foundation (JRF)","All","18 Years to 50 Years   (Adult)","Not Applicable","40","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","17121805","March 2, 2018","December 31, 2021","March 31, 2022","February 5, 2021",,"February 5, 2021","Rush University Medical Center, Chicago, Illinois, United States","""Informed Consent Form: HIPAA Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/ICF_000.pdf|""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/Prot_001.pdf|""Informed Consent Form: Main Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/30/NCT04739930/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT04739930"
247,"NCT03130374","Treatment of Laryngotracheal Stenosis Using Mesenchymal Stem Cells",,"Completed","No Results Available","Tracheal Stenosis|Laryngeal Stenosis|Mesenchymal Stem Cells","Biological: Olfactory mucosa-derived mesenchymal stem cells","Number of patients who didn't require the repeated surgical interventions|Tracheostomy decannulation","The Republican Research and Practical Center for Epidemiology and Microbiology|Belarusian Medical Academy of Post-Graduate Education|The Republican Center for Research and Practice in Otolaryngology","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RRPCEM_MSC1","January 3, 2017","January 4, 2019","May 20, 2019","April 26, 2017",,"June 7, 2019","The Republican Center for Research and Practice in Otolaryngology, Minsk, Belarus|The Republican Research and Practical Center for Epidemiology and Microbiology, Minsk, Belarus",,"https://ClinicalTrials.gov/show/NCT03130374"
248,"NCT01875081","REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)",,"Completed","No Results Available","Alcoholic Liver Cirrhosis","Biological: Livercellgram","Histopathological evaluation (Fibrosis Grade - Laennec Scoring System)|Histopathological evaluation score (Ratio of 1-time injection group to 2-time injection group comparison)|MELD Score|Child-Pugh grade|Liver Function Test (ALT, AST, ALP, Albumin, billirubin, r-GT)|Visual Inspection (Liver volume, Fibroscan)","Pharmicell Co., Ltd.","All","20 Years to 70 Years   (Adult, Older Adult)","Phase 2","72","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-BD-CT-P-002","November 2012","March 2016","March 2016","June 11, 2013",,"March 17, 2016","Pharmicell Co., Ltd., Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01875081"
249,"NCT01325103","Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury",,"Completed","No Results Available","Spinal Cord Injury","Procedure: Stem Cell Transplantation","Feasibility and safety of bone marrow stem cell transplantation in patients with spinal cord injury|Functional improvement in muscle strength|Improvement of sphincters control.","Hospital Sao Rafael|Oswaldo Cruz Foundation|Irep Sociedade de Ensino Superior Médio e Fundamental Limitada|Hospital Espanhol","All","18 Years to 50 Years   (Adult)","Not Applicable","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCI-001","July 2010","December 2012","December 2012","March 29, 2011",,"November 28, 2017","Hospital São Rafael, Salvador, Bahia, Brazil",,"https://ClinicalTrials.gov/show/NCT01325103"
250,"NCT04170426","Autologous Adipose-derived Stem Cells (AdMSCs) for Rheumatoid Arthritis",,"Not yet recruiting","No Results Available","Rheumatoid Arthritis","Biological: autologous adipose derived stem cells","Adverse Events and Sever Adverse Events|Efficacy of Celltex AdMSCs","Celltex Therapeutics Corporation","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","54","Industry","Interventional","Allocation: Randomized|Intervention Model: Sequential Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","CTX0019-001","December 2021","December 2022","December 2024","November 20, 2019",,"July 23, 2021",,,"https://ClinicalTrials.gov/show/NCT04170426"
251,"NCT04612465","Clinical Study to Evaluate Efficacy and Safety of ASC and Fibringlue or Fibringlue in Patients With Crohn's Fistula",,"Recruiting","No Results Available","Crohn's Fistula","Biological: ASC|Drug: Fibringlue","Proportion of subjects who are completely blocked fistula|Proportion of subjects who are more than 50% blocked fistula|Score of evaluation about Investigator satisfaction using questionnaire|Proportion of subjects who are confirmed maintenance of fistula blockage by radiology test|Visual improvement effect of perianal fistula wound through photography of it","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 3","36","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","ANTG-ASC-301","January 9, 2020","December 31, 2021","December 31, 2021","November 3, 2020",,"January 22, 2021","Seoul Natinoal Univetsity Hospital, Seoul, Korea, Republic of|Asan Medical Center, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04612465"
252,"NCT02603744","Autologous Adipose Derived Mesenchymal Stromal Cells Transplantation in Women With Premature Ovarian Failure (POF)",,"Unknown status","No Results Available","Premature Ovarian Failure","Biological: Intraovarian injection of Adipose derived Stromal cells (ADSCs)","ovary mass|ovary abcess|Follicle Stimulating Hormone (FSH) serum level|Anti-Mullerian Hormone (AMH) serum level|Number of antral follicle|Antral follicle volume|Menstruation recurrence rate|Pregnancy rate","Royan Institute","Female","20 Years to 39 Years   (Adult)","Phase 1|Phase 2","9","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Rep-Bio-Royan-001","June 2015","June 2018","November 2018","November 13, 2015",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02603744"
253,"NCT01763099","Mesenchymal Stem Cells Combined With Cord Blood for Treatment of Graft Failure",,"Unknown status","No Results Available","Hematopoietic Stem Cell Transplantation|Mesenchymal Stem Cells|Umbilical Cord Blood|Graft Failure|Hematological Diseases","Biological: Mesenchymal stem cells|Biological: Mesenchymal stem cells and cord blood","hematopoietic recovery|infections, primary underlying disease relapse and any toxic side effects of MSCs treatment","Nanfang Hospital of Southern Medical University|Peking University People's Hospital|Sun Yat-sen University|Guangdong Provincial People's Hospital|Guangzhou General Hospital of Guangzhou Military Command|Southern Medical University, China|Third Affiliated Hospital, Sun Yat-Sen University|Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University|Guangzhou First People's Hospital|Zhongshan People's Hospital, Guangdong, China","All","14 Years to 65 Years   (Child, Adult, Older Adult)","Phase 2","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NFH-MSC-auto-HSCT-2013","January 2013","January 2015","January 2016","January 8, 2013",,"January 16, 2013","Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT01763099"
254,"NCT00976287","Autologous Bone Marrow Mesenchymal Stem Cells Transplantation Via Hepatic Artery in Patients With Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis","Procedure: Hepatic artery infusion|Procedure: Conserved Therapy","The levels of serum alanine aminotransferase (ALT), total bilirubin (TB), prothrombin time (PT), albumin (ALB)","Sun Yat-sen University|Third Affiliated Hospital, Sun Yat-Sen University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","zssy","January 2008","December 2009","June 2010","September 14, 2009",,"September 15, 2009",,,"https://ClinicalTrials.gov/show/NCT00976287"
255,"NCT03887208","Therapy of Scars and Cutis Laxa With Autologous Adipose Derived Mesenchymal Stem Cells","2ABC","Completed","No Results Available","Skin|Scar|Cutis Laxa|Keloid|Cicatrix","Procedure: Laser therapy|Biological: Autologous ADSC injection|Procedure: Normal saline injection","Change in patient's skin condition|Evaluation of skin problems. Assessment of skin related complaints since the last visit.|The assessment of the scar by the patient.|Changes in volume of the skin (USG)|Changes in skin surface morphology (digital imagining)|Record of adverse events","Medical University of Warsaw|Timeless Chirurgia Plastyczna-Janusz Jaworowski|Melitus sp. z o.o.|Polish Stem Cells Bank S.A.","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","2ABC Therapy|2016-004110-10|267976/13/NCBR/2015|PL008125|Z4217","January 31, 2018","January 31, 2019","January 31, 2019","March 22, 2019",,"January 28, 2020","Laboratory for Cell Research and Application, Medical University of Warsaw, Warsaw, Poland|Melitus sp. z o.o., Warsaw, Poland|Timeless Chirurgia Plastyczna Sp. z o. o., Warsaw, Poland",,"https://ClinicalTrials.gov/show/NCT03887208"
256,"NCT04953572","Treatment of Cartilage Defects With Peripheral Blood Stem Cells",,"Not yet recruiting","No Results Available","Cartilage Injury","Genetic: autologous peripheral blood mesenchymal stem cell|Procedure: Microfracture|Combination Product: Microfracture + collagen membrane|Procedure: Autologous osteochondral transplantation","Magnetic Resonance Imaging in the 6th month after surgery|Magnetic Resonance Imaging in the 12th month after surgery|Magnetic Resonance Imaging in the 24th month after surgery|The Western Ontario and McMaster Universities (WOMAC) Osteoarthritis Index|International knee documentation committee (IKDC) Knee Joint Score Sheet","Peking University Third Hospital|Inner Mongolia People's Hospital|Hebei Medical University Third Hospital|Tianjin Hospital","All","18 Years to 60 Years   (Adult)","Phase 1","252","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PekingUTH001","August 1, 2021","December 31, 2023","December 31, 2023","July 8, 2021",,"July 8, 2021","Institute of Sports Medicine, Peking University Third Hospital, Beijing, Beijing, China",,"https://ClinicalTrials.gov/show/NCT04953572"
257,"NCT00659217","Effect of Mesenchymal Stem Cell Transplantation for Lupus Nephritis",,"Unknown status","No Results Available","Lupus Nephritis","Biological: mesenchymal stem cell","the proportion of participants who achieve and maintain remission|Patient survival|Creatinine and proteinuria.|SLE disease activity index|Serology (ANA, dsDNA)|ComplementC3 and C4","Organ Transplant Institute, China","All","18 Years to 60 Years   (Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","fuzhough0713","May 2008","May 2010","May 2010","April 16, 2008",,"April 16, 2008","Fuzhou General Hospital, Fuzhou, Fujian, China",,"https://ClinicalTrials.gov/show/NCT00659217"
258,"NCT01051882","Autologous Cultured Mesenchymal Bone Marrow Stromal Cells Secreting Neurotrophic Factors (MSC-NTF), in ALS Patients.",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: MSC-NTF cells transplantation (IM)|Biological: MSC-NTF cells transplantation (IT)","Safety evaluation and tolerability of a single treatment administration of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Safety evaluation and tolerability of single intrathecal injection (IT) into the cerebrospinal fluid (CSF) of autologous cultured mesenchymal bone marrow stromal cells secreting neurotrophic factors (MSC-NTF)|Changes in the progression rate of the disease as evidenced by changes in the ALS functional rating scale (ALS-FRS)|Changes in muscle strength grading (MVIC) by muscle chart|Changes in forced vital capacity (FVC %) (In the progressive disease stage group only).|Changes in muscle bulk estimated by MRI of the upper and lower extremities|Changes in upper and lower extremities circumference (cm)|Changes in EMG parameters|Need and time to tracheotomy or permanent assisted ventilation|Overall survival, calculating time to death","Brainstorm-Cell Therapeutics|Hadassah Medical Organization","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","12","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC-NTF-001-HMO-CTIL","June 2011","December 2012","March 2013","January 20, 2010",,"January 10, 2019","Hadassah Medical Organization, Jerusalem, Israel",,"https://ClinicalTrials.gov/show/NCT01051882"
259,"NCT00908856","Autologous Cell Therapy After Stroke",,"Withdrawn","No Results Available","Stroke","Biological: autologous bone marrow mononuclear cell transfusion|Biological: marrow stromal cells|Drug: placebo","death|myocardial infarction|pulmonary embolism|ischemic stroke|deep venous thrombosis|other arterial or venous thrombosis|Infection requiring IV antibiotics","University of California, Irvine|University of California, San Diego","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","2003-3040","January 2016","December 2017","December 2017","May 27, 2009",,"February 4, 2016","UC Irvine Medical Center, Orange, California, United States",,"https://ClinicalTrials.gov/show/NCT00908856"
260,"NCT03692221","Mesenchymal Stem Cells for Lumbar Degenerative Disc Disease",,"Not yet recruiting","No Results Available","Disc Degeneration","Drug: MSC Treatment group 1 (low dose)|Drug: MSC Treatment group 2 (high dose)|Other: Healthy Control (no treatment)","Rate of treatment related adverse events|Changes in Pain -Visual Analogue Scale (VAS) for back pain|Changes in Pain - Oswestry Disability Index (ODI) scores over time|changes in Quality of life - Short form Health Survey 36 (SF-36)|changes in MRI monitoring of transplant site","Salim M Hayek|University Hospitals Cleveland Medical Center","All","18 Years to 80 Years   (Adult, Older Adult)","Early Phase 1","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","014924/0012/A002","June 2019","September 30, 2021","September 30, 2022","October 2, 2018",,"April 4, 2019","University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States",,"https://ClinicalTrials.gov/show/NCT03692221"
261,"NCT01652209","To Evaluate the Efficacy and Safety of Hearticelgram®-AMI in Patients With Acute Myocardial Infarction.",,"Recruiting","No Results Available","Acute Myocardial Infarction","Biological: Hearticellgram-AMI","LVEF amount of change|Infarct size amount of change|Left ventricle end systolic size change|Left ventricular end-diastolic size change|Incidence of critical heart events|Heart rate variability change amount|Left ventricular local wall movement disorder index change|N-terminal pro-brain natriuretic peptide (NT-proBNP) change","Pharmicell Co., Ltd.","All","20 Years to 75 Years   (Adult, Older Adult)","Phase 3","90","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-BD-CT-P-003","September 1, 2013","August 31, 2022","December 31, 2023","July 27, 2012",,"October 22, 2021","Kangwon National University Hospital, Chuncheon, Korea, Republic of|Chungnam National University Hospital, Chungnam, Korea, Republic of|Chonnam National University Hospital, Gwangju, Korea, Republic of|Yongin Severance Hospital, Gyeonggi-do, Korea, Republic of|Gachon University Gil Medical Center, Incheon, Korea, Republic of|Inha University Hospital, Incheon, Korea, Republic of|Catholic University of Korea, Seoul ST. Mary's Hospital., Seoul, Korea, Republic of|Korea University Medicine, Seoul, Korea, Republic of|Severance Hospital, Yonsei University College of Medicine, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wŏnju, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01652209"
262,"NCT02838069","A Study Evaluating the Efficacy of a Single Injection Autologous Adipose Derived Mesenchymal Stromal Cells in Patients With Knee Osteoarthritis","ADIPOA-2","Recruiting","No Results Available","Osteoarthritis","Biological: Injection (2x106 ASC/5ml).|Biological: Injection (10x106 ASC/5ml).|Other: Placebo","Improvement of pain or physical function|Disability (WOMAC)|Disability (KOOS)|Disability (SAS)|Change in Quality of life|painkillers consumption|Structural changes (X-Ray)|Structural changes (MRI)","University Hospital, Montpellier|University Hospital, Toulouse|Assistance Publique - Hôpitaux de Paris|NATIONAL UNIVERSITY OF IRELAND, GALWAY (NUIG)|ISTITUTO ORTOPEDICO RIZZOLI (IOR)|Etablissement Français du Sang|Institut National de la Santé Et de la Recherche Médicale, France|ECRIN EUROPEAN CLINICAL RESEARCH INFRASTRUCTURE NETWORK (ECRIN)|HUMAN MED AG (HM)|Stichting Katholieke Universiteit|SPORTS SURGERY CLINIC LIMITED|UNIVERSITA DEGLI STUDI DI PADOVA (UNIPD)|EVANGELISCHES WALDKRANKENHAUS SPANDAU KRANKENHAUSBETRIEBS GGMBH (EWK)|PINTAIL LTD (PT)|Centre National de la Recherche Scientifique, France|UNIVERSITAET ULM (UULM)|Cambridge University Hospitals NHS Foundation Trust|Aries srl (ARIES)","All","45 Years to 75 Years   (Adult, Older Adult)","Phase 2","153","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","UF 9494","September 2016","January 2022","June 2023","July 20, 2016",,"April 13, 2020","UH Montpellier, Montpellier, France",,"https://ClinicalTrials.gov/show/NCT02838069"
263,"NCT04689152","Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis","Cellgram-LC","Recruiting","No Results Available","Alcoholic Cirrhosis","Biological: Cellgram-LC","Transplant free survival (TFS)|Survival rate|Change amount of Child-Pugh score|Change amount of MELD score|Change amount of Liver function test|Change amount of Fibrosis-4|Change amount of FibroScanⓇ|Change amount of EQ-5D|Change amount of EQ-VAS","Pharmicell Co., Ltd.","All","20 Years to 71 Years   (Adult, Older Adult)","Phase 3","200","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-P-07","March 2, 2021","March 2, 2026","March 2, 2026","December 30, 2020",,"August 24, 2021","Soonchunhyang University Hospital, Bucheon, Korea, Republic of|Soonchunhyang University Hospital, Cheonan, Korea, Republic of|Gangwon National University Hospital, ChunCheon, Korea, Republic of|Hallym Univ. Medical Center, ChunCheon, Korea, Republic of|Gangneung Asan Hospital, Gangneung-si, Korea, Republic of|Eunpyeong St. Mary's Hospital, Seoul, Korea, Republic of|Korea University Anam Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Soonchunhyang University Hospital, Seoul, Korea, Republic of|Wonju Severance Christian Hospital, Wonju, Korea, Republic of|Yongin Severance Hospital, Yongin, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT04689152"
264,"NCT03069209","Autologous Bone Marrow-Derived Stem Cell Transplantation in Patients With Premature Ovarian Failure (POF)",,"Active, not recruiting","No Results Available","Premature Ovarian Failure","Biological: Stem Cells","Return of menstrual cycle|Pregnancy|FSH levels|Follicular function|Endometrium thickness","Stem Cells Arabia","Female","19 Years to 39 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCA-POF1","January 2015","June 2021","January 2022","March 3, 2017",,"May 17, 2018","Stem Cells Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT03069209"
265,"NCT00395200","Mesenchymal Stem Cells in Multiple Sclerosis (MSCIMS)","MSCIMS","Completed","No Results Available","Multiple Sclerosis","Procedure: MSC Treatment","Adverse events|Visual function (acuity and colour)|Visual evoked potential latency|Optic nerve Magnetisation Transfer Ratio|Retinal nerve fibre layer thickness (by optical coherence tomography)|Brain lesion Magnetisation Transfer Ratio|MRI brain T1 hypointensity load|Multiple Sclerosis Functional Composite Score|Expanded Kurtzke Disability Status Score","University of Cambridge|Cambridge University Hospitals NHS Foundation Trust|Medical Research Council","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MRCRG44871|REC Reference: 07/Q0108/104","July 2008","December 2010","December 2010","November 2, 2006",,"October 25, 2011","University of Cambridge Dept of Clinical Neurosciences, Cambridge, Cambridgeshire, United Kingdom|University College London Institute of Neurology, London, United Kingdom",,"https://ClinicalTrials.gov/show/NCT00395200"
266,"NCT04029896","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for the Treatment of Cerebral Palsy",,"No longer available","No Results Available","Cerebral Palsy","Biological: HB-adMSCs",,"Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","Male","3 Years and older   (Child, Adult, Older Adult)",,,"Other|Industry","Expanded Access:Individual Patients",,"HBCP01",,,,"July 23, 2019",,"July 6, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04029896"
267,"NCT03933995","Follow up Study(Phase 1) to Evaluate Safety of Autologous Bone Marrow Derived MSCs in Erectile Dysfunction",,"Recruiting","No Results Available","Erectile Dysfunction","Other: no Intervention","Safety Evaluation assessed by Tumor Marker Test.|Safety Evaluation assessed by Serious Adverse Events, cancer incidence and recurrence of prostate cancer.|Safety Evaluation assessed by Vital Signs.","Pharmicell Co., Ltd.","Male","20 Years and older   (Adult, Older Adult)",,"10","Industry","Observational","Observational Model: Other|Time Perspective: Prospective","PMC-P-09","March 11, 2019","February 28, 2022","November 30, 2022","May 1, 2019",,"October 22, 2020","Asan medical center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03933995"
268,"NCT04825730","Follow-up Study for Participants of Jointstem Investigator Initiated Trial by Arthroscopy",,"Not yet recruiting","No Results Available","Degenerative Arthritis|Knee Arthritis","Drug: JOINTSTEM","Adverse Events|Adverse Events (Special Attention Target)","R-Bio","All","20 Years and older   (Adult, Older Adult)","Not Applicable","14","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BS-JS-IIT1-FU","December 1, 2021","December 1, 2027","December 31, 2028","April 1, 2021",,"April 1, 2021",,,"https://ClinicalTrials.gov/show/NCT04825730"
269,"NCT02334878","Stem Cell Therapy for Treatment of Female Stress Urinary Incontinence",,"Completed","No Results Available","Urinary Incontinence, Stress","Biological: Stem Cells,Mesenchymal|Procedure: surgery (TVT)","change in cough test & urodynamic study as a measure of efficacy of treatment|Quality of life as measured by the Incontinence Quality of Life (I-QOL) Instrument Score","Ain Shams Maternity Hospital","Female","18 Years and older   (Adult, Older Adult)","Phase 3","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","FMASU 3098/2014","October 1, 2015","October 30, 2016","December 1, 2016","January 8, 2015",,"September 11, 2017","Maternity hospital, Ain Shams University, Cairo, Egypt",,"https://ClinicalTrials.gov/show/NCT02334878"
270,"NCT01227694","Adult Stem Cell Therapy for Repairing Articular Cartilage in Gonarthrosis",,"Completed","No Results Available","Osteoarthritis, Knee|Knee Injuries|Joint Diseases|Rheumatic Diseases|Cartilage Diseases","Other: Autologous MSC knee implantation","Feasibility of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Safety of autologous bone marrow mesenchymal stem cells (MSC) knee articular infiltration.|Efficacy by imaging procedures.|Clinical outcomes.","Banc de Sang i Teixits|Centro Medico Teknon|Institut de Terapia Regenerativa Tissular|Cetir Sant Jordi, S.a..","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","XCEL-M-09-01","October 2010","July 2012","January 2013","October 25, 2010",,"December 11, 2015","Centro Medico Teknon-ITRT, Barcelona, Spain",,"https://ClinicalTrials.gov/show/NCT01227694"
271,"NCT00557635","Osseous Setting Improvement With Co-implantation of Osseous Matrix and Mesenchymal Progenitors Cells From Autologous Bone Marrow",,"Suspended","No Results Available","Tibia or Femur Pseudo-arthrosis","Procedure: Chirurgical procedure","Evaluate osseous setting at 3-months follow-up and compare our results with past studies|Feasibility and tolerance of this therapeutic strategy","University Hospital, Clermont-Ferrand","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2","50","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CHU-0026","January 2008","November 2011","December 2011","November 14, 2007",,"September 23, 2009",,,"https://ClinicalTrials.gov/show/NCT00557635"
272,"NCT02210624","Safety and Efficacy Assessment of Autologous Bone-marrow Derived Adult Mesenchymal Stem Cell Therapy in Patients With Anoxic(or Hypoxic) Brain Injury Pilot Trial",,"Unknown status","No Results Available","Anoxic Brain Injury","Biological: HYNR-CS inj.","safety assessment|Glasgow Coma Scale(GCS)|FOUR score|Functional Independence Measure(FIM)|Disability Rating Scale(DRS)|Cerebral Performance Category(CPC)scale","Hyun Young Kim|Hanyang University Seoul Hospital","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","4","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HYNR_CS_ABI001","March 2013","December 2018","December 2018","August 7, 2014",,"August 10, 2017","Hanyang University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02210624"
273,"NCT02448849","Autologous BM-MSC Transplantation in Combination With Platelet Lysate (PL) for Nonunion Treatment",,"Unknown status","No Results Available","Bone Fracture","Biological: Percutaneous injection|Other: Percutaneous injection","clinical union|Radiological healing|Pain|Quality of life|Walking distance","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 2|Phase 3","60","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","Royan-Bone-013","June 2015","April 2017","August 2017","May 20, 2015",,"October 30, 2015","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02448849"
274,"NCT03047772","Transplantation Efficacy of Autologous Bone Marrow Mesenchymal Stem Cells With Intensive Atorvastatin in AMI Patients","TEAM-AMI","Unknown status","No Results Available","Myocardial Infarction|Stem Cell Transplantation|Angioplasty, Transluminal, Percutaneous Coronary","Drug: Atorvastatin|Drug: Intensive Atorvastatin|Drug: Low dose BMMSC|Drug: Middle dose BMMSC|Drug: High dose BMMSC|Drug: Transplantation","Changes in left ventricular ejection fraction from baseline to 12 months'","Yuejin Yang|Peking Union Medical College Hospital|The First Hospital of Hebei Medical University|Zunyi Medical College|Chinese Academy of Medical Sciences, Fuwai Hospital","All","30 Years to 75 Years   (Adult, Older Adult)","Phase 2","124","Other","Interventional","Allocation: Randomized|Intervention Model: Factorial Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","2016-807-10.1","March 6, 2018","December 31, 2018","December 31, 2018","February 9, 2017",,"January 25, 2018",,,"https://ClinicalTrials.gov/show/NCT03047772"
275,"NCT03509025","Follow-up Study for Participants Jointstem Clinical Trial",,"Completed","No Results Available","Knee Osteoarthritis","Drug: Jointstem","Adverse Events|WOMAC score|WOMAC 3 subscale score|X-ray","R-Bio","All","18 Years and older   (Adult, Older Adult)","Phase 2","11","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","JM2b-FU","February 8, 2017","December 9, 2020","December 9, 2020","April 26, 2018",,"January 29, 2021","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|GangNam Severance Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03509025"
276,"NCT02940418","Use of Stem Cells in Diabetes Mellitus Type 1",,"Unknown status","No Results Available","Diabetes Mellitus Type 1","Biological: Adipose mesenchymal cells with bone marrow mononuclear cells","Safety of using allogenic ASC assessed by any adverse events","Sophia Al-Adwan|University of Jordan","All","18 Years to 35 Years   (Adult)","Phase 1","20","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","T1DM.UJCTC","February 19, 2017","November 2019","January 2020","October 20, 2016",,"July 24, 2019","Cell Therapy Center, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02940418"
277,"NCT01687777","Mensenchymal Stem Cell (MSC) Included in OrthADAPT Membrane for Rotator Cuff Tears Repair","msctendonrep","Unknown status","No Results Available","Chronic Disease","Biological: Mesenchymal Stem Cells (MSCs)|Biological: OrthADAPT","Constant Shoulder Score|Nuclear Magnetic Resonance (RMN)","Hospital San Carlos, Madrid|Hospital General Universitario Gregorio Marañon","All","55 Years to 80 Years   (Adult, Older Adult)","Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Investigator)|Primary Purpose: Treatment","EC07/90208|2007-007630-19","May 2010","June 2013","December 2013","September 19, 2012",,"September 19, 2012","Hospital Universitario Clinico San Carlos, Madrid, Spain|Hospital Universitario Clinico San Carlos, Madrid, Spain",,"https://ClinicalTrials.gov/show/NCT01687777"
278,"NCT02145897","To Evaluate the Safety and Efficacy of IM and IV Administration of Autologous ADMSCs for Treatment of CLI",,"Unknown status","No Results Available","Critical Limb Ischemia","Biological: Autologous Stromal Vascular Fraction (SVF)|Biological: Autologous Adipose Derieved MSCs|Other: Control","To assess the safety|To assess the efficacy","Kasiak Research Pvt. Ltd.","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KRPL/CLI/11-12/001","August 2014","August 2015",,"May 23, 2014",,"May 23, 2014","Kasiak Research Pvt Ltd, Thane, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02145897"
279,"NCT03298399","Mesenchymal Stromal Cells for Haplo Hematopoietic Cell Transplantation for Sickle Cell Disease",,"Withdrawn","No Results Available","Sickle Cell Disease","Biological: Autologous MSCs","Safety and tolerability of EPIC2016-MSC003 based upon dose limiting toxicities (DLTs)|Primary graft rejection|Late graft rejection|Time to neutrophil engraftment|Time to platelet engraftment|Lineage specific donor chimerism|Immune reconstitution|Acute GVHD|Chronic GVHD|Transplant-related mortality (TRM)|Event-free survival (EFS)|Overall survival (OS)","Emory University|National Heart, Lung, and Blood Institute (NHLBI)","All","12 Years to 40 Years   (Child, Adult)","Phase 1","0","Other|NIH","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRB00090514|1K23HL133446","December 21, 2017","October 25, 2018","October 25, 2018","October 2, 2017",,"November 7, 2018",,,"https://ClinicalTrials.gov/show/NCT03298399"
280,"NCT04368806","A Phase 2b/3a Study to Evaluate the Efficacy and Safety of JointStem in Patients Diagnosed as Knee Osteoarthritis",,"Recruiting","No Results Available","Osteoarthritis, Knee","Drug: JointStem|Other: Placebo Control","Western Ontario and McMaster Universities Arthritis Index (WOMAC) function Score|Visual Analog Scale (VAS) score|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Function)|Western Ontario and McMaster Universities Arthritis Index (WOMAC) subscale (Pain)|Total Western Ontario and McMaster Universities Arthritis Index (WOMAC) score|International Knee Documentation Committee (IKDC) score|36-Item Short Form health survey questionnaires (SF-36) score|Structural changes in knee joint|Kellgren-Lawrence grade|Number and amount of rescue medication use","Nature Cell Co. Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2|Phase 3","140","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JS-OAP3-US01","May 26, 2021","June 30, 2022","December 30, 2022","April 30, 2020",,"July 19, 2021","TriWest Research Associates, El Cajon, California, United States|BioSolutions Clinical Research Center, La Mesa, California, United States|Source Healthcare, Santa Monica, California, United States|International Spine Pain, and Performance Center, Washington, District of Columbia, United States|Rothman Orthopaedic Institute, Egg Harbor Township, New Jersey, United States|Hospital for Special Surgery, New York, New York, United States",,"https://ClinicalTrials.gov/show/NCT04368806"
281,"NCT01913886","Mesenchymal Stem Cells to Treat Ischemic Cardiomyopathy",,"Completed","No Results Available","Ischemic Cardiomyopathy","Procedure: MSCs injection","Change from baseline in left ventricular ejection fraction (LVEF) measured by echocardiogram.|Change in quality of life|Changes in exercise capacity|Changes in plasma inflammatory markers","Alexandra Cristina Senegaglia|Santa Casa de Misericórdia de Curitiba, Brazil|Fundação Araucária|Pontifícia Universidade Católica do Paraná","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC_Isquemica","January 2010","September 2013","March 2016","August 1, 2013",,"December 13, 2017","Pontifícia Universidade Católica do Paraná, Curitiba, Paraná, Brazil",,"https://ClinicalTrials.gov/show/NCT01913886"
282,"NCT03000712","Investigator Initiated Trial to Evaluate the Efficacy and Safety of Intra-articular Injection of ADMSC Comared to Negative Control After High Tibial Osteotomy in the Osteoarthritis Patients.",,"Completed","No Results Available","Degenerative Arthritis|Knee Osteoarthritis","Biological: Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml","MRI scan|WOMAC score|WOMAC sub-scale|Kellgren & Lawrence grade|EQ5D|ROM|KOOS (Knee Injury & Osteoarthritis Outcome Score)|PGIC(Patient Global Impression of Change)|PSQI(Pittsburgh Sleep Quality Index)|Biomarkers|Incidence of adverse reactions and characteristics associated with investigational product","R-Bio","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","26","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","HTO-MSCs","November 2, 2016","May 22, 2020","May 22, 2020","December 22, 2016",,"January 29, 2021","KyungHee University Gangdong Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03000712"
283,"NCT04928287","Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)","PD","Active, not recruiting","No Results Available","Parkinson Disease","Biological: HB-adMSCs|Other: Placebo","Changes in MDS-UPDRS Part II.|Incidence of treatment-emergent Adverse Event (TEAEs).|Incidence of treatment-emergent Serious Adverse Events (SAEs).|AEs of special interest (serious or non-serious) - thromboembolic events.|AEs of special interest (serious or non-serious) - thromboembolism of the extremities|AEs of special interest (serious or non-serious) - infections|AEs of special interest (serious or non-serious) - hypersensitivities.|Laboratory values. CBC|Laboratory values. CMP|Laboratory values. Coagulation Panel|Vital signs. - Respiratory Rate (breaths per minute)|Vital signs. - Heart Rate (beats per minute)|Vital signs. - Body Temperature (Fahrenheit )|Vital signs. - Blood Pressure (mmHg)|Weight in lb.|Physical examination results. General|Physical examination results. Body Systems.|Changes in MDS-UPDS total score.|Changes in MDS-UPDRS Part I.|Changes in MDS-UPDRS Part III.|Changes in MDS-UPDRS Part IV.|Changes in Neuro-QOL. - Communication|Changes in Neuro-QOL. - Social Roles and Activities|Changes in Neuro-QOL. - Anxiety|Changes in Neuro-QOL. - Depression|Changes in Neuro-QOL. - Dyscontrol|Changes in Neuro-QOL. - Fatigue|Changes in Neuro-QOL. - Mobility|Changes in Neuro-QOL. - Well-Being|Changes in Neuro-QOL. - Sleep|Changes in Neuro-QOL. - Fine Motor|Changes in Neuro-QOL. - Stigma|Changes in Neuro-QOL. - Social Roles|Changes in Neuro-QOL. - Cognition|Changes in Parkinson's disease fatigue scale (PFS-16).|Changes in Parkinson's disease Questionnaire (PDQ-39).|Changes in Visual Analog Scale for Pain.|Changes in Dosage of medications taken to treat Parkinson's disease.|Incidence of treatment-emergent Adverse Event (TEAEs) and serious Adverse Events (SAEs).|Incidence and risk of AEs of special interest (serious or non-serious),|Clinically significant changes in laboratory values. - CBC|Changes in Visual Analog Scale for muscle spasms.|Clinically significant changes in vital signs. - Respiratory Rate|Clinically significant changes in vital signs. - Heart Rate|Clinically significant changes in vital signs. - Body Temperature.|Clinically significant changes in vital signs. - Blood Pressure.|Clinically significant changes in vital signs. - Oxygen Saturation.|Clinically significant changes in physical examination results.|Clinically significant changes in weight in lb.|Clinically significant changes in laboratory values. - CMP|Clinically significant changes in laboratory values. - Coagulation Panel","Hope Biosciences Stem Cell Research Foundation|Hope Biosciences","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 2","24","Other|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","HBPD03","June 28, 2021","May 28, 2023","May 28, 2023","June 16, 2021",,"October 29, 2021","Hope Biosciences Stem Cell Research Foundation, Sugar Land, Texas, United States",,"https://ClinicalTrials.gov/show/NCT04928287"
284,"NCT01663376","Safety and Effect of Adipose Tissue Derived Mesenchymal Stem Cells Implantation in Patients With Critical Limb Ischemia",,"Completed","No Results Available","Critical Limb Ischemia","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","Major Adverse Events Analysis (MAEs)|Ankle-Brachial Index (ABI)|Digital subtraction angiography (DSA)|Thermography|Wong-Baker FACES Pain Rating Score|Treadmill test","R-Bio|Pusan National University Hospital","All","20 Years to 80 Years   (Adult, Older Adult)","Not Applicable","20","Industry|Other","Interventional","Allocation: Non-Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-MSCs-CLI","January 2009","March 2010","April 2011","August 13, 2012",,"June 5, 2019","Pusan National University Hospital, Pusan, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01663376"
285,"NCT01314092","Clinical Trials of Autologous Cultured Adipose-derived Stem Cells (ANTG-ASC) on Complex Fistula","ANTG-ASC-210","Terminated","No Results Available","Complex Perianal Fistula","Biological: Autologous cultured adipose derived stem cells(low dose group)|Biological: Autologous cultured adipose derived stem cells(high dose group)","Number of patients with complete closure of fistula (week 8)|Grade of investigator's satisfaction|Number of patients with closed fistula|Photo of target fistula|Number of patients with adverse events","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)","Phase 2","15","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","ANTG-ASC-210","January 2011","September 2014","September 2014","March 14, 2011",,"November 23, 2016","Soon cheun Hyang university bucheon hospital, Bucheon-si, Korea, Republic of|Ewha womwn university mokdong hospital, Seoul, Korea, Republic of|DaeHang Hospital, Seoul, Korea, Republic of|Samsung seoul Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of|Seoul Saint Mary's Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01314092"
286,"NCT02801890","Evaluation of Autologous Adipose Derived Mesenchymal Stromal Cells (AD-MSC) Transplantation in Ultra Filtration Failure (UFF)",,"Completed","No Results Available","Ultra Filtration Failure","Biological: Intravenous injection","Systemic infection|Hepatic failure|Renal failure|Ratio of 4-hour dialysate/plasma creatinine (D/P Cr).|Ratio of 4-hour dialysate/plasma urea (D/P urea )|Ratio of dialysate glucose concentrations (D/D glucose )|peritoneal membrane transport function|Glomerular filtration rate (GFR):","Royan Institute","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","10","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-kidney-006","August 2015","February 2017","March 2017","June 16, 2016",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02801890"
287,"NCT02749448","Mesenchymal Stem Cells Therapy for Treatment of Airway Remodeling in Mustard Patients",,"Unknown status","No Results Available","Pulmonary Disease","Other: mesenchymal stem cell","pulmonary function testing (PFT)|St. George's Respiratory Questionnaire (SGRQ)|6 minute walk test (6MWT)","Dr. Mostafa Ghanei|Baqiyatallah Medical Sciences University","Male","45 Years to 65 Years   (Adult, Older Adult)","Phase 1","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","IRCT2015110524890N1","February 2015","November 2016","February 2017","April 25, 2016",,"July 25, 2016",,,"https://ClinicalTrials.gov/show/NCT02749448"
288,"NCT02016508","Safety Study of Use of Autologous Bone Marrow Derived Stem Cell in Treatment of Age Related Macular Degeneration",,"Unknown status","No Results Available","Age Related Macular Degeneration","Drug: autologous bone marrow derived stem cells","number of subjects with adverse events|Assessment of visual function changes from the base line","Al-Azhar University|Hassan , Hosny , M.D. M.Sc|Samour , Hany M.D. M.Sc|Ismail , Mahmoud M.D. M.Sc|Higazy , Hasan M.D. M.Sc|Abou el kheir, Wael, M.D. M.Sc.|Gabr, Hala , M.D. M.Sc.|Bakry, Sayed , phD. M.Sc.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","NCT 4619792013|4619792013","March 2013","April 2015","June 2015","December 20, 2013",,"December 24, 2013","Al-Azhar university medical school (Benin-cairo) ophthalmology department, Cairo, Nasr city, Egypt",,"https://ClinicalTrials.gov/show/NCT02016508"
289,"NCT01877759","A Clinical Study to Evaluate the Safety and Efficacy of Mesenchymal Stem Cells in Liver Cirrhosis",,"Unknown status","No Results Available","Liver Cirrhosis","Biological: Mesenchymal stem cell","Improvement in Liver function tests|Changes in liver function according to Child-Pugh|Changes in liver function according to MELD Score|Improvement in QUALITY OF LIFE SCALE (QOL)","Chaitanya Hospital, Pune","All","25 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","20","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSCC/BM/2013/LS/01","December 2013","December 2014","December 2014","June 14, 2013",,"October 9, 2013","Chaitanya Hospital, Pune,, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT01877759"
290,"NCT03397095","Sequential Treatment of Extra-Corporeal Shock Wave Combined With aUtologous Bone marRow Mesenchymal Stem Cells on Patients With ischEmic Heart Disease : the S-CURE Study","S-CURE","Recruiting","No Results Available","Ischemic Heart Disease","Combination Product: CSWT+BMMSCs|Device: CSWT+Sham operation","Change from baseline to 6 months follow-up in LVEF.|Change from baseline to 6 months follow-up in infarct size.|Change from baseline to 6 months follow-up in exercise distance increment|Change from baseline to 6 months follow-up in quality of life measured by MLHFQ|Change from baseline to 6 months follow-up in NYHA Classification.|Percent of patients with adverse events.|Change from baseline to 6 months follow-up in exercise time increment.|Change from baseline to 6 months follow-up in quality of life measured by KCCQ","Shanghai 10th People's Hospital","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","120","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","S-CURE","April 3, 2018","December 1, 2019","April 1, 2022","January 11, 2018",,"August 28, 2019","Shanghai Tenth People's Hospital, Tongji University, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT03397095"
291,"NCT01985633","Mesenchymal Stem Cells Enhanced With PRP Versus PRP In OA Knee","MSCPRPOAK","Unknown status","No Results Available","Osteoarthritis, Knee","Biological: Mesenchymal stem cell suspension|Biological: PRP","Pain relief|Functional Outcome","Aditya K Aggarwal|Postgraduate Institute of Medical Education and Research","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","24","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Adi_MSC_PRP_OA_2013","January 2013","June 2014","June 2014","November 15, 2013",,"November 18, 2013","Department of Orthopaedics Postgraduate Institute of Medical Education & Research, Chandigarh, India",,"https://ClinicalTrials.gov/show/NCT01985633"
292,"NCT01751282","Study of the Effectiveness of Autologous Bone Marrow-Derived Mesenchymal Stem Cells in Fibrin to Treat Chronic Wounds",,"Terminated","No Results Available","Non Healing Wounds","Genetic: Stem Cell","Wound closure|Overall rate of wound healing reduction","Roger Williams Medical Center","All","18 Years and older   (Adult, Older Adult)","Phase 1","5","Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RO1AR06034201A1","June 2010","June 2015","June 2015","December 17, 2012",,"October 4, 2016","Roger Williams Medical Center, Providence, Rhode Island, United States",,"https://ClinicalTrials.gov/show/NCT01751282"
293,"NCT02705742","Mesenchymal Stem Cells Transplantation for Liver Cirrhosis Due to HCV Hepatitis",,"Unknown status","No Results Available","Liver Cirrhosis","Biological: Mesenchymal Stem Cells","All cause mortality","Saglik Bilimleri Universitesi Gulhane Tip Fakultesi","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GMMA-HCV-MSC-1","January 2016","July 2017","December 2017","March 10, 2016",,"June 7, 2016","Gulhane Military Medical Academy, Ankara, Turkey",,"https://ClinicalTrials.gov/show/NCT02705742"
294,"NCT03818737","Multicenter Trial of Stem Cell Therapy for Osteoarthritis (MILES)","MILES","Active, not recruiting","No Results Available","Osteoarthritis","Biological: Autologous Bone Marrow Concentrate (BMAC)|Biological: Adipose-derived Stromal Vascular Fraction (SVF)|Biological: Umbilical Cord Tissue (UCT)|Drug: Depomedrol and Normal saline (Corticosteroid injection)","Change in Visual Analog Pain Scale (VAS-pain) scores|Change in Knee Injury and Osteoarthritis Outcome Score (KOOS)|Change in EuroQuality of Life (EQ5D-3L) scores|Change in Patient-Reported Outcomes Measurement Information System (PROMIS 29) scores","Emory University|The Marcus Foundation","All","40 Years to 70 Years   (Adult, Older Adult)","Phase 3","480","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","IRB00108046","March 28, 2019","December 31, 2021","December 31, 2021","January 28, 2019",,"May 11, 2021","Andrews Institute, Gulf Breeze, Florida, United States|The Emory Clinic, Atlanta, Georgia, United States|Duke University, Durham, North Carolina, United States|Sanford Health, Fargo, North Dakota, United States|Sanford Health, Sioux Falls, South Dakota, United States",,"https://ClinicalTrials.gov/show/NCT03818737"
295,"NCT03028428","Intra-articular Injection of MSCs in Treatment of Knee OA",,"Unknown status","No Results Available","Osteoarthritis|Stem Cells|MSC","Biological: Placenta Derived Mesenchymal Stem Cell|Drug: Sodium Hyaluronate","adverse events|radiographic evidence|WOMAC assessment|VAS|SF-36","Affiliated Hospital of Jiangsu University","All","40 Years to 75 Years   (Adult, Older Adult)","Phase 2","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AHJiangsuU-FSK-MSC-OA","December 2016","December 2018","December 2019","January 23, 2017",,"January 30, 2018",,,"https://ClinicalTrials.gov/show/NCT03028428"
296,"NCT01623453","Follow-up Study of Autologous Adipose-derived Stem Cells (ANTG-ASC) for the Complex Fistula (ANTG-ASC-211)","ANTG","Terminated","No Results Available","Perianal Fistula|Primary; Complex","Biological: Autologous adipose derived stem cells(low dose group)|Biological: Autologous adipose derived stem cells(high dose group)","Number of patients with Sustained efficacy of complete closure of fistula|Number of patients with sustained efficacy of closure of fistula|Evaluation of Fecal Incontinence Score|Grade of Investigator's satisfaction|Number of patients with adverse events as a measure of systemic tolerance and physical examinations","Anterogen Co., Ltd.","All","18 Years and older   (Adult, Older Adult)",,"6","Industry","Observational","Time Perspective: Prospective","ANTG-ASC-211","September 2010","September 2014","September 2014","June 20, 2012",,"November 23, 2016","DaeHang Hospital, Seoul, Korea, Republic of|Seoul National University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01623453"
297,"NCT03939741","SVF (Adipose Tissue Derived MSC) Based Therapy for CKD.","StemCell&CKD","Recruiting","No Results Available","Chronic Kidney Diseases","Biological: SVF Containg Autologous Non Expanded ADSC","Incidence of minor adverse events (MAEs) , serious adverse events (SAEs) which may be immediate, early or late - for Phase I|Change from baseline to 24 week visit in glomerular filtration rate (GFR) and split renal function in all patients - for Phase II|Change from baseline to 24 week visit in estimated glomerular filtration rate (eGFR) with serum creatinine level in patients with CKD 4 and below - for Phase II|Change from baseline to 24 week visit in need for dialysis in patients with CKD 5 - for phase II|Change from baseline to all post-treatment visits in body weight|Change from baseline to all post-treatment visits in Blood-pressure|Change from baseline to all post-treatment visits in S.creatinine|Change from baseline to all post-treatment visits in blood urea.|Change from baseline to all post-treatment visits in Hemoglobin level|Change from baseline to all post-treatment visits in urine microalbumin-to-creatinine ratio (UMCR)|Change from baseline to all post-treatment visits in hemoglobin A1c|Change from baseline to all post-treatment visits in random blood sugar (RBS)|Change from baseline to all post-treatment visits in Anti-Hypertensive medication if there is any.|Change from baseline to all post-treatment visits in Hypoglycemic agent if there is any.|Change from baseline to post-treatment visits in urine total protein-creatinine ratio (UPCR)|Change from baseline to all post-treatment visits in urinary Protein-to-creatinine ratio PCR)|Change from baseline to post-treatment level of serum Alpha Feto Protein|Change from baseline to post-treatment level of serum CEA level|Change from baseline to post-treatment level of serum CA 19.9 level|Change from baseline to post-treatment level LDH level|Change from baseline to post-treatment level of Beta 2 Microglobulin level|Change from baseline to post-treatment level of serum CA 125 level (in case of female patients)|Change from baseline to post-treatment level of PSA level (in case of male patients)","Bangladesh Laser & Cell Surgery Institute & Hospital","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","31","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BangladeshLCS001","April 1, 2019","March 31, 2024","March 31, 2025","May 7, 2019",,"July 15, 2020","Bangladesh Laser And Cell Surgery Institute And Hospital, Dhaka, Bangladesh","""Study Protocol, Statistical Analysis Plan, and Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/41/NCT03939741/Prot_SAP_ICF_001.pdf","https://ClinicalTrials.gov/show/NCT03939741"
298,"NCT03968198","Administration of Adipose-derived Stem Cells (ASC) in Patient With Critical Limb Ischemia","ACellDREAM2","Recruiting","No Results Available","Critical Limb Ischemia and Peripheral Artery Disease","Drug: Autologous ASC (for Adipose-derived Stem/Stroma Cell)","Number of patients alive without major amputation|Number of patients alive without critical limb ischemia|New vessels|Blood flow|Wound surface reduction|Ulcer healing|Pain reduction|Wound infection|Immuno measures in blood sample|Immuno measures in vitro","University Hospital, Toulouse|Institut National de la Santé Et de la Recherche Médicale, France|Etablissement Français du Sang","All","18 Years and older   (Adult, Older Adult)","Phase 2","43","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","14 7441 01","March 4, 2020","December 2022","July 2023","May 30, 2019",,"July 30, 2020","CHU de BORDEAUX, Bordeaux, France|CHU de LIMOGES, Limoges, France|Rangueil Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT03968198"
299,"NCT01771640","Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS",,"Completed","No Results Available","Amyotrophic Lateral Sclerosis","Biological: intrathecal injection","Fever|Unconscious|Vomiting|ALS-FRS|FVC","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","8","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Nerve-006","August 2013","October 2014","December 2014","January 18, 2013",,"March 7, 2018","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01771640"
300,"NCT03484741","Mesenchymal Stem Cell Therapy for Type 1 Diabetes Mellitus Patients",,"Unknown status","No Results Available","Type 1 Diabetes Mellitus","Biological: MSC and PRP","Fasting blood glucose|Hemoglobin A1c (HbA1c) level|Adverse events|Insulin dose|C-peptide|Blood insulin level","Van Hanh General Hospital|University of Science Ho Chi Minh City","All","18 Years to 45 Years   (Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","DIME 1001","April 1, 2017","November 2018","November 2018","April 2, 2018",,"April 4, 2018","Van Hanh Geral Hospital, Ho Chi Minh City, Ho Chi Minh, Vietnam",,"https://ClinicalTrials.gov/show/NCT03484741"
301,"NCT04501341","BM-MNC and UCMSC for Type 2 Diabetes Mellitus Patients",,"Recruiting","No Results Available","T2D","Biological: Bone-marrow aspiration, Intra-pancreatic Catheterisation of BM-MNC|Biological: Intravenous Infusion of UC-MSC","Decreasing total daily dose of insulin (>= 30%)|Increasing of C-peptide level|Decreasing of insulin resistance level|Immunology/inflammatory markers|Adverse events|HbA1c","Indonesia University|Dr Cipto Mangunkusumo General Hospital","All","30 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","15","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","132/PT02.FK25/U.Eu113/METEND/V","March 14, 2016","December 1, 2021","December 1, 2021","August 6, 2020",,"August 6, 2020","Faculty of Medicine, Universitas Indonesia, Jakarta Pusat, DKI Jakarta, Indonesia",,"https://ClinicalTrials.gov/show/NCT04501341"
302,"NCT02525432","Autologous Stem Cell Study for Adult TBI (Phase 2b)",,"Enrolling by invitation","No Results Available","Brain Injuries, Traumatic|Brain Injuries, Acute|TBI (Traumatic Brain Injury)","Biological: Placebo Infusion|Biological: Autologous BMMNC Infusion","Macro and micro structural properties of grey matter (GM) and white matter (WM) regions will measured using high-resolution anatomical MRI and diffusion tensorm imaging and comparisons made between groups.|Brain imaging measures of GM and WM structural integrity will be compared to functional and neurocognitive scores and comparisons made between groups.|Compare neuro-inflammatory biomarkers between groups..|Measure the number of participants with infusion related adverse events.|Measure spleen ultrasound size over time and corresponding changes in inflammatory cytokines.|Determine if microglial activation is associated with TBI and can be accurately measured with brain PET and DT-MRI imaging when compared to PET imaging data from healthy volunteers (enrolled under a different protocol).|Quantify the extent and location of microglial activation by brain PET imaging and how activity correlates with performance of neurocognitive outcomes measures.|Determine the extent to which an IV infusion of autologous BMMNC post-injury impacts microglial activation by brain PET imaging.","The University of Texas Health Science Center, Houston|United States Department of Defense|U.S. Army Medical Research and Development Command","All","18 Years to 55 Years   (Adult)","Phase 2","55","Other|U.S. Fed","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","HSC-MS-16-0283","November 21, 2016","October 2022","December 2022","August 17, 2015",,"April 28, 2021","UT Southwestern Medical Center, Dallas, Texas, United States|The University of Texas Health Science Center at Houston, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02525432"
303,"NCT01984450","A Study to Compare Two Techniques for Articular Cartilage Repair:ACIC Vs. MCIC",,"Unknown status","No Results Available","Articular Cartilage Defect","Procedure: ACIC|Procedure: MCIC|Device: implant with a collagen + fibrin gel mixture","Clinical outcome|Radiological outcome","Shetty-Kim Research Foundation","All","18 Years to 65 Years   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SKRF 002","January 2014","December 2016","June 2017","November 14, 2013",,"November 14, 2013","Kent Knee Unit, Walderslade, Kent, United Kingdom",,"https://ClinicalTrials.gov/show/NCT01984450"
304,"NCT02566655","Clinical Trial of Intravenous Infusion of Fucosylated Bone Marrow Mesenchyme Cells in Patients With Osteoporosis","CSM/OP/2011","Completed","No Results Available","Osteoporosis|Spinal Fractures","Biological: Fucosylated MSC for Osteoporosis","Rate of serious and non-serious adverse events related to the procedure.|Number of new fractures|Pain, measured by Visual Analog Scale|Functionality, measured by Oswestry Disability Questionnaire|Quality of Life, measured by EuroQoL-5D test|Bone resorption, measured by biochemical index|Bone formation, measured by biochemical index|Bone metabolism, measured by biochemical index|Bone Mineral Density , measured by dual energy x-ray absorptiometry (DXA)|Bone structure, measured by histomorphometric evaluation|Trabecular bone density measured by quantitative computed tomography of the radius","Red de Terapia Celular|Instituto Murciano de Investigación Biosanitaria Virgen de la Arrixaca|Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia|Hospital Universitario Virgen de la Arrixaca|Spanish National Health System|Public Health Service, Murcia|BIONAND, Universidad de Málaga, IBIMA, Ciber-bbn|Grupo de Tecnología Sanitaria CIBER-BBN, Inst. Biomecánica de Valencia","Female","50 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Industry|Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","CSM/OP/2011|2012-005814-20","September 2015","December 2016","May 2018","October 2, 2015",,"October 8, 2020","Hospital Clínico Virgen de la Arrixaca, El Palmar, Murcia, Spain",,"https://ClinicalTrials.gov/show/NCT02566655"
305,"NCT02135380","Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis",,"Unknown status","No Results Available","Idiopathic Pulmonary Fibrosis","Biological: Autologous Stromal Vascular Fraction (SVF)|Biological: Autologous Adipose Derived MSCs (ADMSCs)|Other: Control","Safety|Efficacy","Kasiak Research Pvt. Ltd.","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 1|Phase 2","60","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KRPL/IPF/11-12/002","August 2014","August 2015",,"May 9, 2014",,"May 13, 2014","Kasiak Research Pvt Ltd, Thane, Maharashtra, India",,"https://ClinicalTrials.gov/show/NCT02135380"
306,"NCT02107118","Stem Cells for the Improvement of Erectile and Cardiac Function in Aging Men",,"Withdrawn","No Results Available","Erectile Dysfunction|Cardiac Disease","Biological: ARM 1: AdMSC: adipose stem cells|Other: ARM 2: Placebo","Improvements in IIEF scores of greater than 2|Improvements in RHI (reactive hyperemic index) scores of greater than 0.3","Baylor College of Medicine","Male","40 Years and older   (Adult, Older Adult)","Phase 1","0","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","H-34570 No.11-13-40-07","May 2015","March 2020","February 2022","April 8, 2014",,"May 25, 2015","Baylor College of Medicine, Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT02107118"
307,"NCT03990805","A Phase 3 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis",,"Completed","No Results Available","Degenerative Arthritis|Knee Osteoarthritis","Biological: JOINTSTEM|Drug: saline","Change of Western Ontario and McMaster Universities Osteoarthritis Index(WOMAC) scores from baseline|Change of Visual Analog Scale (VAS) scores from baseline|WOMAC 3 subscale score|VAS score|KOOS|SF-36|IKDC|Measuring of Kellgren-Lawrence grade|Measuring of Femoro-tibial anatomical angle(FTA)|Measuring of Hip-Knee-Ankle angle(HKA)|Measuring of Joint Space Width|MRI scan|Use of rescue medication","R-Bio","All","20 Years to 100 Years   (Adult, Older Adult)","Phase 3","260","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","BSR-CTph3-JS1","June 11, 2019","December 15, 2020","December 15, 2020","June 19, 2019",,"January 29, 2021","Chungbuk National University Hospital, Cheongju-si, Korea, Republic of|Yeungnam University Hospital, Daegu, Korea, Republic of|Keimyung University Dongsan Medical Center, Daegu, Korea, Republic of|Chonbuk National University Hospital, Jeonju, Korea, Republic of|Gyeongsang National University Hospital, Jinju-si, Korea, Republic of|Kyunghee University Medical Center, Seoul, Korea, Republic of|Yonsei University Health System, Seoul, Korea, Republic of|Soonchunhyang University Hospital Seoul, Seoul, Korea, Republic of|KyungHee University Gangdong Hospital, Seoul, Korea, Republic of|Gangnam Severance Hospital, Seoul, Korea, Republic of|Samsung Medical Center, Seoul, Korea, Republic of|Chunang University Hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT03990805"
308,"NCT03067870","Transplantation of Autologous Bone Marrow Derived Stem Cells in Patients With Rheumatoid Arthritis",,"Active, not recruiting","No Results Available","RheumatoId Arthritis|Osteoarthritis, Knee|Osteoarthritis, Hip","Biological: Stem Cell Transplantation","Evaluation of Pain Reduction measured by VAS scaling|Evaluation of the Physical Activity measure by WOMAC scoring|Evaluation the resurfacing of articular cartilage by MRI","Stem Cells Arabia","All","17 Years to 75 Years   (Child, Adult, Older Adult)","Phase 1","100","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCA-RA1","November 2016","December 2021","February 2022","March 1, 2017",,"March 17, 2020",,,"https://ClinicalTrials.gov/show/NCT03067870"
309,"NCT02975960","ADMSCs for the Treatment of Systemic Sclerosis",,"Completed","No Results Available","Systemic Sclerosis","Biological: injection of autologous stromal vascular fraction","Change from baseline modified Rodnan Skin score (mRSS) of hands at 12 weeks|Change from baseline Raynaud's condition score at 12 weeks|Change from baseline Visual Analog Score for pain the hands at 12 weeks|Changes from baseline mRSS (total) at 12 weeks|Change from baseline Kapandji score at 12weeks|Change from baseline Cochin hand function scale at 12 weeks|Change from baseline Systemic sclerosis HAQ at 12 weeks|Change from baseline peripheral vasculature at 12 weeks|Change from baseline finger circumference at 12 weeks","The Catholic University of Korea|Seoul St. Mary's Hospital","All","18 Years and older   (Adult, Older Adult)","Not Applicable","7","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KC16TISI0343","October 25, 2016","October 30, 2017","January 20, 2018","November 29, 2016",,"January 25, 2018","Seoul St. Mary's hospital, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT02975960"
310,"NCT00587990","Prospective Randomized Study of Mesenchymal Stem Cell Therapy in Patients Undergoing Cardiac Surgery (PROMETHEUS)","PROMETHEUS","Terminated","Has Results","Stem Cell Transplantation|Ventricular Dysfunction, Left","Biological: Lower dose mesenchymal stem cell (MSC) injection|Genetic: Placebo|Biological: Higher dose MSC injection","Number of Patients With Serious Adverse Events|Change in Infarct Scar Size (ISS) Over 18 Month Period|Left Ventricular Function (LVF) in Region of MSC Injection|Regional Left Ventricular Wall Thickening|Left Ventricular End Diastolic Wall Thickness|Change in Left Ventricular End Diastolic and Systolic Volume|Change in Left Ventricular Ejection Fraction|Change in Peak Volume Oxygen|Change in Six Minute Walk Test|Change in NYHA Functional Class|Minnesota Living With Heart Failure Questionnaire Scores|Incidence of Major Adverse Cardiac Events (MACE)|Number of Participants With Abnormal 48-Hour Ambulatory ECG Recordings|Change in Pulmonary Function|Serial Troponin Values (ng/mL)|Creatinine Kinase - Muscle/Brain (MB) (ng/mL)|Number of Clinically Significant Laboratory Values|Rate of Treatment Emergent Adverse Events|Number of Abnormal Echocardiogram Readings 2 Days Post CABG.","Joshua M Hare|National Heart, Lung, and Blood Institute (NHLBI)|Johns Hopkins University Specialized Center for Cell Based Therapy|The Emmes Company, LLC|University of Miami","All","21 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","9","Other|NIH|Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","20070598|U54HL081028","November 2007","June 2011","June 2011","January 8, 2008","April 2, 2015","September 10, 2019","University of Miami Miller School of Medicine, Miami, Florida, United States|Johns Hopkins University School of Medicine, Baltimore, Maryland, United States",,"https://ClinicalTrials.gov/show/NCT00587990"
311,"NCT01210950","Distraction Osteogenesis in Limb-length Discrepancy With Mesenchymal Cell Transplantation",,"Completed","No Results Available","Leg Length Inequality","Biological: cell and RPR injection","effect of mesenchymal cell transplantation to decrease limb inequal|improve life quality","Royan Institute","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1","6","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Bone-006","September 2009","December 2013","December 2013","September 29, 2010",,"April 28, 2014","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT01210950"
312,"NCT02641769","Intra-Testicular Transplantation of Autologous Stem Cells for Treatment of Non-Obstructive Azoospermia Male Infertility.",,"Recruiting","No Results Available","Non-obstructive Azoospermia","Biological: Stem Cell Transplantation","Appearance of different germ cells in testicles through the progress of spermatogenesis will be assessed by the count of cells using histological studies.|General improvements of testicular morphology will be assessed with histological studies.|Improvement in sexual function will be assessed using a questionnaire","Stem Cells Arabia","Male","21 Years to 50 Years   (Adult)","Phase 1|Phase 2","50","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","SCA-INF1","January 2014","June 2020","January 2021","December 29, 2015",,"March 17, 2020","Stem Cells of Arabia, Amman, Jordan",,"https://ClinicalTrials.gov/show/NCT02641769"
313,"NCT02208713","Intramuscular Transplantation of Muscle Derived Stem Cell and Adipose Derived Mesenchymal Stem Cells in Patients With Facioscapulohumeral Dystrophy (FSHD)",,"Unknown status","No Results Available","Dystrophy","Biological: Intramuscular injection","Myalsia|Mass formation|Hematoma|Muscle bulk|CPK","Royan Institute","All","18 Years to 50 Years   (Adult)","Phase 1","21","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","Royan-Nerve-007","May 2014","November 2017","December 2017","August 5, 2014",,"April 27, 2017","Royan Institute, Tehran, Iran, Islamic Republic of",,"https://ClinicalTrials.gov/show/NCT02208713"
314,"NCT02472002","Mesenchymal Stem Cell Administration in the Treatment of Coronary Graft Disease in Heart Transplant Patients","MESHT","Suspended","No Results Available","Coronary Disease|Heart Transplant","Biological: Mesenchymal cell therapy","myocardial perfusion measured in MRI.|complications of catheterization|complications of endomyocardial injection|systolic function|diastolic function|immunomodulation induced MSCs in the blood|immunomodulation induced MSCs in myocardial biopsy","Assistance Publique - Hôpitaux de Paris","All","18 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","14","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","P 100102","January 2014","January 2018","January 2018","June 15, 2015",,"February 23, 2017","Département de cardiologie du Pr Michel KOMADJA, Paris, France",,"https://ClinicalTrials.gov/show/NCT02472002"
315,"NCT02855073","Clinical Trial to Compare ReJoinTM to Sodium Hyaluronate Injection for Knee Osteoarthritis Cartilage Defects",,"Unknown status","No Results Available","Defect of Articular Cartilage|Knee Osteoarthritis","Biological: ReJoinTM|Drug: Sodium Hyaluronate","WOMAC scores|VAS scores|SF-36 scores|Outbridge scoring|CRP|Cartilage defect size|Cartilage volume","Cellular Biomedicine Group Ltd.|Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2","28","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","CBMG-ReJoinTM-CL-1.0","July 2014","December 2019","December 2019","August 4, 2016",,"December 17, 2018","Shanghai ninth people's hospital, Shanghai, Shanghai, China",,"https://ClinicalTrials.gov/show/NCT02855073"
316,"NCT00956891","Therapeutic Effects of Liver Failure Patients Caused by Chronic Hepatitis B After Autologous MSCs Transplantation",,"Completed","No Results Available","Liver Failure|Mesenchymal Stem Cells",,"Short-term therapeutic effects of transplantation.|Long-term outcomes of transplantation.","Sun Yat-sen University","All","15 Years to 70 Years   (Child, Adult, Older Adult)",,"158","Other","Observational","Observational Model: Case-Control|Time Perspective: Retrospective","SunYat-senU 5010 hepatitisB","May 2005","June 2009","July 2010","August 11, 2009",,"December 7, 2010","The Third Affiliated Hospital Of Sun Yat-sen University, Guangzhou, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT00956891"
317,"NCT01585857","ADIPOA - Clinical Study",,"Completed","No Results Available","Osteoarthritis","Biological: Autologous adipose derived stem cells administrated for intra-articular use","Recording of Serious Adverse Events|Functional status of the knee|Quality of life","University Hospital, Montpellier","All","50 Years to 75 Years   (Adult, Older Adult)","Phase 1","18","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","8606","April 2012","December 2014","December 2014","April 26, 2012",,"December 4, 2014","UH Montpellier, Montpellier, France|Orthopädische Klinik, Würzburg, Germany",,"https://ClinicalTrials.gov/show/NCT01585857"
318,"NCT02145923","Effectiveness and Safety of MMSCs for Enhancing Hematopoietic Recovery and Prophylaxis of Neutropenic Enterocolitis",,"Unknown status","No Results Available","Neutropenic Enterocolitis|Myeloablative Chemotherapy Induced Bone Marrow Aplasia","Procedure: Peripheral blood stem cell mobilisation and collection|Drug: High-dose chemotherapy|Drug: Bone marrow derived allogeneic MMSCs infusion|Procedure: Autologous peripheral blood stem cells infusion","Number of serious adverse events (SAEs) and serious adverse reactions (SARs)|Time of hematopoietic recovery|Neutropenic enterocolitis|Infectious complications|Transfusion needs","Burnasyan Federal Medical Biophysical Center","All","18 Years to 65 Years   (Adult, Older Adult)","Phase 1|Phase 2","16","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Prevention","RU-FMBC-05-01-14","May 2014","June 2016","December 2016","May 23, 2014",,"June 10, 2015","State Research Center Burnasyan Federal Medical Biophysical Center FMBA of Russia, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02145923"
319,"NCT02209311","Effectiveness and Safety of Method of Maxilla Alveolar Process Reconstruction Using Synthetic Tricalcium Phosphate and Autologous MMSCs",,"Unknown status","No Results Available","Partially Edentulous Maxilla|Alveolar Bone Atrophy|Alveolar Bone Loss","Procedure: Oral mucosa biopsy|Procedure: Sinus lift with implantation of tissue engineered construction|Device: Dental implant","Number of serious adverse events (SAEs) and serious adverse reactions (SARs)|Quality of life monitoring|Changes in bone tissue volume|Correlation of morphometrical analysis using cone beam CT scan with absolute value of the newly formed bone","Central Clinical Hospital w/Outpatient Health Center of Business Administration for the President of Russian Federation","All","20 Years to 60 Years   (Adult)","Phase 1|Phase 2","12","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","RU-CCH-06-01-14","September 2014","October 2017","March 2018","August 5, 2014",,"November 30, 2016","Federal State Budgetary Institution ""Central Clinical Hospital with Outpatient Health Center"" of the Business Administration for the President of the Russian Federation; Center for Biomedical Technologies, Moscow, Russian Federation|A.I. Evdokimov Moscow State Medical Stomatological University, Moscow, Russian Federation",,"https://ClinicalTrials.gov/show/NCT02209311"
320,"NCT03248466","PRG Combined With Autologous BMMSCs for Treatment of Diabetic Foot Ulcer",,"Unknown status","No Results Available","Diabetic Foot Ulcer","Biological: PRG combined with BMMSCs transplantation","Amputation rate|hospital stay|Wound healing time|Transcutaneous oxygen partial pressure","Third Military Medical University","All","20 Years to 70 Years   (Adult, Older Adult)","Early Phase 1","60","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Parallel Assignment|Masking: Single (Outcomes Assessor)|Primary Purpose: Treatment","endocrine department of TMMU","August 30, 2017","January 1, 2020","July 1, 2020","August 14, 2017",,"August 14, 2017","Southwest Hospital of the Third Military Medical University, Chongqing, Chongqing, China|Endocrine Department, the First Affiliated Hospital of the Third Military Medical University, Chongqing, Chongqing, China",,"https://ClinicalTrials.gov/show/NCT03248466"
321,"NCT01309061","The Effect of Human Adipose Tissue-derived MSCs in Romberg's Disease",,"Completed","No Results Available","Progressive Hemifacial Atrophy|Romberg's Disease","Procedure: Autologous Adipose Tissue derived MSCs Transplantation","The volume change of fatty layer|Clinical lab tests|Fat absorption rate","R-Bio|Asan Medical Center","All","18 Years to 75 Years   (Adult, Older Adult)","Not Applicable","5","Industry|Other","Interventional","Allocation: Randomized|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","KSC-Facial-Stem","March 2008","December 2009","February 2010","March 4, 2011",,"June 5, 2019","ASAN Medical Center, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01309061"
322,"NCT03112122","Study for the Treatment of the Bone Marrow Edema:Core Decompression VS Bone Marrow Concentrate (BMC) VS Bone Substitute","BME-TARGET","Terminated","No Results Available","Bone Marrow Edema","Biological: autologous bone marrow concentrate|Biological: bone substitute i-FactorTM|Procedure: core decompression","change of Visual Analogue Scale (VAS) score|International Knee Documentation Committee (IKDC) subjective score|Knee Injury and Osteoarthritis Outcome (KOOS) Score|Tegner Activity Level Scale","Istituto Ortopedico Rizzoli","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 4","1","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","BME-TARGET","March 11, 2016","December 31, 2017","December 31, 2017","April 13, 2017",,"August 9, 2018","Rizzoli Orthopaedic Institute, Bologna, Italy",,"https://ClinicalTrials.gov/show/NCT03112122"
323,"NCT03645460","Gene Transfer for ADA-SCID Using an Improved Lentiviral Vector (TYF-ADA)",,"Recruiting","No Results Available","Adenosine DeAminase Severe Combined ImmunoDeficiency (ADA-SCID)","Genetic: TYF-ADA gene-modified autologous stem cells","Overall survival up to a year|1. Success of immune reconstitution|2. Change of infection status","Shenzhen Geno-Immune Medical Institute","All","1 Month and older   (Child, Adult, Older Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-18003","October 30, 2018","December 31, 2020","December 31, 2021","August 24, 2018",,"September 20, 2019","Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03645460"
324,"NCT03925649","Individual Patient Expanded Access IND of Hope Biosciences Autologous Adipose-derived Mesenchymal Stem Cells for Treatment of SCI",,"No longer available","No Results Available","Spinal Cord Injury at C5-C7 Level","Biological: HB-adMSCs",,"Hope Biosciences|The University of Texas Health Science Center, Houston","Male","18 Years and older   (Adult, Older Adult)",,,"Industry|Other","Expanded Access:Individual Patients|Intermediate-size Population|Treatment IND/Protocol",,"HBSCI01",,,,"April 24, 2019",,"July 6, 2021","Memorial Hermann Hospital-Clinical Research Unit (MMH-CRU), Houston, Texas, United States",,"https://ClinicalTrials.gov/show/NCT03925649"
325,"NCT01351610","Tolerability and Efficacy of Intravenous Infusion of Autologous MSC_Apceth for the Treatment of Critical Limb Ischemia",,"Completed","No Results Available","Critical Limb Ischemia|Peripheral Artery Disease","Biological: PTA + Infusion of MSC_Apceth|Procedure: PTA","Collection of adverse events|Safety laboratory values|ECG findings|Analysis of inflammation markers|Comparison of course of haemodynamic and vascular processes","Apceth GmbH & Co. KG","All","40 Years to 80 Years   (Adult, Older Adult)","Phase 1|Phase 2","25","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC_Apceth_001","March 2011","October 2014","October 2015","May 11, 2011",,"December 15, 2015","Isar Medizin Zentrum, Munich, Bavaria, Germany",,"https://ClinicalTrials.gov/show/NCT01351610"
326,"NCT04482413","Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease",,"Not yet recruiting","No Results Available","Alzheimer Disease","Drug: AstroStem and Donepezil Placebo|Drug: Donepezil and AstroStem Placebo","ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive subscale)|MMSE (Mini-mental status examination)|C-SSRS (Columbia Suicide Severity Rating Scale)|NPI (Neuropsychiatric Inventory)|ADCS-CGIC (Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change)|Treatment related Adverse Events","Nature Cell Co. Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 2","80","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Treatment","AST-ADP2-US02","December 1, 2021","December 1, 2022","December 20, 2023","July 22, 2020",,"March 26, 2021",,,"https://ClinicalTrials.gov/show/NCT04482413"
327,"NCT02674399","A Phase 2 Study to Evaluate the Efficacy and Safety of JointStem in Treatment of Osteoarthritis",,"Completed","Has Results","Osteoarthritis, Knee","Drug: JointStem|Drug: Synvisc-One","Change From Baseline on Western Ontario and McMaster Universities Arthritis Index (WOMAC) Score in JointStem Group|Change From Baseline on Visual Analog Scale (VAS) in JointStem Group|MRI Improvement Evaluation in JointStem Group|Change From Baseline on WOMAC Between JointStem and Positive Control Groups|Change From Baseline on VAS Between JointStem and Positive Control Groups|Change From Baseline on Knee Injury & Osteoarthritis Outcome Score (KOOS) Between JointStem and Positive Control Groups|Change From Baseline on Lysholm Knee Scoring Scale Between JointStem and Positive Control Groups|Change From Baseline on International Knee Documentation Committee (IKDC) Between JointStem and Positive Control Groups|Change From Baseline on RAND-36 Score Between JointStem and Positive Control Groups|Change From Baseline on WOMAC in JointStem Group|Change From Baseline on VAS in JointStem Group|Comparison of MRI Improvement Evaluation in JointStem Group|Change of Lysholm Knee Scoring Scale From Baseline at Months 6, 9 and 12|Change of KOOS Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of IKDC Score From Baseline at Month 6, 9 and 12 for JointStem Group|Change of RAND-36 Score From Baseline at Month 6, 9 and 12 for JointStem Group","Nature Cell Co. Ltd.|KCRN Research, LLC","All","22 Years to 60 Years   (Adult)","Phase 2","28","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","JS-OAP2-US01","February 16, 2016","March 12, 2018","December 28, 2018","February 4, 2016","July 13, 2021","August 10, 2021","Orthopedic Pain Specialists, Santa Monica, California, United States|Walnut Creek, California, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/99/NCT02674399/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT02674399"
328,"NCT03117738","A Study to Evaluate the Safety and Efficacy of AstroStem in Treatment of Alzheimer's Disease",,"Completed","Has Results","Alzheimer Disease","Drug: AstroStem|Other: Placebo-Control","Treatment Related Adverse Events|ADAS-Cog (Alzheimer's Disease Assessment Scale-cognitive Subscale)|MMSE (Mini-mental Status Examination)|CDR-SOB (Clinical Dementia Rating-Sum of Boxes)|NPI (Neuropsychiatric Inventory)|GDS (Geriatric Depression Scale)|ADCS-ADL (Alzheimer's Disease Cooperative Study Activities of Daily Living)|C-SSRS (Columbia Suicide Severity Rating Scale)","Nature Cell Co. Ltd.","All","50 Years and older   (Adult, Older Adult)","Phase 1|Phase 2","21","Industry","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AST-ADP2-US01","May 9, 2017","June 26, 2019","August 31, 2019","April 18, 2017","July 9, 2021","August 10, 2021","ATP Clinical Research, Costa Mesa, California, United States|Syrentis Clinical Research, Santa Ana, California, United States|Valden Medical, Honolulu, Hawaii, United States","""Study Protocol"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/Prot_000.pdf|""Statistical Analysis Plan"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/SAP_001.pdf|""Informed Consent Form"", https://ClinicalTrials.gov/ProvidedDocs/38/NCT03117738/ICF_002.pdf","https://ClinicalTrials.gov/show/NCT03117738"
329,"NCT02403947","MEsenchymal StEm Cells for Multiple Sclerosis","MESEMS","Terminated","No Results Available","Multiple Sclerosis","Drug: Mesenchymal stem cells|Drug: Suspension media","Safety of MSCs infusion, number, timeframe of occurrence and severity of Adverse Events|efficacy: number of contrast-enhancing lesions (GEL) at MRI scan|Efficacy of the experimental treatment in term of combined MRI activity|Efficacy assessed by combined unique MRI activity, volume of GEL, and volume of BH|Efficacy assessed by combined unique MRI activity, volume of GEL and volume of BH|Efficacy: Number of relapses|Efficacy: Time to sustained progression of disability","University Hospital, Toulouse","All","18 Years to 50 Years   (Adult)","Phase 1|Phase 2","1","Other","Interventional","Allocation: Randomized|Intervention Model: Crossover Assignment|Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","12 394 03","February 2015","December 2017","December 2017","March 31, 2015",,"December 3, 2018","Purpan Hospital, Toulouse, France",,"https://ClinicalTrials.gov/show/NCT02403947"
330,"NCT03351868","FANCA Gene Transfer for Fanconi Anemia Using a High-safety, High-efficiency, Self-inactivating Lentiviral Vector",,"Recruiting","No Results Available","Fanconi Anemia","Genetic: Gene-modified autologous stem cells","Safety in patients using CTCAE version 4.0 standard to evaluate the level of adverse events|Treatment responses|Quality of life","Shenzhen Geno-Immune Medical Institute","All","2 Years to 20 Years   (Child, Adult)","Not Applicable","10","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","GIMI-IRB-17021","December 1, 2017","December 31, 2020","December 31, 2021","November 24, 2017",,"September 19, 2019","Capital Institute of Pediatrics affiliated Children's hospital, Beijing, Beijing, China|Beijing Children's Hospital, Beijing, Beijing, China|Shenzhen Geno-immune Medical Institute, Shenzhen, Guangdong, China",,"https://ClinicalTrials.gov/show/NCT03351868"
331,"NCT04435249","ENgineered Tissue Repair of BronchopleUral fiSTula","ENTRUST","Not yet recruiting","No Results Available","Bronchopleural Fistula","Other: BPF-001","Safety: Emergent or worsening Serious Adverse Events (SAEs) related to the BPF implant during the 3 months post-defect repair|Efficacy: Bronchopleural Fistula (BPF) closure at 3 months assessed by visual appearance and no clinical signs of leaks.|Change from Baseline in Physiological and Quality of Life scores at 3, 6, 9, 12 months, Evaluation Questionnaire 5D (EQ-5D), 6-minute walking test (6MWT), ambulatory oxygen (O2).|Safety and tolerability: - Adverse Events (AEs) including pre-defined postoperative AEs of special interest up to 30± 3 days post implantation- Related AEs reported after 3, 6, 9, 12, 24 and 36 months|Viability and the integrity of the repair area (closure) visually via bronchoscope. Integrity assessed by visual appearance of no visible leaks- Structural closure of the defect and visual health of the defect area and surrounding tissue|Absence of other surgical interventions at 6, 9, 12, 24 and 36 months","Cell Therapy Catapult|Videregen Therapeutics|Papworth Hospital NHS Foundation Trust|Royal Free Hospital NHS Foundation Trust","All","18 Years to 64 Years   (Adult)","Phase 1|Phase 2","5","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","UK-2019-004939-24","January 4, 2022","September 2023","November 2024","June 17, 2020",,"October 20, 2021",,,"https://ClinicalTrials.gov/show/NCT04435249"
332,"NCT04308213","Study on Shoulder Arthritis Treatment With Intra-articular Injections of Autologous Bone Marrow Aspirate.","Stemshoulder","Recruiting","No Results Available","Shoulder Arthritis","Device: Marrow Cellution System","Change of the Constant-Murley score|Change of the VAS pain score|Change of range of motion (ROM)|clinical change based on the DASH scale (disability of the arm, shoulder and Hand)|clinical change based on the , American Shoulder and Elbow Surgeons (ASES) score|evaluation of shoulder MRI results|evaluation of shoulder X-ray (XR) results","Istituto Clinico Humanitas","All","35 Years to 75 Years   (Adult, Older Adult)","Not Applicable","30","Other","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","955","November 12, 2019","April 30, 2024","September 30, 2024","March 13, 2020",,"March 17, 2020","Humanitas Research Hospital, Rozzano, Milano, Italy",,"https://ClinicalTrials.gov/show/NCT04308213"
333,"NCT03455335","Autologous Stem Cells for the Treatment of No Option Critical Limb Ischemia",,"Completed","No Results Available","Critical Limb Ischemia","Drug: 20 million hMSCs|Drug: 40 million hMSCs|Drug: 80 million hMSCs","The number of Serious Adverse Events that are attributable to the treatment|The severity of Serious Adverse Events that are attributable to the treatment|Amputation free survival|median time to amputation,|Change in Transcutaneous Pressure of Oxygen TcPO2|Change in Ankle Brachial Index|Collateral vessel formation|Change in Ischemic rest pain|Change in Ulcer size|Change in Quality of Life","National University of Ireland, Galway, Ireland|University Hospital of Limerick","All","18 Years to 85 Years   (Adult, Older Adult)","Phase 1","12","Other","Interventional","Allocation: Non-Randomized|Intervention Model: Sequential Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","2013-001","March 23, 2015","October 31, 2019","October 31, 2019","March 6, 2018",,"March 4, 2021","Galway University Hospital, Galway City, Galway, Ireland",,"https://ClinicalTrials.gov/show/NCT03455335"
334,"NCT02582489","Autologous Bone Marrow Aspirate Concentrate in Patients Undergoing Meniscectomy",,"Recruiting","No Results Available","Osteoarthritis Post-meniscectomy","Biological: Bone Marrow Aspirate Concentrate|Procedure: Standard Meniscectomy","International Knee Documentation Committee (IKDC) Score|Patient reported outcomes throughout follow-up period|Synovial fluid analysis|Radiographic analysis","Rush University Medical Center","All","18 Years and older   (Adult, Older Adult)","Not Applicable","100","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Double (Participant, Investigator)|Primary Purpose: Prevention","15090903","December 22, 2017","November 2021","January 2022","October 21, 2015",,"December 3, 2020","Rush University Medical Center, Chicago, Illinois, United States",,"https://ClinicalTrials.gov/show/NCT02582489"
335,"NCT03838250","Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC",,"Recruiting","No Results Available","Alcoholic Liver Cirrhosis","Biological: Cellgram™ (Bone marrow-derived MSCs)","Incidence of Serious Adverse Events|Number of patients with Hepatocellular carcinoma (primary liver cancer) development|Incidence of Adverse Events|Liver stiffness measurement|How well the Liver is functioning|Chronic liver disease as assessed by the Child-Pugh score|Model for End-Stage Liver Disease (MELD) Score|Overall survival|Quality of life as assessed by 36-Item Short Form Survey (SF-36) Questionnaire","Pharmicell Co., Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 1","10","Industry","Interventional","Allocation: N/A|Intervention Model: Single Group Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","PMC-P-08","June 20, 2019","March 2021","June 2021","February 12, 2019",,"October 22, 2020","University of Utah, Salt Lake City, Utah, United States",,"https://ClinicalTrials.gov/show/NCT03838250"
336,"NCT01739777","Randomized Clinical Trial of Intravenous Infusion Umbilical Cord Mesenchymal Stem Cells on Cardiopathy","RIMECARD","Completed","No Results Available","Dilated Cardiomyopathy","Biological: ucMSC|Other: Controls","• Change in global left ventricular ejection fraction|• Change in functional capacity measured in O2 consumption|• Occurrence of major adverse cardiac event|• Change in high sensitivity C-reactive protein (hs CRP)|• Reduction in level of B-type natriuretic peptide (BNP)","Universidad de los Andes, Chile","All","18 Years to 75 Years   (Adult, Older Adult)","Phase 1|Phase 2","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Triple (Participant, Care Provider, Outcomes Assessor)|Primary Purpose: Treatment","UANDES-C4C|CORFO-11IEI-9766","December 2012","June 2015","June 2015","December 3, 2012",,"June 4, 2015","Universidad de los Andes, Santiago de Chile, Chile",,"https://ClinicalTrials.gov/show/NCT01739777"
337,"NCT01392105","Safety and Efficacy of Intracoronary Adult Human Mesenchymal Stem Cells After Acute Myocardial Infarction","SEED-MSC","Completed","No Results Available","Acute Myocardial Infarction","Drug: Mesenchymal stem cell|Drug: Control group","Absolute changes in global LVEF by SPECT|Changes in left ventricular end-diastolic volume (LVEDV)|Changes in left ventricular end-systolic volume (LVESV)|Changes in regional wall motion score index (WMSI) by Echocardiography|Major adverse cardiac event (MACE)","Yonsei University|FCB-Pharmicell Co Ltd.","All","18 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","80","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: None (Open Label)|Primary Purpose: Treatment","MSC2-Version 6.0","March 2007","May 2010","May 2010","July 12, 2011",,"July 12, 2011","Yonsei University Wonju College of Medicine, Wonju Christian Hospital, Wonju, Gangwon-do, Korea, Republic of|Inha University Hospital, Inchon, Korea, Republic of|Yonsei Cardiovascular Center and Cardiovascular Research Institute, Yonsei University College of Medicine, Seoul, Korea, Republic of",,"https://ClinicalTrials.gov/show/NCT01392105"
338,"NCT01759823","Bone Marrow Derived Stem Cell Transplantation in T2DM",,"Completed","No Results Available","Type 2 Diabetes Mellitus","Biological: mesenchymal stem cell transplantation|Other: control|Biological: MNC's TRANSPLANTATION","Reduction of insulin requirement by ≥ 50% by the end of 6 months of autologous bone marrow derived stem cell transplantation and Improvement in Glucagon stimulated C - peptide levels and hyperglycemic clamp for assessment of beta cell function","Postgraduate Institute of Medical Education and Research","All","30 Years to 70 Years   (Adult, Older Adult)","Phase 2|Phase 3","30","Other","Interventional","Allocation: Randomized|Intervention Model: Parallel Assignment|Masking: Single (Participant)|Primary Purpose: Treatment","stem cell therapy in T2DM","December 2012","December 2014","October 2015","January 3, 2013",,"October 27, 2015","Postgraduate Institute of Medical Education and Research, Chandigarh, UT, India",,"https://ClinicalTrials.gov/show/NCT01759823"
